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Abstract 
Many patients with emphysema remain breathless despite optimal medical therapy. Non-
pharmacological approaches to reduce the volume of hyperinflated lungs include lung volume 
reduction surgery (LVRS) which is effective in selected patients with upper lobe predominant 
emphysema and low exercise capacity.  Bronchoscopic techniques to reduce lung volume are 
also being developed.  
Studies of two bronchoscopic techniques to achieve lung volume reduction (LVR) are presented 
in this thesis; LVR coils (LVRCs) and endobronchial autologous blood instillation. In a trial of 
LVRCs we demonstrate for the first time in a randomised controlled setting, that treatment with 
LVRCs results in statistically and clinically meaningful improvements in quality of life, lung 
function and exercise capacity compared with controls, and that benefits are maintained up to 
12 months following treatment compared to baseline. In two pilot studies, we used autologous 
blood instilled endobronchially aiming to achieve lung volume reduction by inducing 
parenchymal scarring and fibrosis. Instilling 180-240 mls of autologous blood withdrawn from 
patients during the bronchoscopic procedure directly into a giant bullae resulted in significant 
reduction in bulla size over subsequent months in three of five patients, with associated 
improvements in lung function, exercise capacity and quality of life.  However a randomised 
controlled trial of instilling 60 mls of autologous blood into three segments of one lobe in 
patients with heterogeneous emphysema was ineffective. 
In addition, I investigated the use of a novel 3-dimentional measurement system, optoelectronic 
plethysmography (OEP), to track abdominal and chest wall movements during respiration. This 
showed that successful lung volume reduction approaches were associated with significant 
improvements in lower rib cage paradoxical inspiratory movements after lung volume 
reduction. Improvements in chest wall asynchrony were larger the worse the asynchrony was 
at baseline, and those with larger improvements in asynchrony derived greater benefits in lung 
function and other clinical outcomes following LVR.  
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1.1  AIMS 
The aim of this work is to assess the safety and efficacy of novel minimally invasive approaches 
to lung volume reduction in patients with severe emphysema, and to assess the role 
optoelectronic plethysmography can play in measuring responses to both surgical and 
bronchoscopic lung volume reduction with view to identifying those most likely to respond to a 
specific lung volume reduction technique thus improving patient selection and matching. 
 
1.2  HYPOTHESES 
• Patients with advanced emphysema could achieve sustained improvements in quality of 
life, lung function parameters and exercise tolerance 3 months following treatment with 
lung volume reduction coils when compared to best medical care, and benefits are 
maintained up to 12 months following treatment. 
• Patients with advanced heterogeneous emphysema could derive benefits in lung 
function, exercise tolerance, and quality of life following treatment with endobronchial 
autologous blood lung volume reduction, as compared with sham treated controls.  
• Bronchoscopic intrabullous autologous blood instillation into giant bullae could lead to 
significant reduction in bulla size with clinical benefit. 
• Optoelectronic plethysmography (OEP) could demonstrate improvements in gas 
trapping during forced expiratory manoeuvres, demonstrate changes in compartmental 
lung volumes, and assess changes in thoracoabdominal chest wall asynchrony before 
and after lung volume reduction. 
 
1.3  CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
Chronic obstructive pulmonary disease (COPD) is characterised by damage to small airways and 
alveolar walls, with an associated reduction of lung elastic recoil leading to airflow limitation. 
Premature airway closure during expiration leads to gas trapping with increased residual 
volume, and is accompanied by dynamic hyperinflation where increased operating volumes are 
necessary to maintain expiratory flow and minute ventilation. COPD is a common condition that 
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affects millions of adults worldwide with a prevalence and burden projected to increase in the 
coming decades due to ongoing exposure to tobacco smoke, particularly in the developing 
world, along with population demographic changes and increasing life expectancy.(1) It is now 
the third leading cause of death globally (2) with a prevalence above 5% in both Europe (3) and 
the United States.(4) Patients with COPD suffer from physical impairment, incapacity, reduced 
quality of life, and premature death. The high prevalence and chronicity of COPD begets high 
healthcare resource utilisation.  
 
1.3.1  DEFINITION 
COPD is an umbrella term incorporating features of chronic and minimally reversible airways 
obstruction associated with bronchitis, emphysema and chronic asthma. Chronic bronchitis and 
emphysema were initially described in the early 19th century by Charles Badham and  René 
Laennec,(5) respectively. In 1961, clearer definitions of chronic bronchitis and emphysema 
were proposed at the CIBA Symposium,(6) and COPD definitions continued to distinguish these 
different phenotypes of COPD for several decades.   
Chronic bronchitis is defined as a chronic productive cough for three months in each of two 
successive years in a patient in whom other causes of chronic cough have been excluded.(7) 
Airflow limitation in chronic bronchitis is secondary to narrowing of airway calibre and 
increase in airway resistance. Emphysema is defined as abnormal and permanent enlargement 
of the airspaces that are distal to the terminal bronchioles, accompanied by destruction of the 
airspace walls and without obvious fibrosis.(8) Airflow limitation in emphysema is due to small 
airway collapse resulting from the loss of elastic recoil and decrease in airway tethering. In 
practice, most patients with COPD suffer from a combination of emphysema and chronic 
bronchitis in varying degrees, and it is a rarity for a patient to suffer uniquely from one or the 
other of these two disease processes. 
In 1998, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was 
initiated by the National Heart, Lung, and Blood Institute (NHLBI) and the World Health 
Organization (WHO).  The aim was to produce recommendations for the management of COPD 
based on the best scientific information available. The “Global Strategy for Diagnosis, 
Management and Prevention of COPD” report was first published in 2001 (9) and has been 
updated regularly since, with free global access via the GOLD website. These reports are a major 
worldwide reference for COPD care and have served to unify the varying definitions and 
Zaid Zoumot 
CID: 00541359  
 
      
 20 
diagnostic criteria of COPD proposed by the American Thoracic Society (ATS), European 
Respiratory Society (ERS), and the British Thoracic Society (BTS) over the past 2 decades. GOLD 
defines COPD as ‘‘a preventable and treatable disease with some significant extrapulmonary 
effects that may contribute to the severity in individual patients. Its pulmonary component is 
characterised by airflow limitation that is not fully reversible. The airflow limitation is usually 
progressive and associated with an abnormal inflammatory response of the lung to noxious 
particles or gases.’’ Of note is that this definition does not include any distinction between 
chronic bronchitis and emphysema, and it recognises the presence of non-pulmonary 
components of COPD. There is also a new emphasis on the “preventable and treatable” nature of 
this condition. This is an attempt at combating the prevalent nihilistic view taken by some 
healthcare professionals (and patients) that COPD is relentlessly progressive and irreversible, 
and that the available treatments are ineffective. 
Although bronchodilators can, to a limited extent, improve airflow obstruction in patients with 
emphysema, most patients with emphysema–predominant COPD respond less well to medical 
therapy. Alternative treatments in the form of surgical and non-surgical lung volume reduction 
have therefore been developed and targeted at emphysematous lung disease.   
 
1.3.2  DIAGNOSIS AND STAGING 
Key symptoms which should raise suspicion of COPD include chronic cough, chronic sputum 
production, and dyspnoea, particularly if combined with a history of inhalational exposure to 
tobacco or biomass smoke or occupational dusts and chemicals. Patients with these features 
should undergo pulmonary function testing (PFTs) which are used to diagnose and determine 
the severity of COPD. A post-bronchodilator forced expiratory volume in 1 second (FEV1) to 
forced vital capacity (FVC) ratio (FEV1/FVC) of <0.7 indicates airway obstruction. If this is 
irreversible and there is no alternative explanation for the patient’s symptoms and airflow 
obstruction (e.g., bronchiectasis, vocal cord paralysis, tracheal stenosis), then the diagnosis of 
COPD applies. 
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1.3.2.1 Assessment of severity 
GOLD recommends assessment of four aspects of disease: Symptoms; degree of airflow 
obstruction; risk of exacerbations; and comorbidities.  
The modified Medical Research Council (mMRC) dyspnoea scale or the COPD Assessment Test 
(CAT) (10) allow an assessment of the level of disability caused by dyspnoea, and the CAT also 
offers a broader range of information on the impact of COPD on the patient’s life and well-being. 
Spirometry is used to assess the level if airflow obstruction, which generally correlates with 
symptoms, exercise tolerance, physical impairment, frequency of exacerbations and hospital 
admissions. However COPD is an extremely heterogeneous disease and there is huge variation 
in how patients are affected at different degrees of FEV1 impairment.  Nevertheless in the 
absence of a validated severity assessment tool that encompasses the multidimensional nature 
of COPD, GOLD, the ATS/ERS joint guidelines, and the National institute of Health and Clinical 
excellence (NICE) guidelines all recommend using FEV1 as a percentage of predicted as a 
marker of the severity of airflow obstruction. There is acknowledgment in all guidelines that 
this may not reflect the impact of the disease in any individual particularly the risks posed by 
exacerbation rates, and thus the “Combined COPD assessment” was introduced by GOLD in 
2011 (discussed below). In terms of the severity of airway obstruction, NICE changed the FEV1 
cut off points in 2004 to match those in the updated GOLD and the ATS/ERS guidelines, 
although the terminology was slightly different: an FEV1 of 50–80% predicted constituted mild 
airflow obstruction, 30–49% moderate airflow obstruction, and 30% severe airflow 
obstruction. The GOLD and ATS/ERS guidelines describe symptomatic patients with FEV1 >80% 
predicted (but FEV1/FVC ratio <0.7) as suffering from mild (stage I) airflow obstruction, with 
moderate (stage II), severe (stage III) and very severe (stage IV) as one moves down the cut-off 
points. The 2004 NICE guidelines effectively ruled out COPD as a diagnosis in patients with an 
FEV1/FVC ratio of <0.7 but FEV1 > 80% predicted. However, guidelines were adjusted in the 
2010 update to mirror GOLD severity staging thereby diagnosing patients with FEV1/FVC ratio 
of <0.7 and an FEV1 of >80% with mild COPD, provided they are symptomatic (Table 1.1).  
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Table 1.1: Grading of severity of airflow obstruction (11) 
  
NICE clinical 
guideline 
(2004) 
ATS/ERS (2004) 
(7) 
GOLD (2010) 
NICE clinical 
guideline (2010)  
(12) 
Post-
bronchodilator 
FEV1/FVC 
FEV1 % 
predicted 
Severity of airflow obstruction 
< 0.7 ≥ 80%  Mild Stage 1 – Mild Stage 1 – Mild* 
< 0.7 50–79% Mild Moderate Stage 2 – Moderate Stage 2 – Moderate 
< 0.7 30–49% Moderate Severe Stage 3 – Severe Stage 3 – Severe 
< 0.7 < 30% Severe Very severe 
Stage 4 – Very 
severe** 
Stage 4 – Very 
severe** 
*Symptoms should be present to diagnose COPD in people with mild airflow obstruction  
**Or FEV1 < 50% with respiratory failure. 
 
 
Exacerbations in COPD accelerate the decline in lung function and have a significant negative 
impact on quality life and overall health status. High exacerbation rates thus correlate with poor 
outcomes generally and also with mortality. Therefore an assessment of exacerbation rates was 
felt to be an important component of assessing a patient’s overall COPD disease severity. The 
combined COPD assessment (Figure 1.1) introduced by GOLD in 2011 aimed to address this 
with the first part of the assessment relating to symptoms status (mMRC ≥2 or CAT ≥10, vs. 
mMRC<2 or CAT<10). The degree of airflow obstruction (GOLD stage I-II vs. GOLD stage III-IV) 
then stratifies patients into high or low risk groups, with the annual exacerbation rate (≥2 or 
<2) further used to assess risk (the higher risk determines risk level in case of disagreement 
between airflow obstruction and exacerbation rate risk. Therefore patients can be classified into 
one of four groups (A,B,C or D) depending on symptom burden and risk of 
progression/mortality. 
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Figure 1.1: Combined COPD Assessment. GOLD 2011. 
 
 
Other pulmonary function tests are also helpful in establishing a diagnosis of COPD and 
assessing severity. Reduction in inspiratory capacity (IC) and vital capacity (VC), accompanied 
by increased total lung capacity (TLC), functional residual capacity (FRC), and residual volume 
(RV) are indicative of hyperinflation and gas trapping. Impairment in the diffusion capacity of 
the lungs as measured by carbon monoxide diffusing capacity (TLCO) correlates with increasing 
severity of emphysema.  
There is a growing recognition that COPD is a multisystem disorder with extrapulmonary 
manifestations which include nutritional abnormalities and skeletal muscle dysfunction. 
Frequently occurring comorbidities which should be considered when assessing a patient with 
COPD include cardiovascular disease, metabolic syndrome, osteoporosis, lung cancer and 
depression/anxiety. 
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1.3.3  EPIDEMIOLOGY 
The Burden of Obstructive Lung Disease (BOLD) study showed that the pooled prevalence of 
COPD was 11.8% in men and 8.5% in women over 40 years old, with variations in geographical 
distribution and sex which correlate with differences in the prevalence of smoking.(13) Similar 
prevalence rates were found in a study of five Latin American countries (The Proyecto Latino 
Americano de Investigacion en Obstruccion Pulmonar (PLATINO) study).(14) The World Health 
Organisation (WHO) estimates that 80 million people have moderate to severe COPD, and that 
more than 3 million people died of COPD in 2005 - corresponding to 5% of all deaths 
globally(15). COPD is the only major cause of death whose incidence is on the increase and is 
now the third leading cause of death worldwide (exceeded only by ischaemic heart disease and 
cerebrovascular disease).(2, 16) 
In the UK, the population prevalence of clinically significant COPD was estimated to be 1.7% for 
men and 1.4% for women – approximately 900,000 people.(17) However, it is estimated that a 
further 2 million people have undiagnosed COPD. (18) In 2005, 24160 people died as a result of 
COPD in the UK,(19) more than bowel cancer or prostate cancer. In fact, more women died of 
COPD than from breast cancer in 2005. Between 2007 and 2009, COPD accounted for 4.8% of all 
deaths in England.(2) 
COPD imposes a heavy burden on the National Health Service (NHS). There are approximately 
1.5 million GP consultations per year attributable to COPD and there are 24 million lost working 
days per year in the UK. COPD exacerbations account for 10% of emergency admissions to UK 
hospitals (>100,000 admissions), and over 1 million bed-days. Various studies have estimated 
the direct costs to be between 486 million to 982 million pounds per year with additional 
indirect costs totalling 1.5 billion pounds.(20, 21)  
Both worldwide and in the UK, the gap between the prevalence of COPD in men and women is 
narrowing almost to equality, in par with the increase in smoking rates amongst women. In the 
UK, the rate of COPD has been increasing nearly three times faster amongst women than 
men.(22) There is evidence to suggest that women are more susceptible to smoking related 
COPD than men.(23) 
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1.3.4  RISK FACTORS 
1.3.4.1 Cigarette smoking 
The primary cause of COPD is exposure to tobacco smoke, overwhelmingly the most important 
risk factor accounting for as much as 90% of COPD risk.(24, 25)  Tobacco smokers have a higher 
prevalence of respiratory symptoms and airflow obstruction, and an increased annual decline in 
FEV1 compared to non-smokers (>60mls per year compared to the normal physiological decline 
of 20-30 mls per year). In fact, lung function testing abnormalities and lung structural changes 
probably predate the presence of clinical signs and symptoms of airway obstruction in cigarette 
smokers.(26) The risk of developing COPD and the severity of disease directly correlate with the 
length and degree of exposure to tobacco smoke, and the total pack-years smoked predicts 
mortality in COPD. Smoking cessation at any age reduces the risk of developing smoking related 
diseases, with smokers who give up by their early 30’s avoiding most of these risks, and their 
life expectancy being not significantly different from those who have never smoked.(24) 
It has been estimated that around 15% of smokers will develop COPD, with genetic and 
environmental risk factors influencing an individual’s susceptibility to the damaging effects of 
tobacco smoke.(26)  Cannabis smoke may have a synergistic effect in combination with tobacco 
smoke in terms of risk of COPD, in particular causing lung destruction and bullous 
emphysema.(27)  However data is inconsistent on the association of cannabis smoke and 
worsening lung function. One study followed up a cohort of adult cannabis smokers for 8 years 
with no age related accelerated decline  in FEV1 seen.(28) 
1.3.4.2 Environmental factors 
COPD does occur in individuals who have never smoked.  Traffic-related and industry-related 
air pollution may play a role in the aetiology of COPD, but this is likely a small role particularly 
compared to the effects of tobacco smoke. 
An under-appreciated risk factor for COPD is exposure to occupational organic and inorganic 
dusts and chemical agents and fumes. The NHANESIII survey estimated that occupational agent 
exposure causes 19.2% of COPD overall, and 31.1% in never smokers.(29)   
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In developing countries, the use of wood, animal dung, crop residues and coal for indoor 
cooking and heating leads to high levels of indoor air pollution and is probably a major 
contributor to the worldwide prevalence of COPD, especially amongst young women. Almost 3 
billion people use biomass fuels and coal as their main source of energy for cooking and heating 
worldwide, and this accounts for the high prevalence of COPD amongst non-smoking women in 
parts of the developing world.(30) 
1.3.4.3 Airway Hyper-responsiveness 
Numerous observational studies have suggested that heightened airway responsiveness to 
aero-allergens and other triggers is an independent risk factor for the development of 
COPD.(31, 32) It is stipulated that chronic bronchial hyper-reactivity and associated airway 
inflammation eventually result in airway remodelling leading to a more fixed obstruction 
similar to that seen in smoking-related chronic bronchitis. A particularly more accelerated 
decline in FEV1 has been reported in patients who smoke tobacco and suffer from airways 
hyper-responsiveness, but the exact causative relationship between these two factors remains 
unclear.(33, 34) 
Other observational studies have demonstrated an increased risk of COPD in atopic individuals.  
In a longitudinal study of over 1000 men without asthma, atopy predicted a 9.5 ml/year excess 
annual rate of decline of FEV1.(35) 
1.3.4.4  Molecular factors 
Molecular mechanisms for COPD have been assessed using several different methods, including 
studies of gene polymorphisms, antioxidant enzyme function, metalloproteinase dysregulation, 
and abnormalities that cause excess elastase. These will be discussed in turn below and in the 
pathophysiology section of this chapter. 
1.3.4.5  Genetic Factors 
α-1 antitrypsin deficiency is the commonest known genetic risk factor for emphysema, causing 
approximately 1% of all cases of COPD. α -1 antitrypsin is a protease inhibitor synthesised in the 
liver, its main purpose being to neutralise elastases released by neutrophils in areas of 
inflammation and in response to tobacco smoke. Unopposed elastase activity, occurring in lungs 
when circulating α -1 antitrypsin levels are extremely low leads to destruction of structural 
elements in the lung interstitium and ultimately to panacinar emphysema. The average age at 
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which patients with α -1 antitrypsin deficiency develop emphysema is 40 years for smokers and 
53 years for non-smokers. Over 70 alleles of the α -1 antitrypsin gene, which is found on 
chromosome 14, have been identified. Persons who are homozygous for the normal allele 
(PiMM) have normal serum levels of α -1 antitrypsin, whereas heterozygous individuals with 
one normal allele and one abnormal allele (commonest PiMS and PiMZ) will express a normal 
phenotype albeit with reduced serum levels of α -1 antitrypsin. The PiZ genotype accounts for 
over 95% of cases of severe α -1 antitrypsin deficiency emphysema.  
Other gene polymorphisms which have been implicated in emphysema include polymorphisms 
of the tumour necrosis factor α (TNF-α), microsomal epoxide hydrolase, transforming growth 
factor β, and Leptin receptor (LEPR) genes. TNF-α gene polymorphisms may influence host 
defences by increasing long-term tissue inflammation leading to chronic bronchitis.(36) 
However, no benefit was seen with Infliximab therapy (anti-TNF-α antibody) in patients with 
moderate and severe COPD in a randomised trial.(37) A reduction of microsomal epoxide 
hydrolase, which reduces smoking related epoxide intermediaries, probably predisposes 
individuals to oxidative injury and subsequent COPD. (38) Gene polymorphisms of transforming 
growth factor β1, which are peptides involved in cellular growth, differentiation, and activation, 
have been associated with development of COPD in smokers.(39) Lung function decline in 
tobacco smokers has been associated with polymorphisms of the LEPR gene.(40) 
A high prevalence of COPD is found in patients with inherited connective tissue disorders such 
as Marfan’s syndrome, Ehler-Danlos syndrome, and cutis laxa.  
1.3.4.6  Infections 
History of severe as well as recurrent respiratory viral and bacterial chest infections in 
childhood have been associated with an increased risk of developing COPD in adulthood (41, 
42) as has a history of airway bacterial colonisation.(43) It has also been suggested that latent 
respiratory viral infections may also play a role in the pathogenesis of COPD.(44) A history of 
pulmonary tuberculosis is associated with airflow obstruction due to a combination of scarring 
following airway infection, and lung parenchymal destruction with loss of airway tethering. A 
Chinese study of 8784 subjects demonstrated that prior pulmonary tuberculosis (based on 
radiographic evidence) was associated with an increased risk of airflow obstruction 
independent of other risk factors such as smoking.(45) Males were 4.1 times and females 1.7 
times more likely to suffer from  airways obstruction after adjusting for confounders in a sub-
analysis of the PLATINO cohort (5751 subjects over 40 years of age).(46) Although an 
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association has been made between tuberculosis and COPD, the evidence is insufficient to infer 
a causative relationship. 
 
1.3.4.7 Bronchopulmonary dysplasia 
Bronchopulmonary dysplasia, also known as neonatal chronic lung disease, is a result of 
premature births, and is defined by dependence on supplemental oxygen for more than 28 days 
post-partum. Bronchopulmonary dysplasia leads to airflow obstruction and hyperinflation on 
pulmonary function testing, and radiographic emphysema on computed tomography (CT) in 
those who survive to adulthood.(47) 
 
1.3.5  PATTERNS OF EMPHYSEMA 
Emphysema is characterised by damage and destruction of the alveoli and airspaces distal to 
the terminal bronchioles thereby diminishing the alveolar surface area available for gas 
exchange.  The loss of elasticity and hence elastic recoil due to the damage to the alveolar walls, 
as well as narrowing of the airways due to the loss of structural elements, both contribute to 
airflow limitation. The terminal bronchioles can also collapse on expiration due to the latter. 
These factors lead to gas trapping and hyperinflation. In severe cases, alveolar walls can become 
destroyed creating bullae and collateral ventilation.  
Emphysema has three morphologic patterns: Centrilobular, panacinar, and paraseptal. In 
centrilobular emphysema, the destruction is limited to the respiratory bronchioles and the 
central portions of the acini, sparing the distal alveoli. Panacinar emphysema involves the 
alveolus distal to the terminal bronchiole in its entirety. Paraseptal emphysema involves distal 
airway structures, alveolar ducts, and sacs, and can lead to the formation of bullae.   
Centrilobular emphysema is the morphology most commonly seen in cigarette smokers and is 
usually worst in the upper lobes. Panacinar emphysema is the morphology which is most often 
seen in patients with homozygous α-1 antitrypsin deficiency, and predominantly affects the 
lower lobes. Paraseptal emphysema is usually localised around the septae and pleurae, and can 
lead to pneumothoraces particularly in patients with apical disease. It may not be associated 
with airflow obstruction. 
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1.3.6  PATHOPHYSIOLOGY OF EMPHYSEMA 
Most cases of COPD are the result of exposure to noxious stimuli, predominantly cigarette 
smoke. There is likely a significant genetic and/or epigenetic susceptibility as only 15-20% of 
smokers develop COPD. Chronic inflammation is thought to cause tissue destruction and impair 
tissue healing. It also disrupts immune defences increasing susceptibility to recurrent infections 
which themselves cause further damage to the airways, parenchyma and pulmonary 
vasculature. The noxious agents lead to an increase in the number of activated 
polymorphonuclear leukocytes and macrophages which release chemotactic factors and 
cytokines recruiting more cells and amplifying inflammation. Released proteases can directly 
cause lung damage, and growth factors lead to structural change. Proteases are usually cleared 
by antiproteases before destruction of elastin and structural elements ensues, but in patients 
with COPD this does not occur satisfactorily. The imbalance between proteases and 
antiproteases is worsened in predisposed individuals by a heightened inflammatory response, a 
deficiency of antiproteases, and direct impairment of antiproteases activity by tobacco smoke 
and free radicals. 
Human leukocyte elastase is thought to be the main protagonist of lung destruction in 
emphysema. Others include proteinase-3, macrophage-derived matrix metalloproteinases 
(MMPs) and cysteine proteinases. The release of oxidants by phagocytes secondary to the free 
radicals in tobacco smoke can lead to increased oxidative stress and cell death. There is 
increasing evidence in the literature to suggest that dysregulation of apoptosis and ineffective 
removal of apoptotic cells by macrophages plays a major function in airway inflammation in 
emphysema.(48) Roles for CD8+ T lymphocytes, accelerated aging and autoimmune 
mechanisms have also been suggested in the pathogenesis of COPD. 
The progressive damage to the alveolar walls accompanied by damage to the pulmonary 
capillary bed in emphysema results in a decrease of the surface area available for gas exchange 
and hence the ability to oxygenate blood. Hyperventilation and a lower cardiac output are the 
result leading to a significant mismatch in ventilation and perfusion. Excessive mucus 
production, mucus gland hypertrophy, and airway wall inflammation result in airflow 
obstruction. The loss of structural elements and pulmonary vasculature results in a reduction in 
the elastic recoil of the lung. To compensate, COPD patients breathe at higher lung volumes and 
this improves airway opening and lung recoil, at the expense of much higher work of breathing 
and inspiratory effort.  
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Airflow limitation in COPD is greatest during expiration as positive intrathoracic pressures tend 
to compress or collapse airways, which have lost some of their structural support mechanisms. 
Usually during exercise, increasing expiratory flow by breathing faster and more forcefully to 
increase pleural and alveolar pressures, allows complete exhalation of the increased tidal 
volume prior to the next breath. In COPD (particularly emphysematous lungs), however, 
increasing the force of breathing in expiration may not achieve this goal as this leads to 
increased small airway collapse and worsening airflow obstruction. As a result, exhalation may 
not be completed before the onset of the following breath. This is can also occur at rest but is 
commonest during exercise, when the respiratory rate is faster. The end expiratory lung volume 
(EELV) (already increased at rest due to reduced elastic recoil of the damaged lungs) gradually 
increases further as small volumes of air from the previous breath remain within the lungs 
before the following breath is initiated. This results in an increase in the volume of air in the 
lungs, or dynamic hyperinflation.(49) 
In patients with emphysema, dynamic hyperinflation probably plays a more important role in 
the development of exertional dyspnoea than airways obstruction.(50) It is likely that the 
majority of dyspnoea relief following treatment of airway bronchospasm in an exercising COPD 
patient is a result of the correction of hyperinflation rather than the relief of bronchospasm per 
se.(51) In fact, the improvement in exercise capacity brought about by several treatment 
modalities, including bronchodilators, oxygen therapy, lung volume reduction surgery (LVRS), 
and manoeuvres learned in pulmonary rehabilitation, is more likely due to minimising dynamic 
hyperinflation rather than reducing airflow obstruction. Additionally, hyperinflation has been 
shown to predict survival better than FEV1.(52) 
 
1.3.7  RISK REDUCTION AND MEDICAL MANAGMENT OF COPD 
A practical multi-dimensional approach to managing patients with COPD is advocated by 
NICE,(53) and this relies on addressing different factors in tandem to one another, rather than 
the previous “escalator” approach for the addition of therapy. These factors are smoking, 
breathlessness and exercise limitation, frequent exacerbations, respiratory failure, cor 
pulmonale, abnormal BMI, chronic productive cough and anxiety and depression. Similarly, 
updated GOLD guidance adopts the approach of targeting the most relevant components of 
symptom limitation and risk reduction depending on combined COPD assessment grouping. 
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1.3.7.1 Smoking cessation 
Smoking cessation is the single most important intervention for all stages of COPD severity. 
Smokers who give up by their early 30’s will avoid most of the risks of smoking-related diseases 
and their life expectancy will not be significantly different from those who have never 
smoked.(24) For all levels of COPD severity, giving up arrests the accelerated decline in FEV1. 
The potential benefits are not in dispute. Encouragement of smoking cessation and referral to 
smoking cessation support programs as well as trials of therapy with bupropion, nicotine 
replacement therapy or Varenicline should be first line management for all COPD patients who 
continue to smoke.(12) 
1.3.7.2 Breathlessness and exercise limitation 
Bronchodilators are the cornerstone of managing the symptoms of breathlessness and exercise 
limitation, and the NICE guidelines (12) suggest initially a trial of pro re nata (prn) short-acting 
Beta2 agonists, followed by the additions of a short acting anticholinergic. If symptoms persist 
adding a long acting Beta2 agonist (LABA) or a long acting anticholinergic (LAMA) is suggested. 
Adding an inhaled corticosteroid in a combination inhaler for a trial period of 4 weeks is then 
suggested in patients with moderate to severe disease, with a plan to discontinue if there is no 
benefit, however this advice is controversial in the absence of exacerbations. New ultra-long 
acting bronchodilators are becoming available, combining a LABA and a LAMA in single daily 
dose inhalers with novel improved delivery mechanisms, and appear to offer  a promising and 
superior alternative to currently available combinations. Regular theophylline is the final 
medical step in managing these symptoms. 
Pulmonary rehabilitation is a process which encompasses physical training, disease education, 
psychological support, social support and nutritional advice. The UK guidelines recommend that 
all patients considered functionally disabled with an MRC score III or above should be offered 
pulmonary rehabilitation. However, evidence points to significant benefit irrespective of 
baseline lung function, age or exercise capacity.(54) Significant improvements in exercise 
tolerance, dyspnoea and fatigue are seen. Although these programmes do not significantly alter 
lung function they do have important effects on quality of life which far exceed benefits derived 
from the most effective bronchodilators. Furthermore, benefits to the cardiovascular system of 
regular exercise are well recognised. Pulmonary rehabilitation should be considered an 
essential component of COPD management, and therapy cannot be considered optimised 
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without regular participation in pulmonary rehabilitation courses crucially with maintenance of 
regular exercises and high activity levels following course completion. 
 
1.3.7.3 Frequent Exacerbations 
Annual influenza vaccination as well as pneumococcal vaccination for all patients with COPD is 
advised.  Providing patients with “back-up” courses of antibiotics and prednisolone to be started 
early as symptoms of infective exacerbations begin to manifest is recommended. Adding long-
acting inhaled corticosteroids (in a combination inhaler) for patients suffering two or more 
exacerbations in a one year period is recommended. A recent randomised controlled trial of 
1577 patients with emphysema demonstrated a significant reduction in exacerbation frequency 
and an increase in the median time to the next exacerbation in those cohort treated with 
prophylactic azithromycin compared to placebo.(55) However this option needs to be 
considered with care in routine clinical practice as there is a significant  risk of hearing 
impairment, arrhythmias (particularly those with long QT), and liver dysfunction. 
 
1.3.7.4 Respiratory Failure  
The beneficial effects of long term oxygen (O2) therapy (LTOT) on survival in subjects with 
COPD and severe resting hypoxemia were demonstrated in two randomised controlled clinical 
trials: the Nocturnal Oxygen Treatment Trial (56) and the MRC study.(57) The NOTT 
demonstrated a survival benefit of continuous nocturnal oxygen therapy, and the MRC trial 
showed a survival benefit in those receiving O2 for at least 15 hours per day over those 
receiving no O2. This did not, however, appear until after 500 days. The benefit was seen in 
those with an arterial blood partial pressure of oxygen (PaO2) on room air of <7.3kPa, or <8kPa 
in the presence of pulmonary arterial hypertension (PAH), right ventricular impairment, or 
polycythaemia.  These trials demonstrated a relationship between survival and the average 
daily duration of O2 use.  Median survival in those using oxygen for 18 hours a day was 
approximately twice as long as those receiving no oxygen. Non-invasive ventilation is now 
standard of care in the treatment of both acute and symptomatic chronic type 2 respiratory 
failure in patients with COPD. 
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1.3.7.5 Abnormal Body Mass Index (BMI)  
There is strong evidence that low BMI and reduced muscle mass directly correlates with 
deterioration of severity of COPD and quality of life parameters. Dietetic input, nutritional 
supplements and physiotherapy are useful. On the other end of the spectrum, high BMI can be 
detrimental and cause significant worsening of symptoms due to increasing workload of 
mobility and other day-to-day activities. A downward cycle of worsening symptoms and 
reduced activity levels can ensue. Weight reduction measures are advocated in those with high 
BMI. 
 
1.3.7.6 Chronic productive cough 
Mucolytics should be prescribed and continued in patients with chronic productive cough who 
show a positive response to these drugs.(12) The use of short 7 day courses of mucolytics for 
treatment of acute infective exacerbations is now licensed in the UK.   
 
1.3.8  NON-MEDICAL MANAGEMENT OF COPD 
COPD is progressive and irreversible and inevitably leads to an “end stage” which is minimally 
responsive to medical therapy. Surgical interventions have a risk of both morbidity and 
mortality, and are therefore directed only to patients who remain symptomatic despite optimal 
medical treatment. Attempts to surgically correct lung hyperexpansion and poor perfusion of 
emphysematous lung parenchyma included several procedures which have been unsuccessful 
in the past, such as costochondrectomy, phrenic crush, pneumoperitoneum, pleural abrasion, 
lung denervation, and thoracoplasty. Three surgical procedures have, however, demonstrated 
significant success and these are bullectomy, reduction pneumoplasty or lung volume reduction 
surgery (LVRS), and lung transplantation. Minimally invasive bronchoscopic techniques to 
achieve lung volume reduction (LVR) have also shown some recent success. The non-medical 
approaches to managing COPD will be discussed below.    
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1.3.8.1 Bullectomy 
In severe cases of emphysema, areas of alveolar destruction coalesce creating bullae which can 
become so large that they occupy more than 30% of the hemithorax (termed “giant bullae”). 
These may compress adjacent lung tissue reducing perfusion and ventilation to healthier tissue.  
Surgical removal of giant bullae has been a standard treatment in selected patients for many 
years (58) and this has been achieved via standard lateral thoracotomy, bilateral resections via 
midline sternotomy, and video-assisted thoracoscopy (VATS).(59) Patients who are 
symptomatic and have an FEV1 of less than 50% predicted have a better outcome after 
bullectomy.(58) Benefits result from expansion of compressed lung tissue and improved 
ventilatory mechanics, with short term benefits in hypoxemia, hypercapnia, gas trapping, and 
dyspnea reported in the published literature (predominantly uncontrolled retrospective 
studies).(59) A recent series of 43 patients treated with giant bullectomy reported significant 
improvements in spirometry, residual volume (RV) and exercise capacity as measured by the 6-
minute walk distance  (6MWD) with benefits persisting for at least 3 years.(60) Postoperative 
bronchopleural air leak is the main potential complication. Randomised controlled trials of giant 
bullectomy have not been performed.  An alternative approach for frail patients with large 
single bullae is the Monaldi procedure and its modified form (the Brompton technique). (61) 
1.3.8.2 Transplantation 
Lung transplantation is a well-established therapeutic modality for patients with end-stage lung 
disease. It involves complex and meticulous care of the recipient and the donor pre-transplant, 
careful organ retrieval and preservation, a complicated transplant operation, and intensive 
postoperative care and follow-up. COPD has now become the most common diagnosis leading to 
lung transplantation, accounting for 37% of transplants worldwide.(62) There is much evidence 
showing that lung transplantation improves quality of life and functional indices in patients 
with COPD, however survival data is contradicting.(63) Nevertheless, transplantation is a 
palliative procedure and most clinicians feel that the improvements in quality of life justify the 
procedure in patients with end-stage COPD. This makes the decision to proceed to 
transplantation more difficult in COPD than in patient with other end-stage respiratory diseases 
where there is also a clear survival benefit. International guidelines have therefore been 
produced to aid clinicians and patients regarding the optimal timing of referral for this 
treatment option.(64) Previous LVRS or bullectomy are not contraindications for subsequent 
lung transplantation. 
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Referral to transplant centres should be considered in patients with diffuse disease when the 
BMI, Obstruction, Dyspnoea, Exercise capacity (BODE) index is ≥5, post-bronchodilator FEV1 is 
<25 % of predicted, resting PaO2 <60 mmHg, there is evidence of chronic hypercapnoeic type II 
respiratory failure, there is an accelerated decline on FEV1, or an increase in the frequency and 
severity of infective exacerbations. Lung transplantation should be offered to patients who have 
any of the following: FEV1 <20% predicted; hypercapnoea; associated pulmonary hypertension; 
or a BODE score of ≥7. Potential lung transplant recipients must be ambulatory, have adequate 
nutritional status, and no co-morbidities that would hinder recovery in the peri- and post-
operative periods or prohibit the necessary post-operative immunosuppressive and anti-
infective therapies.  An adequate social support network and high motivation and compliance 
levels are essential to ensure the intensive medical and rehabilitation treatments and follow-up 
appointments post-transplantation are strictly adhered to. 
In recent years, more than 50% of COPD patients undergoing lung transplantation have had 
bilateral lung transplants, as recent data have shown divergence of the survival curves beyond 
one year following surgery.(62) Cumulative 5 year survival for COPD patients undergoing 
transplantation is 50%, with an 88% 1 year survival rate.  
Despite offering the hope of improved survival and quality of life to many patients with COPD, 5 
year survival remains disappointing with obliterative bronchiolitis, infection, renal 
insufficiency, and malignancy all contributing to late attrition. Nevertheless this survival rate 
remains higher than that of COPD patients managed with optimal medical therapy who have 
BODE scores of ≥7 or those with FEV1 and transfer factor <20% of predicted, and therefore 
should always be considered and patient referred for transplant assessment if within the 
referral criteria detailed above. Unfortunately low lung donation rates, adverse donor 
demographics, preferential double lung use, and the relatively old age of most patients with 
COPD are likely to keep this option limited to a very small subgroup of the COPD population, but 
this should not deter from appropriately timed referrals to a transplant centre or deny patients 
the opportunity of an effective and proven therapy. 
1.3.8.3 Lung Volume Reduction 
Lung volume reduction improves lung function by improving the elastic recoil of the lung, which 
in turn increases the outward pull on the bronchioles. This reduces terminal bronchiole collapse 
and improves expiratory airflow thereby reducing gas trapping. The decrease in the functional 
residual capacity improves diaphragmatic and intercostal muscle function and reduces the 
work of breathing. In carefully selected patients, lung volume reduction surgery (LVRS) has 
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been clearly shown to be effective at improving outcomes.(65, 66)  It is, however, associated 
with significant morbidity, a 5% mortality rate (66) and a modest cost-benefit return.(67) 
Unfortunately, only a small minority of patients with emphysema are fit enough to undergo 
LVRS, and therefore a variety of alternative techniques are being developed to achieve lung 
volume reduction. These techniques include the insertion of unidirectional endobronchial 
valves, insertion of lung volume reduction coils to internally compress hyperinflated 
emphysematous areas of lung, biologic endobronchial sclerosing agents, autologous 
intrabronchial blood instillation aimed at inducing lobar atelectasis and collapse, and 
percutaneous transpleural airway bypass (‘spiracles’). The different lung volume reduction 
methods will be discussed in turn. Section 1.3.8.3.2 contains various modified excerpts from a 
review written by the author,(68) with the publisher’s permission. 
1.3.8.3.1 Lung Volume Reduction Surgery 
Brantigan described unilateral thoracotomy and resection of the most diseased-appearing 
portion of emphysematous lungs coupled with lung denervation in 33 patients 1957.(69) 
However surgical mortality rates of over 18% meant the procedure never gained widespread 
acceptance.  Cooper et al. revived LVRS in the early 1990s by refining the procedure with the 
use of staple sutures and pericardial strips to buttress the suture line, thereby reducing the 
incidence of post-operative air leaks and simplifying the procedure.(70)  Volume reduction is 
achieved by making a series of wedge excisions in areas where the emphysematous changes are 
most marked. The aim is to resect 20-35 % of each lung, removing as much diseased lung as 
possible while preserving the greatest amount of functioning lung. The group demonstrated 
that LVRS improved symptoms, lung function and gas trapping with an acceptable operative 
risk (4.8% perioperative mortality) (70) and several small randomised controlled trials 
followed which showed superiority of LVRS over best medical care.(65, 66, 71) 
Physiological effects of LVRS 
Lung volume reduction surgery (LVRS) involves resection of the worst affected area of 
emphysematous lung. Lung volumes improve because bullous areas, which expand at the 
expense of healthier lung, have been resected. The precise mechanisms by which this translates 
to clinical improvement are not known with certainty, but is likely to be due to a combination of 
factors: 
• The remaining relatively healthier lung has more preserved parenchymal structural 
integrity and therefore greater elastic recoil. This allows the lung to  empty more 
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effectively.(72) Using the coefficient of retraction, an indicator of elastic recoil of the lung 
calculated as the ratio of maximal static recoil pressure (measured using oesophageal 
balloons) to total lung capacity, Sciurba et al. demonstrated a significantly greater increase 
in exercise capacity in 16 patients who demonstrated increases in elastic recoil following 
LVRS compared to 4 patients who did not have increased elastic recoil.(73)   
• LVRS improves matching between the size of the lungs and the capacity of the thorax which 
contains them. This increases vital capacity (VC) and hence the FEV1.(72) 
• Removal of severely damaged and less ventilated portions of lung reduces dead space. 
• Improvement in the outward circumferential pull on small airways and terminal 
bronchioles improves expiratory airflow by maintaining airway patency, or a “re-
tensioning” effect.  
• A return of the diaphragm to the usual curved shape and length due to reduction of the 
functional residual capacity (FRC) leads to improvement in the mechanical function of the 
diaphragm and intercostal muscles.(74, 75) There is contradicting evidence on whether 
diaphragm strength actually increases (76) or not.(77) Furthermore, increases in the 
abdominal contribution to tidal volume and improved synchrony of the diaphragm with 
other inspiratory muscles have been reported.(78) 
• Reduction in dynamic hyperinflation is arguably the most significant factor contributing to 
improvements in exertional dyspnoea.(79) 
• The benefits in lung ventilation mechanics with tidal breathing occurring at lower lung 
volumes might reduce respiratory muscle and diaphragm fatigue, and reduces the work of 
breathing. 
• Decreased central respiratory drive might improve the patients’ sensation of dyspnoea. 
• The reduction of intrathoracic pressure improves left ventricular (LV) end-diastolic 
dimension and LV filling post LVRS, resulting in improved LV function.(80) 
The best evidence around the indications for LVRS comes from the National Emphysema 
Treatment Trial (NETT), which randomised more than 1200 patients to LVRS or usual care.(66) 
An early result was the identification of a high risk group (FEV1 <20% predicted with either a 
homogeneous pattern of disease or a TLCO of <20% predicted) which had a high mortality. 
Subsequent enrolment from this patient group was stopped. Analysis was based on a priori 
categories of exercise capacity and pattern of emphysema.  At 24-months a survival benefit was 
apparent in surgical patients with a low exercise capacity and upper-lobe predominant 
emphysema. Excluding the high risk group, procedural (90 day) mortality was 5.5% in the NETT 
trial, with serious morbidity after LVRS observed in 59% of patients (persistent air leak (33%), 
respiratory failure (22%), pneumonia (18%), cardiac arrhythmias (24%)).(66)  
Zaid Zoumot 
CID: 00541359  
 
      
 38 
A subsequent report from the NETT data demonstrated that the beneficial effects LVRS were 
sustained, with increased survival in the LVRS group at a median 4.3 years of follow-up (0.11 
deaths per person/year in the LVRS group versus 0.13 in the medical group (RR=0.85; p<0.02). 
(67) Patients with upper lobe predominant emphysema and low baseline exercise capacity had 
the largest benefit with >70% still alive at 5 years compared with <50% of those treated 
medically (RR=0.57, p<0.01). This group also had improvements in exercise capacity (p<0.001) 
and quality of life (p<0.001). The cost of LVRS was $140,000 per quality adjusted life year 
(QALY) gained at 5 years, and projected to be $54,000 per QALY gained at 10 years.(67)  
National and international guidelines now recommend that LVRS be considered in patients with 
upper lobe predominant disease and low exercise capacity.(8, 12) Yet LVRS remains vastly 
underutilised with only 90 LVRS operations performed in the United Kingdom in 2010 
according to the Society of Cardiothoracic Surgery register, and 119 performed in 2008 under 
Medicare in the USA.  This underutilization of LVRS is likely multifactorial and due to a 
combination of lack of expertise, a complicated and expensive certification system for Medicare 
in the USA, lack of knowledge by patients and physicians alike, and a misinterpretation of the 
NETT trial as showing no mortality benefit and high morbidity. Nevertheless, safer, faster and 
less invasive approaches to achieve lung volume reduction are needed. The approaches that 
have been studied are discussed in more detail below.
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Table 1.2: Bronchoscopic Lung Volume Reduction Techniques. (Author’s own work reproduced with permission from Clinics in Chest Medicine (68)) 
Approach Technique Mechanism of action 
Pattern of 
disease most 
likely to benefit 
Likely influence 
of collateral 
ventilation? 
Possible limitations and 
complications 
Available evidence Active trials 
Devices 
occluding 
airways 
Endobronchial 
valves 
 
One way valves allow air and 
secretions to escape the target 
segments of lung whilst 
preventing air from re-entering 
causing atelectasis. 
Heterogeneous disease 
without collateral 
ventilation 
Collateral ventilation 
prevents atelectasis 
and limits success 
Effect limited in the presence of 
collateral ventilation. 
Risk of pneumothorax likely in the 
range of ~25% in the responder 
population. 
Zephyr®: Single arm open 
label n=98 (81); RCTs n= 321 
(82), 171 (83) 
Spiration®: Observational 
n=91 (84) 
Pivotal trial recruiting 
 
 
Pivotal trial soon 
Agents inducing 
an 
inflammatory 
response 
Polymeric lung 
volume 
reduction 
Air within the hydrogel foam 
sitting in the alveoli is absorbed 
leading to collapse of the alveoli 
with selective inflammation, 
shrinkage and scarring. 
Heterogeneous disease No effect  High risk of post procedural severe 
pneumonia and COPD exacerbation. 
Phase 2 dose-ranging study 
n=25 (85), unblinded n=20 
(86) 
Pivotal trial recruiting 
 Bronchoscopic 
thermal vapour 
ablation 
(‘steam’) 
The steam causes acute tissue 
injury which is followed by 
scarring and fibrosis, and 
shrinkage of the targeted lung 
parenchyma. 
Heterogeneous disease No effect. High risk of post-procedural 
pneumonia and COPD exacerbation. 
 
Single arm unblinded n=44 
(87)  
Pivotal trial recruiting 
 Bronchoscopic 
intrabullous 
blood 
instillation 
Instilled blood induces an 
inflammatory response leading to 
scarring and contraction of giant 
bulla. 
Giant bulla No effect. Blood in the airways post procedure 
may increase the risk of infection. 
Single arm unblinded n=5 
(88) 
Safety and feasibility trial 
recruiting 
Airway bypass 
techniques 
Exhale® airway 
bypass drug 
eluting stents 
Airway stents between 
emphysematous lung parenchyma 
and large airways offer a low 
resistance path for trapped air to 
escape. 
Homogenous disease Enhances effect – 
pathological 
connections between 
lobes allow trapped gas 
to escape form a wider 
area of 
emphysematous lung. 
Maintaining stent patency is a major 
difficulty 
Single arm unblinded n=36 
(89) 
RCT n=315  (90) 
Nil 
 Percutaneous 
transpleural 
airway bypass 
(‘spiracles’) 
The pneumonostomy tube 
provides an alternate route for 
gas trapped in the 
emphysematous lung to escape. 
Homogenous disease Enhances effect – 
pathological 
connections between 
lobes allow trapped gas 
to escape form a wider 
area of 
emphysematous lung. 
A permanent pneumostoma and the 
need to change the pneumonostomy 
tube on a daily basis may deter 
patients. 
Spontaneous closure of 
pneumostoma. 
Single arm unblinded n=6 
(91) 
Nil 
Devices leading 
to mechanical 
compression  
RePneu Coil®  
lung volume 
reduction 
The coils internally compress 
treated segments of lung, and may 
increase lung recoil reducing gas 
trapping and preventing dynamic 
hyperinflation. 
Heterogeneous and 
homogeneous, 
RV>200% predicted, 
no bullous destruction 
No effect. Many coils are no longer visible in the 
airways once released making the 
procedure irreversible. May preclude 
future LVRS. 
Single arm unblinded  
n=11,16 (92, 93);  
RCT n=45 (94) 
Pivotal trial recruiting 
RCT = Randomised controlled trial; LVRS = lung volume reduction surgery 
1.3.8.3.2 Bronchoscopic lung volume reduction 
Table 1.2 summarises the bronchoscopic approaches, the most recent supporting evidence, and 
their ongoing study. It is worth noting that these approaches are generally in the early phases of 
development and the various trials have not adopted as strict a measure of optimisation of 
medical care (pharmacological non-pharmacological including pulmonary rehabilitation) prior 
to patient enrolment or in control arms as did the NETT trial and other randomised controlled 
trials of LVRS.  
Endobronchial valves 
This approach, the most widely studied non-surgical approach to lung volume reduction, 
involves placing unidirectional valves into segmental airways allowing gas to escape but not re-
enter the worst affected lobe of the lung, with the aim of causing lobar collapse and atelectasis. 
The mechanisms of benefit resemble those of LVRS; improved ventilation and perfusion of 
previously crowded healthier lung parenchyma, re-tensioning of the small airways, and a return 
to the FRC reducing the work of breathing with improved respiratory mechanics. A valve is 
needed to allow air to leave the target segment as simple blockers have the risk of acting as 
valves in the wrong direction leading to acute localised hyperinflation.(95) Valves are deployed 
bronchoscopically and this can be done using moderate sedation or general anaesthesia. Early 
clinical experience showed that patients with significant lung volume reduction following valve 
placement had improvements in exercise capacity (96) and reduced dynamic 
hyperinflation.(97)  
For this approach to be successful, complete occlusion and isolation of the target lobe is 
required. Damage to the interlobar fissures allows air to bypass the valves and enter via the 
adjacent lobe preventing atelectasis. Similarly, imprecise placement of the valves or unusual 
airway anatomy can prevent formation of a tight seal between the valve base and the airways. 
Improvement in lung function may occur in the absence of radiological volume reduction, 
perhaps by the diversion of airflow to healthier lung, but benefits are greatest where atelectasis 
occurs.  Follow up of patients from an early Brompton case series of 19 patients treated using a 
first generation airway valve suggests that successful lung volume reduction with radiological 
atelectasis is associated with a survival advantage; 0/5 deaths at six years in patients who 
developed atelectasis compared to 8/14 deaths where atelectasis had not occurred 
(p<0.02).(98) 
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Lobar volume reduction is associated with a risk of pneumothorax which may be due to air leak 
(typically secondary to damage to the overstretched untreated lobe which expands fill the 
thoracic cavity), or occur ex vacuo as the target area of lung collapses. These may resolve 
spontaneously or require intercostal drainage. 
There are two Conformité Européenne (CE) marked valves commercially available in Europe; the 
Zephyr® valve and the Spiration® (Intrabronchial Valve (IBV)). Neither is approved by the USA 
Food and Drug administration.   The Zephyr valve, manufactured initially by Emphasys Medical 
(Redwood City, CA) and now by Pulmonx Inc. (Palo Alto, Calif., USA), is made of a nitinol frame 
structure with a silicone cover and a central duckbill-type valve (Figure 1.2). In the 
Endobronchial Valves for Emphysema PalliatioN Trial (VENT) trial (82) 321 patients with 
heterogeneous emphysema were randomly assigned to receive either endobronchial valves or 
standard medical care. At six months there was a statistically significant but not clinically 
meaningful benefit in FEV1 and the 6MWD.  This occurred at the expense of a small increase in 
COPD exacerbations (7.9%) and minor haemoptysis (5.2%).  There were nine pneumothoraces 
(3 unresolved after 7 days), occurring in a significant proportion of the small number of patients 
who developed atelectasis (9 of 37, or 24%). However the officially quoted and misleading 
pneumothorax rate from this study is 4.5% for all treated patients. Higher emphysema 
heterogeneity was associated with a better response, and in patients where lobar exclusion was 
accomplished (intact interlobar fissures and correct valve placement confirmed on CT), there 
were much larger improvements in lung function (∆FEV1 +23%, ∆RV -57%). As mentioned 
above, this was the case in only 37 of the 214 patients in the endobronchial valve treatment 
arm. Prospective trials are needed to establish if this subgroup of responders (heterogeneous 
disease without collateral ventilation) can be accurately identified prospectively, and 
randomised controlled trials are being conducted at present.  
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Figure 1.2: Zephyr® valve – duckbill valve open during expiration. 
CT fissure integrity is currently, and somewhat arbitrarily, defined as fissures >90% complete in 
at least one axis. An endobronchial catheter-based device (Chartis® System, Pulmonx, Inc., Palo 
Alto, Calif., USA) has been developed for measuring collateral ventilation (Figure 1.3). 
Gomplemann et al. reported positive and negative predictive values of 71% and 83% 
respectively for treatment response.  The overall accuracy of the test was 75%.(99) This may 
prove useful for target lobe selection however the additional benefit over accurate fissure 
analysis on cross sectional imaging, especially with the development of 3-dimensional software 
specifically designed to assess fissure integrity, is unclear and may not justify the high 
additional expense. 
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Figure 1.3: Chartis assessment. Outcomes from a lobe with (a) no collateral ventilation, and (b) one 
which is collateral ventilation positive. Expiratory flow (orange) gradually reduces in collateral 
ventilation negative lobes or is stable if collateral ventilation is present, whilst inspiratory pressure (blue) 
is maintained. 
The IBV (Spiration Inc., Redmond, WA – now Olympus) is an umbrella shaped device which 
when expanded allows air and secretions to exit around the periphery of the valve (Figure 1.4). 
A central proximal rod can be grasped to collapse the umbrella and facilitate removal. In a 
multicentre pilot trial of 91 patients with severe heterogeneous emphysema, a mean of 6.7 
valves were inserted per patient resulting in nine pneumothoraces and one fatality. Although 
quality of life and CT measured lobar volumes improved in this unblinded study, lung function 
did not.(84) This is probably because a non-lobar occlusion approach was adopted; the 
investigators elected to leave one segment of the right upper lobe and one segment of the lingua 
unoccluded in order to minimise the risk of pneumothorax. Eberhardt et al. later directly 
compared a unilateral occlusive strategy against a bilateral non-occlusive strategy,(100) and a 
greater improvement was seen in the unilateral complete occlusion group confirming our 
understanding regarding complete lobar isolation as a predictor of success for endobronchial 
valves.  
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Figure 1.4: Spiration® Valve 
Polymeric (biological) lung volume reduction  
Biological lung volume reduction aims to reduce lung volume through tissue remodelling, by 
inducing an intense inflammatory reaction which leads to scarring and shrinkage of the treated 
lung segments. Benefits are not experienced for several weeks and the mechanism of action is 
independent of the presence of collateral ventilation.(101) Polymeric lung volume reduction 
(PLVR) (Aeriseal®, Aeris Therapeutics, Inc.; Woburn, MA) involves bronchoscopic deployment 
of a biodegradable gel into subsegmental bronchi. The solution, which contains aminated 
polyvinyl alcohol and buffered cross-linker creates a hydrogel foam when delivered to the distal 
airways. As gas within the foam (which fills damaged alveoli) is absorbed, the foam which is 
now adherent to the alveolar tissue collapses and as it does so reduces lung volume and 
hyperinflation. An open-label multi-centre exploratory phase II clinical study with PLVR 
hydrogel administered to eight subsegmental sites in 25 patients with upper lobe emphysema 
showed improvements in lung function and functional parameters, which persisted at 6 months 
(∆FEV1 +10%, ∆RV/TLC ratio -7.4%, ∆mMRC -1.0points, ∆6MWD +28.7m, ∆SGRQ 9.9 
points).(102) The safety profile was acceptable in this study but almost all patients experienced 
an intense flu-like inflammatory reaction, leading to some severe COPD exacerbations. The 
Aeriseal® is now CE marked and a multicentre pivotal randomised controlled trial is currently 
underway.  
Bronchoscopic thermal vapour ablation (“steam”) 
The bronchoscopic thermal vapour ablation (BTVA) system (Uptake Medical, Seattle, Wash., 
USA) delivers heated water vapour bronchoscopically via a dedicated catheter into the targeted 
emphysematous lung segments and like  biological LVR aims to induce scarring and shrinkage 
by means of acute tissue injury which is followed by scarring and fibrosis, leading to lung 
volume reduction. The dose of thermal energy to achieve 10 calories/g lung tissues is calculated 
Zaid Zoumot 
CID: 00541359      
 45 
 
from a pre-procedure CT assessment of lung density, with procedures to treat a single lobe 
lasting approximately 30 minutes. The pooled results of two single arm open label studies (87) 
comprising 44 patients showed a 716ml (48%) reduction in CT-measured volume of the target 
lobe, accompanies by improvements in FEV1 (∆+17%), SGRQ (∆-14 points), mMRC (∆-0.9) and 6 
minute walk distance (∆+46.5m). Twenty nine serious adverse events were recorded of which 
the majority were COPD exacerbations or infections attributed to the inflammatory reaction, 
including one death.  
Lung volume reduction coils 
The RePneu© coil (PneumRx Inc., Mountain View, Calif., USA) is an implantable coil-like device 
composed of Nitinol, a super-elastic memory shape alloy.  The self-actuating implant is 
delivered bronchoscopically under fluoroscopic guidance into the targeted airways and when its 
sheath is removed recoils to its original pre-determined shape (resembling a baseball seam) 
(Figure 1.5). The intended physiological benefit of the coil implant is to compress 
emphysematous lung thereby reducing lung volume with the resultant improvement in lung 
ventilation mechanics. The coils increases lung tension and elastic recoil which may prevent 
expiratory airway collapse. This reduces static gas trapping and probably dynamic 
hyperinflation as well. Two small pilot studies in predominantly heterogeneous disease 
demonstrated safety of coil insertion procedures with substantial improvements in 
physiological and clinical outcomes.(103, 104) Safety data after >1350 coils have been 
implanted in 164 patients has shown no deaths, no device migration or expectoration, six 
pneumothoraces (resolved quickly with intercostal chest drain insertion) and nine pneumonias 
in eight patients (which did not require prolonged hospital stay).(unpublished data from 
PneumRx) 
This technique underwent further study at our institution as part of this thesis and is discussed 
in more detail in chapter 3. 
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Figure 1.5: RePneu© lung volume reduction coil 
Bronchoscopic instillation of autologous blood for lung volume reduction 
The various bronchoscopic lung volume reduction techniques discussed here have in common 
major limitations in that they are very expensive and are likely to have limited availability, 
costing many thousands of pounds per procedure. They require the deposition of implants in 
the airways or the use of biological gels and sclerosants, which involve leaving foreign material 
risking infection, migration and device failure. Furthermore, the inclusion criteria are very 
specific limiting the suitability of these procedures to small subgroups of patients with 
emphysema. A Japanese group proposed the use of small volumes of autologous blood (2-5 mls) 
mixed with thrombin to achieve volume reduction, and in a case report they showed significant 
reductions in static lung volumes and dyspnoea in a 59 year old man with right upper lobe 
emphysema after infusion of blood and fibrinogen into a large bulla,(105) and a further open 
label series of 12 patients receiving this treatment had improvements in lung function, with no 
significant complications (unpublished data by Soichiro Kanoh, presented at the World 
Bronchology Conference, Tokyo 2008). This technique uses no foreign implants, and should 
represent dramatic cost savings. It has the potential of being performed at any bronchoscopy 
suite by any competent bronchoscopist. Unlike endobronchial valves, its success should be 
unaffected by the presence of collateral ventilation. If effective, it can theoretically be offered to 
patients with a wide variety of patterns of emphysema, including bullous disease, and not only 
restricted to heterogeneous upper lobe disease. This approach is examined in this thesis and 
will be discussed in more detail in chapter 4. 
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Artificial airway bypass tracts 
A different approach to reduce gas trapping is creating artificial, extra-anatomical, low 
resistance airways which allow trapped gas to escape. In contrast to endobronchial valves, 
collateral ventilation is advantageous in this approach. To date, two techniques have been 
studied : Airway Bypass Stents and transpleural pneumonostomy.   
Exhale® Airway Bypass drug eluting stents (Broncus Inc.; Mountain View, CA) are placed 
bronchoscopically through cartilaginous airways into emphysematous lung parenchyma, and 
serve as conduits which allow trapped gas to escape reducing both static and dynamic 
hyperinflation (Figure 1.6). CT mapping is used to target the areas with the most severe 
emphysema and a Doppler probe to avoid airway wall blood vessels. Initial pilot data in patients 
with homogenous emphysema showed encouraging benefits in physiological and functional 
parameters persisting up to 6 months post treatment.(89) However, results from a double-blind 
multicentre sham-controlled pivotal trial of 315 patients was disappointing.(90)  Significant 
reductions in lung volumes were seen immediately post procedure but these did not persist. 
Two hundred and twelve patients with severe homogeneous emphysema and severe gas 
trapping were randomised to receive up to six Exhale stents implanted bronchoscopically, and 
107 to sham bronchoscopy. On day 1 following the procedure, between group differences in the 
reduction in residual volume of 26% (p = 0.017) and an improvement in the FVC of 27% 
(p<0.001) were seen. Significant differences were also seen in CT-measured lobar volumes and 
FEV1.  Unfortunately, these benefits were not maintained, with lung function measures and CT-
measured lobar volumes returning to baseline by 3 months following treatment. This was 
primarily a result of bypass airway occlusion by stent granulation tissue or mucus, or stent 
expectoration. Although this study served as a proof of concept of transbronchial airway bypass, 
the problem of stent occlusion will need to be addressed before further attempts to implement 
it are made. Sirolomus as an alternative to Paclitaxel and increasing stent diameter form 
possible options though these will probably be accompanied by an increase in adverse events.  
A similar bypass physiologic approach but an alternative to the transbronchial one is creating a 
transpleural pneumonostomy (an airway bypass directly between the lung and the atmosphere 
through the chest wall). This is achieved through a minimally-invasive transthoracic surgical 
approach in a procedure that takes approximately 1 hour to complete. This is similar to an 
intrabullous drainage procedure (the Brompton/Monaldi technique (106)) but with a 
permanent tract being fashioned to allow a pathway for air to escape. The PortAero 
Pneumostoma System (PortAero Inc., CA) was developed and the patient is required to change 
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the PortAero tube daily to maintain tube patency. A pilot study was undertaken in six patients, 
and in the four patients who retained the bypass tube for 3 months or more, there was a 23% 
increase in FEV1.(91)  Refinement of the technique and tube system is underway to attempt 
prevention of tract closure and tube blockage.  
 
Figure 1.6: Exhale® stent with view through stent into emphysematous lung parenchyma. 
 
Figure 1.7: PortAero “spiracles”. A patient self-replacing his pneumonostomy tube. 
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1.4  OPTOELECTRONIC PLETHYSMOGRAPHY 
Optoelectronic plethysmography (OEP) is a system for indirectly measuring lung volumes based 
on an automatic motion analyser which detects the positions of 89 passive markers composed 
of a thin film of retro-reflective paper on plastic hemispheres (5-10mm diameter). The markers 
are placed on the skin using bioadhesive hypoallergenic tape. Six-eight infrared detection 
cameras surrounding the patient record non-invasively real-time breath-by-breath images of 
the markers and their movement (see Figure 1.8). Dedicated software uses the data received 
from the infrared cameras to compute 3-dimensional (3D) co-ordinates of the markers by 
stereo-photogrammetric techniques. The individual markers correlate to specific points on the 
chest wall, allowing for movements of the whole chest wall or any specific component of the 
chest wall to be accurately measured. It is a non-invasive and non-ionizing method that does not 
make assumptions regarding the number of degrees of freedom of the chest wall, does not 
require a mouthpiece, nose clip or any similar device, and its calibration does not require 
respiratory manoeuvres by a biological control. By combining chest wall volume changes with 
preliminary measurements of VC and FRC, it is possible to accurately determine absolute lung 
volumes at any point during the breathing cycle.(107, 108) These measurements also allow 
accurate measurement of not only total lung volumes, but also partial thoracic volumes. The 
standardised subdivisions of chest wall movements using OEP are upper rib cage, lower rib cage 
and abdomen. The lower ribcage movements have been shown to be a good estimate of 
diaphragmatic movement.(109) 
 
1.4.1  HISTORY OF OEP 
The technique of performing spirometry to measure dynamic lung volumes using a  
pneumotacograph, although a well known and generally reliable one, can in itself alter natural 
breathing frequency, TV, dead space ventilation and breath awareness. Hence breathing 
patterns during testing may not be representative of the subject’s natural state.(110) 
Furthermore, results may be affected by humidity and temperature variations. Spirometry 
requires the subject to be fully cooperative, be able to follow commands, achieve a tight seal 
around a mouthpiece, and be in a seated upright position. The pneumotacograph needs to be 
calibrated before each test. In an attempt to address these problems, alternative methods of 
measuring lung function have been sought. Konno and Mead first attempted estimating changes 
in lung volumes using crude direct writing recorders to plot x–y axis coordinates of the thoracic 
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dimensions.(111)  More accurate techniques of motion analysis to measure lung volumes were 
subsequently developed, such as a system which employed a linear magnetometer to estimate 
tidal volumes by using tuned coils placed on the anterior and posterior thorax to measure the 
cross-sectional area of the rib cage and abdomen. The next step was to develop a system which 
allowed differentiation between the lower and upper ribcage volumes, and Ferrigno and 
Pedotti’s “Elaboratore di immagini televisive” motion analysis system (ELITE System; BTS, Milan, 
Italy) was developed in 1985 and used a digitised video system and automatic motion analyser 
to identify objects of predetermined shape (such as the person’s chest) and monitor its 
trajectory in 3D and real time.(112) Using an algorithm originally developed to measure 
movements of the joints and limbs, calculations of the movements of the pulmonary ribcage, 
abdominal ribcage and abdomen were possible but the error was unacceptably high (±21·3%) 
compared with traditional spirometry. Rather than using circumferential geometry, Cala and 
colleagues (108) used traditional cubic geometry of 86 markers and this improved accuracy of 
measurement of the chest wall  and decreased the error to <3·5%. This refinement of the ELITE 
technology was patented as the optoelectronic plethysmography system, or OEP (BTS 
Bioengineering, Milan, Italy). The latest technology uses 89 markers (seven horizontal lines, five 
vertical lines, two mid-axillary lines, and seven extra markers) arranged in anatomical 
structures between the sternal notch and the level of the superior iliac crest, being 37 anterior 
markers, 42 posterior and 10 lateral (figure 1.9), with up to eight infrared cameras improving 
accuracy even further. The boundary between the pulmonary rib cage and the abdominal rib 
cage is at the level of the xiphoid process, and between the abdominal rib cage and abdomen 
along the costal margins anteriorly and at the lowest point of the costal inferior margin 
posteriorly. The midline markers over the sternum and vertebral processes delineate left from 
right.  
 
Figure 1.8: Optoelectronic plethysmography - principles of measurement. (BTS handbook 2011) 
Compartmental chest wall 
movements and volume 
changes  
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Figure 1.9: OEP Eighty nine marker configuration setup.   
 
The OEP system at the Royal Brompton Hospital uses eight cameras which allow real time 3D 
determination of the coordinates of each marker, and visualisation of the geometric model being 
analysed. The cameras operate at 30-60 Hz and are synchronized with axial diodes that emit 
infrared light. Infrared beams are emitted by each camera and the reflection back from each 
marker is captured and transferred to a parallel processor, which calculates 2D coordinates of 
all markers “viewed” by at least two camera, before calculating the 3D coordinates of the 
different markers by sterophotogrammetry (3D geometric information is extracted from the 
combination of at least two 2D images obtained by two cameras at the same moment of time 
from two different positions). After the 3D coordinates of each marker are obtained, the volume 
of the chest wall is calculated through the connection of points to constitute a net of tetrahedral 
triangles. Gauss’ theorem is then used to calculate the internal volume of each shape and the 
total chest wall volume being the sum of these volumes.  
  
1.4.2  VALIDATION 
Cala et al. demonstrated that OEP lung volume measurements correlate strongly with 
pneumotachographic values during both quiet breathing and slow vital capacity 
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manoeuvres.(108) There is no literature on correlation between OEP and forced expiratory 
manoeuvres as there is a discrepancy, with blood shift and gas compression the likely culprits.  
OEP lung volume measurements were validated in ventilated patients in intensive care,(113) in 
subjects in the supine and prone positions, (114) in newborns,(115)  and in group of COPD 
patients.(116) In the latter study, OEP was also validated for use during cycle ergometry in 
COPD patients of both sexes. In terms of repeatability, there was <10% variability in lung 
volume measurements after repeated exercise of 9 healthy subjects.(117) 
 
1.4.3  APPLICATIONS OF OEP 
At present, OEP is used predominantly in the research setting. In the future it may have broad 
applicability to patient populations such as very young children, patients with neuromuscular 
disease and patients who cannot be tested with classical pneumotachographic testing, as it does 
not require breathing into a mouth piece and is less reliant on compliance and forced 
manoeuvres. It can obtain accurate measurements over the whole breathing cycle, and over 
extended periods of time. It may have applications in assessing response to medical and non-
medical therapies, an area under investigation in this thesis. 
Vogziatzis et al. have demonstrated that OEP can reliably detect exercise induced dynamic 
hyperinflation in patients with COPD.(116) The same group evaluated dynamic lung 
hyperinflation during incremental cycle ergometry in a later study,(118) with two phenotypic 
patterns found: ‘early hyperinflators’ demonstrated progressive increases in end-expiratory 
lung volume at the onset of exercise; and ‘late hyperinflators’ showed increases in end-
expiratory lung volumes in the last third of exercise. Both groups achieved the same peak work 
rate despite a significantly greater end-expiratory lung volume in the “early hyperinflators”. A 
subsequent study found that lower ribcage paradox (diaphragmatic paradoxical breathing) at 
rest is associated with early-onset hyperinflation, and in this group dyspnoea is the main factor 
limiting exercise, whereas leg fatigue becomes a more important symptom limiting exercise in 
COPD patients without diaphragmatic paradox.(119) OEP has also been used to study the effects 
of pulmonary rehabilitation in patients who had lung upper lobectomies. Tidal volumes 
improved by 32% in the non-operated lung following pulmonary rehabilitation, significantly 
compensating for the lost tidal volumes of the resected contralateral lobe.  
Zaid Zoumot 
CID: 00541359      
 53 
 
In the context of emphysema and lung volume reduction, the ability to divide lung volumes into 
six different compartments offers the potential of detailed information on the effects of LVR in 
terms of changes in airways obstruction, ventilation volume shifts, changes in dynamic 
hyperinflation, diaphragm dysfunction and asynchronous respiration. Breath by breath data, 
which can be obtained at rest as well as during exercise, may allow a better understanding of 
the physiology and mechanics of lung ventilation in response to LVR, the focus of study in 
Chapter 5. 
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Chapter 2 
Methods 
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2.1  ETHICAL APPROVAL OVERVIEW 
The Ethics Committee of the Royal Brompton and Harefield NHS Trust approved the LVR coil 
study and autologous blood LVR study. The London-Westminster Research Ethics Committee 
approved the OEP LVR study. All subjects who participated in trials reported in this thesis 
provided written informed consent. 
 
2.2  STATISTICAL ANALYSIS 
Statistical analyses will be discussed in the appropriate chapters. 
 
2.3 STATIC AND DYNAMIC LUNG VOLUMES AND GAS 
TRANSFER MEASUREMENTS 
The clinical physiologists at the Royal Brompton Hospital lung function department performed 
all testing using the Compact Master Lab system (Jaeger, Germany). This ensured that the strict 
quality control measures adopted by this department of specialist physiologists applied to the 
results presented in this thesis. The European Coal and Steel Workers cohort was used to obtain 
standardised reference values.(120)  
 
2.3.1  CALIBRATION 
Calibration was performed on all pneumotachographs prior to every patient test using a 3.0 
litre calibration syringe. The plethysmographs underwent automatic calibration twice daily, and 
a biological control was also used to test the equipment daily. The “body box” was also tested on 
a daily basis using a biological control.  The gas analysers used to measure gas transfer were 
calibrated four times a day using a standard helium (He) calibration gas, and the 
pneumotachograph was calibrated using a 3.0 litre syringe prior to testing each patient.  
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2.3.2  TECHNIQUE 
Spirometry was performed by placing a mouthpiece in the participant’s mouth whilst in the 
sitting position, and applying a nose clip. The participant was then instructed to take a full 
breath in to TLC, and then exhale as hard and as fast as they possibly can until they reach the 
RV. At this point they were instructed to inhale as hard and as fast as possible until they are 
back to TLC. For bronchodilator reversibility testing, 400 mcg of salbutamol from a metered 
dose inhaler was administered using a spacer device after the first set of spirometry testing, 
which was repeated 15 minutes after the administration of salbutamol.   
For static lung volumes, the patient was seated in the sealed body box with a nose clip applied 
and asked to breathe quietly for several breaths into a mouthpiece. The shutter was then closed 
at the tidal volume (TV) end-expiratory position (i.e., FRC), and the patient asked to pant. The 
gas volume trapped in the lungs was then calculated by applying Boyle’s law; Intrathoracic gas 
volume (ITGV) at FRC being alveolar pressure multiplied by the change in the body box gas 
volume when panting, divided by the change in alveolar pressure (measured at the mouth) 
when panting against a closed shutter. 
Gas transfer was measured using a single breath technique. The inspiratory and expiratory 
carbon monoxide (CO) concentrations were used to calculate the total lung CO uptake. Several 
measurements were performed to confirm that results were reproducible. TLCO was corrected 
(TLCOc) to serum haemoglobin concentrations of 14.6 g/dl for adult males and 13.5 g/dl for 
adult females, using haemoglobin levels measured from capillary blood testing.   
 
Figure 2.1: Lung volume compartments and subdivisions based on volume-time spirogram. Adapted 
from Forster RE et al. 1986.(121) (Publisher does not require permissions to re-use) 
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2.4  ARTERIAL BLOOD GASES 
Arterial blood gas (ABG) analyses were performed by clinical physiologists at the at the Royal 
Brompton Hospital lung function department using end capillary blood samples from the 
participants’ earlobe.  Analysis for pH, and partial pressures of O2 and CO2 were performed 
using the Rapidlab 348 analyser (Bayer, Germany).  
 
2.5 HIGH RESOLUTION COMPUTED TOMOGRAPHY OF THE CHEST  
High resolution Computed Tomography (HRCT) scanning was performed using a Siemens 
Sensation 64 (a 32 detector scanner with a rotation time of 0.33 seconds). Non-contrast 
volumetric spiral acquisition with contiguous slices was taken with the participant in the supine 
position at full inspiration.  Slices were reconstituted at 1mm slice thickness on 1mm for lung 
windows and 10mm on 10mm mediastinal windows for all patients studied as part of all studies 
in this trial. HRCTs of participants involved in the LVR coil trial also had images reconstituted as 
6mm on 3mm for lung windows to allow optimal density assessments using dedicated software 
(discussed in more detail in chapter 3). 
 
2.6   HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRES 
2.6.1  ST. GEORGE’S RESPIRATORY QUESTIONNAIRE 
The St. George’s Respiratory Questionnaire (122) is a 76-item health status survey specific for 
respiratory disease. It is designed to measure impact of the disease on overall health, daily life, 
and perceived well-being. It has been in existence for over 20 years, and there is a large body of 
evidence concerning its validity. A four point change in the score has been consistently found to 
correlate with a clinically significant change.(123) The participants self-completed the 
questionnaires taking the previous four weeks in consideration. A researcher was available to 
clarify any questions which the participants might have. Questionnaire answers were entered 
into a dedicated Excel calculator which provided total, impact, activity, and symptom SGRQ 
scores. 
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2.6.2  MRC DYSPNOEA SCALE 
The Medical Research Council (MRC) breathlessness scale comprises five statements that 
describe almost the entire range of respiratory disability from none (Grade 1) to almost 
complete incapacity (Grade 5). It was devised by Fletcher and co-workers whilst studying the 
respiratory difficulties of Welsh coal miners at the Pneumoconiosis Unit in the 1940s and 1950s. 
It has been used extensively for over 50 years, and correlates with activity levels and prognosis.  
The “modified MRC scale” (mMRC) version of this breathlessness scale, with gradings from 0-4, 
was used in the studies reported in this thesis (Table 2.1). 
Table 2.1: The modified Medical Research Council (mMRC) dyspnoea scale. 
mMRC Statement 
0 I only get breathless with strenuous activity 
1 I get breathless when hurrying on the level or up a slight hill 
2 I walk slower than other people of the same age on the level because of 
breathlessness or have to stop for breath when walking at my own pace 
on the level 
3 I stop for breath after walking 100 metres or after a few minutes on the 
level 
4 I am too breathless to leave the house 
 
2.7  EXERCISE TESTING 
 
2.7.1  6 MINUTE WALKING DISTANCE 
The 6 minute walking distance (6MWD) is a well validated test of exercise capacity in patients 
with COPD, and is commonly used both in clinical practice and in research. In one study of 112 
patients with stable severe COPD,(124) the mean smallest difference in 6MWD that was 
associated with a noticeable clinical difference in the patients' perception of exercise 
performance was 54m (95% confidence interval, 37–71m). Therefore an improvement of more 
than 70m in the 6MWD after an intervention is necessary to be 95% confident that the 
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improvement was significant. However many patients with COPD may only manage relatively 
short walking distances and in these circumstances a 10 % change in the 6MWD has been 
suggested to be of clinical significance.(125) More recent studies investigating the MCID for the 
6MWD in larger COPD populations suggest lower distances than Redelmeier’s et al.’s study; 26 
metres in Puhan’s study of the NETT trial cohort and response to lung volume reduction surgery 
(1218 patients) using quality of life measures as the anchor ,(126) and 30 metres in Polkey et 
al.’s study of 2112 patients from the Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate Endpoints (ECLIPSE) study cohort where an MCID for change in 6MWD was assessed 
as a function of death.(127) 
The ATS criteria (128) for measuring the 6MWD were strictly adhered to in all studies reported 
in this thesis. All tests were performed in the same 30 metre long corridor at the Royal 
Brompton Hospital. The participant was seated for 10 minutes at the start line before the start 
of the test. Blood pressure, heart rate, oxygen saturations and Borg scores (see below) for 
breathlessness and fatigue were taken. The following instructions were given to the participant:  
“The object of this test is to walk as far as possible for 6 minutes. You will walk back and forth in 
this hallway. Six minutes is a long time to walk, so you will be exerting yourself. You will probably 
get out of breath or become exhausted. You are permitted to slow down, to stop, and to rest as 
necessary. You may lean against the wall while resting, but resume walking as soon as you are able.  
You will be walking back and forth around the cones. You should pivot briskly around the cones 
and continue back the other way without hesitation. Now I'm going to show you. Please watch the 
way I turn without hesitation."   Demonstrated.  
"Are you ready to do that? I am going to use this counter to keep track of the number of laps you 
complete. I will click it each time you turn around at this starting line. Remember that the object is 
to walk AS FAR AS POSSIBLE for 6 minutes, but don't run or jog.  
Start now or whenever you are ready." (128) 
The timer was started when the patient started walking. Standardised phrases of 
encouragement were given to the patient as per the ATS guidelines(128). The number of laps 
and partial laps was documented, as well as the number of stops. At the end of the 6 minutes, 
the participant was instructed to stop and a chair was wheeled to the patient. The walking 
distance was recorded, as well as the post-walk Borg dyspnoea and fatigue scores, blood 
pressure, and pulse rate and oxygen saturations.   
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2.7.2  CYCLE ERGOMETRY 
Cycle ergometry was performed as part of the OEP study in chapter 5, simultaneously with OEP 
recordings. The reflective markers were positioned on the patient’s torso before patients 
mounted the bicycle and the seat and arm rest heights adjusted. Standard positioning of the 12 
lead ECG monitoring pads interfered with OEP marker tracking, and therefore if there was no 
evidence of inducible coronary ischaemia on maximal incremental cycle ergometry testing, the 
leads were positioned on the periphery of the OEP markers around the lower abdomen, 
maintaining accurate monitoring of pulse rate only, for the steady state submaximal cycle 
ergometry test. Cycle ergometry was otherwise unaffected by the OEP equipment and 
recordings. I performed all but two cycle ergometry tests with in conjunction with a respiratory 
physiologist. 
Cycle ergometry was preferred to treadmill testing in my study as reduced walking capacity is 
associated with an excessively high ventilatory demand in COPD. Cycle ergometry is associated 
with a more efficient pattern of breathing in patients with COPD compared to treadmill 
walking.(129) Subjects wore a nose clip and breathed through a mouthpiece for the duration of 
their cycle ergometer test. A magnetically braked cycle ergometer was used (Jaeger Ergoline 
800). Continuous monitoring of oxygen saturations and cardiac pulse via a 12-lead ECG trace 
were performed throughout testing. Breath-by-breath respiratory analysis was performed using 
a metabolic analysis system (Oxycon device, Jaeger Systems, Germany). Continual sampling of 
inspired and expired oxygen concentrations enabled calculation of oxygen uptake. Carbon 
Dioxide output was measured using an infrared CO2 analyser. A turbine spirometer within the 
mouthpiece measured breath-by- breath TVs and minute ventilation (VE). The data from every 
eight breaths were averaged and data recorded. Minute-by-minute Borg scores of 
breathlessness and fatigue were recorded by asking the patient to point at the Borg scales 
during exercise. 
During exercise, resistance was adjusted to maintain the required workload with the patient 
encouraged to maintain peddling at 60 revolutions per minute (RPM). Patients’ maximum 
oxygen utilisation (VO2max) and minute ventilation (VEmax) were determined by measured 
data from the last 30 seconds of every minute.  
Prior to each exercise test automated gas and volume calibrations were performed and 
adjustments made for barometric pressures, humidity and room temperature. Weekly 
calibration of parameters was performed using biological controls. 
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2.7.2.1 Incremental cycle ergometry test 
Five minutes of rest were recorded before subjects started to cycle. IC manoeuvres were 
performed with the patient sat on the cycle ergometer every minute throughout the test. Initial 
workload was set to 0 watts for 1 minute of cycling, and then increased by 5 Watts every 
minute. The participants cycled until they were no longer able to maintain peddling at 60rpm 
due to exhaustion. This was followed by 3 minutes of recovery. The reason for cessation of 
exercise was recorded. Borg scores for exertion and dyspnoea were recorded every minute. 
Standardised encouragement was given equally to all participants to ensure that subjects gave 
their best performance. The incremental cycle test was used to determine subjects’ maximum 
workload. The incremental test was only performed on the first baseline visit. 
2.7.2.2 Steady state submaximal cycle ergometry test 
A minimum of two hours of rest after the incremental test was stipulated before the participant 
started the endurance test. Five minutes of rest were followed by 1 minute of unloaded cycling 
and then a constant workload set to 75% of the maximum workload achieved for at least 30 
seconds during the incremental cycle test was applied.  IC measurements were taken with the 
patient sat on the cycle ergometer every minute throughout the test. The subject cycled until 
exhaustion and this is followed by 3 minutes of rest. The cycling time and reason of cessation 
were recorded. Minute by minute Borg scores were obtained throughout the test.  
 
2.7.3   BORG SCORE 
The Borg scoring systems were developed to allow subjects to rate dyspnoea and perceived 
exertion, and have been validated as being reliable and reproducible.(130) When asked, 
subjects pointed to charts (Table 2.2) to indicate their level of symptoms. In studies performed 
as part of this thesis, scores were obtained before and immediately after the 6MWD and every 
minute during exercise testing. 
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Table 2.2: Borg’s rating of perceived exertion 
 Borg’s scale of breathlessness 
0 No breathlessness at all 
0.5 Just noticeable 
1 Very slight 
2 Slight 
3 Moderate 
4 Somewhat severe 
5 Severe 
6  
7 Very severe 
8  
9 Very very severe 
10 Maximal 
 
 Borg’s rating of perceived exertion 
6 No exertion at all 
7 Extremely light 
8  
9 Very light 
10  
11 Light 
12  
13 Somewhat hard 
14  
15 Hard 
16  
17 Very hard 
18  
19 Extremely hard 
20 Maximum exertion 
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2.8 OPTOELECTRONIC PLETHYSMOGRAPHY 
Before the start of the cycle ergometry tests, 89 reflective markers were carefully positioned on 
the subject’s torso in a grid following a specific protocol (BTS biomedical engineering 
handbook) (Figure 1.9). This was done using two-sided hypoallergenic circular adhesive tape. 
Details of reflective marker and infrared camera positioning, OEP system calibration, patient 
testing and data analysis is discussed in depth in section 5.2 of this thesis. 
Once the OEP setup was complete and a geometric model obtained, two sets of recordings were 
made: (1) Three forced expiratory manoeuvres (as described in section 2.3.2) with 
simultaneous recordings of pneumotachographic values with via a mouthpiece whilst in the 
sitting position and with nose clip applied; (2) Steady state submaximal cycle ergometry test as 
detailed above (section 2.7.2).   
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Chapter 3 
Lung Volume Reduction Coils for the treatment of 
severe emphysema: A randomised controlled trial 
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3.1  BACKGROUND 
 The RePneu© lung volume reduction coil (LVRC) (PneumRx Inc., Mountain View, Calif., USA) is 
an implantable coil-like device composed of Nitinol, a biocompatible super-elastic memory 
shape alloy.  The self-actuating implant is delivered bronchoscopically under fluoroscopic 
guidance into the targeted airways and when its sheath is removed recoils or “springs back” to 
its original pre-determined shape (figure 3.1). It was designed with the intended physiological 
benefit of replicating the effects of LVRS; to compress the most emphysematous areas of the 
lung parenchyma and hence reducing lung volume with resultant improvements in lung 
ventilation mechanics. Air flow to treated portions of lung should therefore reduce and more 
airflow diverted to healthier untreated portions (figure 3.2). Additionally, the coils increase 
elasticity and recoil to the whole lung thereby lessening expiratory small airway collapse thus 
improving expiratory flow rates and reducing compliance. Theoretically these factors should 
combine to reduce gas trapping and improve dynamic hyperinflation. Reducing the volume of 
the hyperinflated emphysematous lung improves diaphragmatic efficiency and reduces the 
work of breathing.  Unlike unidirectional endobronchial valves, the coils’ mechanism of action 
should be independent of the presence or absence of collateral ventilation, and should achieve 
immediate mechanical effect. 
The implant derives its strength from the Nitinol wire.  Originally, implants were manufactured 
in seven lengths (70 mm, 85 mm, 100 mm, 125 mm, 150 mm, 175mm and 200 mm) however 
the manufacturers have limited these to the 100, 125 and 150 mm lengths in their 2nd 
generation of products. Smaller coils were very seldom used, and early data showed no 
additional benefit in patients treated with coils longer than 150mm, with a theoretical higher 
risk of pneumothorax due to puncture of the lung by the distal end of the coil.  Ten millimetres 
of the proximal end of the implant has a smaller diameter than the rest of the coil to reduce 
rigidity, lessen the pressure of the coil in the proximal large airways, minimise airway wall 
trauma, and facilitate recapture if necessary.  The distal and proximal ends of the coil terminate 
with a smooth atraumatic ball. The distal end is designed to reside in airways with a diameter of 
approximately 2 mm.  The LVRC Delivery System is sterilised by Ethylene Oxide and the coils 
are sterilized by Electron Beam. 
Figure 3.1: 150 mm lung volume 
reduction coil (LVRC) 
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Figure 3.2: Lung Volume Reduction Coil Delivery system. (a) guide wire, (b) catheter, (c) modified 
forceps, (d) loading cartridge.  
 
The delivery system includes a guide wire, delivery catheter, cartridge and forceps (figure 3.3). 
The guide wire serves as a flexible tool which enables the identification of suitable airways for 
treatment, and ensure the tip of the LVRC is a safe distance from the pleural edge (>35mm) after 
deployment. Once the guidewire is in the desired location, the delivery catheter is passed over 
the guide wire until the distal ends align.  The Guide wire contains fluoroscopically visible 
markers which allow accurate determination of the appropriate coil length.  The guide wire is 
then removed from within the delivery catheter and forceps are used to pull the desired coil 
into the rigid straight cartridge. The cartridge is then connected to the delivery catheter and the 
coil advanced inside the catheter until the distal end reaches the distal tip of the catheter. The 
catheter is pulled back whilst maintaining the position of the coil, which is monitored 
fluoroscopically as it recoils to its predetermined shape as it is released from the straightening 
effect of the catheter. The coil can be removed or repositioned by reversing the deployment 
procedure, provided the proximal end of the coil is visible and can be grasped using the forceps. 
Pilot work informed the number of coils required per treated lung, with 10 coils achieving good 
safety and effectiveness.(103) At our institution, we perform these procedures using moderate 
sedation in the bronchoscopy suite unless there is a contraindication to do so, however most 
treatments worldwide are performed in the operating theatres under general anaesthesia. 
 
a 
d c 
b 
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Figure 3.3: Diagram of the Lung Volume Reduction Procedure Using Coils. PneumRx © 
 
Figure 3.4: Pictorial representation of the coil deployment process: (a) guide wire inserted into target 
sub-segment, (b) catheter passed over guide wire, (c) guide wire removed and replaced with straightened 
coil, (d&e) catheter retracted releasing coil which retakes its predetermined shape, (f) multiple coils 
deployed in target lobe. 
 
Two pilot studies of 11 (103) and 16 (104) patients with predominantly heterogeneous disease 
demonstrated the safety of coil insertion procedures and observed substantial improvements in 
physiological and clinical outcomes. These studies informed the design and power of a 
randomised controlled trial, which is the subject of this chapter. In addition to these early 
clinical trials, procedures have been performed commercially in three European centres and the 
manufacturer  (PneumRx Inc.) has recently released efficacy (Table 3.1) and safety (Table 3.2) 
data combining data of the 2 clinical trials along with the procedures performed commercially 
(>1350 coils implanted in 142 subjects, including 28 patients treated at our institution).  In 
terms of investigator reported serious adverse events (SAEs), there were no deaths, no episodes 
of device migration or expectoration, six pneumothoraces, and nine pneumonias in eight 
patients (which did not require prolonged hospital stay). The SAE profile of the coils was 
 
a c b 
d e f 
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comparable to the control patient population in the EASE trial (90), the largest sham procedure 
group in a similar population (all EASE trial procedures were performed under general 
anaesthesia).  Twelve month outcome and safety data from 84 patients treated with LVRCs in 
non-randomised, unblinded multicentre studies was presented in a spoken abstract 
presentation at the Chest2012 conference in Atlanta, Georgia in October 2012.(131) The cohort 
included patients with varying degrees of heterogeneity as well as homogenous disease 
distribution (details were not provided). The authors reported mean ±SD improvements in the 
6MWT of 63.04±13.79 metres, reduction in the RV of -0.61±0.13 litres, and reduction in the 
SGRQ of -12.06±2.43 points. These improvements were sustained at 12 months.  
 
Table 3.1: Combined Efficacy data at 6 months from 250 LVRC procedures in 143 subjects 
180 days post- 
baseline 
Change from baseline p-value  % Change from 
baseline 
p-value 
6MWD (m) +49.07 ± 8.26 <.0001 +19.53% ± 3.46% <.0001 
RV (L) -0.67 ± 0.09 <.0001 -12.08% ± 1.51 <.0001 
FEV1 (L) +0.13 ± 0.02 <.0001 +17.30% ± 2.81% <.0001 
SGRQ (points) -11.43 ± 1.41 <.0001   
TLC (L) -0.29 ± 0.07 <.0001 -3.33% ± 0.82% 0.0001 
RV/TLC -11.43 ± 1.41 <.0001 -19.11% ± 2.56% <.0001 
 
Table 3.2: Combined safety data at 6 months from 250 LVRC procedures in 143 subjects (unpublished 
data, with permission from PneumRx Inc.). 
Reported SAE PneumRx studies 
(up to 6 Months) 
EASE sham control 
(6 Months reported data) 
Pneumothorax 4/246 procedures = 1.6% 1/107 procedures = 1% 
Haemoptysis (>25mls) 2/246 procedures = 0.8% 0/107 procedures = 0% 
COPD exacerbation/ 
pneumonia 45/246 procedures = 18.3% 18/107 procedures = 17% 
 
The aim of our study was to investigate the safety and effectiveness of the LVRCs in patients 
with severe heterogeneous and homogeneous emphysema in a randomised controlled study. 
Patients with homogeneous disease were included in this study as the pilot data suggested 
similar benefits regardless of the degree of emphysema heterogeneity.  
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3.2  METHODS 
 
3.2.1  STUDY DESIGN 
This trial was a prospective randomised controlled open label trial. Research ethics committee 
and NHS Trust R&D approval was obtained and all patients provided written informed consent. 
Patients were recruited between February 2010 and October 2011.  
After fulfilling all the inclusion and exclusion criteria, subjects were block randomised in a 
treatment to control ratio of 1:1 by opening pre-completed, opaque, sequentially numbered, 
sealed envelopes. The block size was 4 (the investigators were not aware of the block size until 
completion of study recruitment).  
The primary outcome time point was 3 months following the final treatment, after which 
subjects in the control arm crossed-over to the treatment arm (treatment to control ratio of 
2:1). Follow-up of all patients extended to 12 months following the final LVRC treatment. 
 
3.2.2  STUDY OUTCOMES 
Primary Endpoint 
 The between group difference in the change in SGRQ from baseline to three month post 
final treatment. 
Secondary Endpoints 
1) The between group difference at three months post final treatment in: 
 Percent change in FEV1 from baseline.  
 Percent change in FVC from baseline. 
 Change in the RV from baseline.  
 Change in the TLC from baseline.  
 Change in the 6MWD from baseline.  
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 Change in the mMRC Dyspnoea Scale from baseline.  
 Responder rates for primary and secondary outcome measures.  
2) Change in SGRQ, FEV1, FVC, RV, TLC, 6MWD and mMRC in the treatment arm 6 and 12 
months after treatment as compared to baseline. 
3) Adverse Event profile 
 
3.2.3  SAMPLE SIZE CALCULATION 
The number of patients needed to demonstrate statistical significance (α<0.05, β=0.84) of the 
difference in the proportion of patients reporting an improvement in SGRQ of 4 points or more 
was estimated to be 42 (1:1 randomisation).  This is based on a pilot study driven estimated 
treatment effect of 0.6 (60% treated patients report an SGRQ improvement > 4) and a placebo 
effect in the control group of 0.2 (20% Control patients report an SGRQ change >4). The aim was 
to recruit 45 subjects to account for possible drop-outs. This thesis reports on 36 subjects 
recruited at our institution.  
 
3.2.4  PATIENT SELECTION 
Subjects with GOLD stage III-IV emphysema were recruited from the respiratory clinics at the 
Royal Brompton Hospital and the Chelsea and Westminster Hospital, after discussion in an 
appropriate multidisciplinary meeting. Patients with severe airflow obstruction, significant 
hyperinflation and limiting breathlessness with no contraindications prohibiting bronchoscopy 
were considered. The inclusion and exclusion criteria are listed below.  
Inclusion Criteria: 
 Aged ≥35 years 
 HRCT scan indicates unilateral or bilateral emphysema 
 HRCT scan indicates homogeneous or heterogeneous emphysema 
 Post-bronchodilator FEV1 ≤45% predicted 
 Total lung capacity >100% predicted 
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 Patient has marked dyspnoea score ≥2 on modified Medical Research Council scale 
 Patient has stopped smoking for a minimum of 8 weeks before enrolment 
 Patient (or legal guardian if applicable) read, understood, and signed the informed 
consent form 
Exclusion Criteria: 
 A change in FEV1 greater than 20% post-bronchodilator 
 A single-breath diffusing capacity for carbon monoxide <20% predicted 
 A history of recurrent clinically significant respiratory infection, or clinically significant 
bronchiectasis 
 Uncontrolled pulmonary hypertension defined by right ventricular pressure >50 mm Hg 
as evidenced by echocardiogram 
 An inability to walk >140 metres in 6 minutes 
 Other diseases that can compromise survival—e.g., lung cancer or renal failure 
 An inability to tolerate bronchoscopy under heavy sedation or anaesthesia 
 Giant bullae greater than a third of lung volume 
 Previous lung volume reduction surgery, lung transplant, or lobectomy 
 Participation in other pulmonary drug studies within 30 days of enrolment 
 Taking greater than 20 mg prednisone (or similar steroid) daily 
 On clopidogrel or unable to stop treatment for 1 week before the procedure 
 Other disease that would interfere with completion of study or follow-up assessments, 
or that would adversely affect outcomes 
The investigators ensured that patients had been on optimal medical therapy for at least 3 
months prior to enrolment. This was performed at their initial clinic review before screening, 
which was delayed by 3 months if changes to treatment were made or felt needed. Definition of 
optimal medical therapy was not stipulated in the study protocol, but at our site we ensured 
that patients were on long acting inhaled beta-2 agonists and antimuscarinic agents, as well as 
inhaled corticosteroids if appropriate, and were complying with therapy. Additional medication 
such as theophylline, nebulised bronchodilators, prophylactic antibiotics, LTOT and NIV were 
prescribed as needed. Pulmonary rehabilitation was not an inclusion criteria for this trial, 
nevertheless we ensured all patients had taken part in a pulmonary rehabilitation course in the 
past and maintain regular exercises.  
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3.2.5  STUDY SCHEDULE 
Tables 3.3 and 3.4 summarise the testing schedules for patients in the treatment and control 
arms, respectively. Subjects had a clinical examination and review of health status at every visit 
(except for the telephone assessments one week following each treatment visit, both in the 
control and treatment arms). The control treatment involved a clinical assessment with no 
other interventions or investigations. One week after each procedure, a researcher contacted 
the subject via telephone to check on overall status and ask about any possible adverse events. 
All subjects at our institutions were recruited with a plan to proceed to bilateral sequential 
LVRC treatments. The more severely affected lung was treated first, followed by a follow-up 
assessment after 1 month. The contralateral lung was then treated at the earliest available 
opportunity provided there were no contraindications, with further follow-up assessments at 1 
month, 3 months, 6 months and 12 months after the second treatment. 
Subjects in the control group underwent an identical protocol of “control treatment” and follow-
up visits to the treatment group up to the 3 month follow-up visit. Investigation results from 
this visit were considered the subjects’ baseline results as they crossed over into the treatment 
arm and proceeded to follow the treatment arm schedule. A CT scan was performed at the 3 
month visit in the treatment arm, but not in the control arm, in order to minimise radiation 
exposure on the basis that no parenchymal lung changes or volume changes should have 
occurred without any intervention.
Table 3.3: Testing schedule for patients in the LVRC treatment arm 
Tx, treatment; F/u, follow-up; SGRQ, St George’s Respiratory Questionnaire, ECG, electrocardiogram;, mMRC, modified Medical Research Council dyspnoea scale. 
 
 
Procedure 
/Assessment 
Visit 1 Pre-Tx 
Visit 2 
Tx 1 
Visit 3 
Phone call 
(1 week post 
Tx 1) 
Visit 4 
F/u 
(1 month post 
Tx 1) 
Visit 5 
Tx 2 
Visit 6 
Phone call 
(1 week post 
Tx 2) 
Visit 7 
F/u 
(1 month post 
Tx 2) 
Visit 8 
F/u 
(3 months 
post Tx 2) 
Visit 7 
F/u 
(6 months 
post Tx 2) 
Visit 7 
F/u 
(12 months 
post Tx 2) 
Informed 
Consent 
X          
Medical History X          
Physical 
Examination 
X X  X X  X X X X 
SGRQ X   X   X X X X 
Spirometry X   X   X X X X 
Lung Volumes X   X   X X X X 
Haematology, 
Coagulation, 
Blood 
Chemistry 
X 
 
 
        
Blood Gases X       X X X 
ECG X          
Echocardiogra
m 
X          
mMRC X   X   X X X X 
6 Minute Walk 
Test 
X   X   X X X X 
Concomitant 
Medication / O2 
Use 
X X X X X X X X X X 
Pregnancy 
Testing 
X X   X      
HRCT Scan X       X X  
Chest X-Ray X          
Bronchoscopy / 
LVRC 
Placement 
 X   X      
Review Patient 
Status 
X X X X X X X X X X 
Exit Study          X 
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Table 3.4: Testing schedule for patients in the control arm 
Procedure 
/Assessment 
Visit 1 Pre-Tx 
Visit 2 
Control Tx 1 
Visit 3 
Phone call 
(1 week post 
control Tx 1) 
Visit 4 
F/u 
(1 month post 
control Tx 1) 
Visit 5 
Control Tx 2 
Visit 6 
Phone call 
(1 week post 
control Tx 2) 
Visit 7 
F/u 
(1 month post 
control Tx 2) 
Visit 8 
F/u 
(3 months post 
control Tx 2) 
Informed Consent X        
Medical History X        
Physical 
Examination to 
include SpO2 
X X  X X  X X 
SGRQ X   X   X X 
Spirometry X   X   X X 
Lung Volumes X   X   X X 
Haematology, 
Coagulation, Blood 
Chemistry 
X 
 
 
      
Blood Gases X       X 
ECG X        
Echocardiogram X        
Dyspnoea Scale 
mMRC 
X   X   X X 
6 Minute Walk Test X   X   X X 
Concomitant 
Medication / O2 Use 
X X X X X X X X 
Pregnancy Testing X        
High Resolution CT 
Scan 
X        
Chest X-Ray X        
Bronchoscopy / 
LVRC Placement 
        
Review Patient 
Status 
X X X X X X X X 
Tx, treatment; F/u, follow-up; SGRQ, St George’s Respiratory Questionnaire, ECG, electrocardiogram;, mMRC, modified Medical Research Council dyspnoea scale. 
3.2.6 STATIC AND DYNAMIC LUNG VOLUMES AND GAS TRANSFER 
MEASUREMENTS: 
Lung function testing was performed as per schedules summarised in tables 3.3 and 3.4. The 
lung function physiologists at the Royal Brompton Hospital lung function department 
performed all testing using the Compact Master lab system (Jaeger, Germany) as detailed in 
section 2.3. The European Coal and Steel Workers cohort is used to obtain standardised 
reference values(120).  
 
3.2.7  ARTERIAL BLOOD GASES 
Arterial blood gas (ABG) analysis was performed as per schedules summarised in tables 3.3 and 
3.4 by the lung function department physiologists at the Royal Brompton Hospital. This is 
performed using end capillary blood sample from the participant’s earlobe.  Analysis for pH, and 
for partial pressures of O2 and CO2 were performed using the Rapidlab 348 analyser (Bayer, 
Germany).   
 
3.2.8  HRCT ANALYSIS FOR EXCLUSION AND TREATMENT PLANNING 
 
HRCT scanning was performed as per schedule summarised in tables 3.3 and 3.4 and detailed in 
section 2.5 Volumetric spiral acquisition with contiguous slices (1mm slice thickness on 1mm 
for lung windows, and 10mm on 10mm mediastinal windows) was taken with the subject in the 
supine position at full inspiration. Images were also reconstituted to form 6mm slices every 
3mm for lung windows to optimise images for processing by the dedicated density analysis 
software Pulmo-CMS Version 2.1.5 (Medis Specials, Leiden, the Netherlands). This software was 
used to analyse all baseline CT scans and provide a density map of the lungs. The degree and 
distribution of emphysematous lung destruction allowed determination of suitability for LVRC 
treatment (severe bullous destruction excluded patients), as well as treatment planning.  
Patients with heterogeneous disease had treatment of the worst affected lobe. Patients with 
homogenous disease had coils inserted in the upper and lower lobes (avoiding the lingua/right 
middle lobe).  
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Pulmo-CMS automatically detected the lungs in CT volume scans after the investigator 
calibrated each scan for blood (using the aorta) and air (outside the patient). The investigator 
then selected a tracheal seed point and the lung fields were automatically detected by the 
software. The Relative Area (RA) of pixel values below -950 Hounsfield Units (HU) for each axial 
slice in each lung (ignoring the extreme apices and bases) was calculated, and heterogeneity of 
each lung determined by the lung’s RA slope. This is defined as the slope in the plot of RAs (or 
percentage of lung with a density of less than -950 HU) against sequential slice numbers from 
superior to inferior (figure 3.5). Heterogeneous disease produced a slope-like profile (as in 
figure 3.5a), with a greater degree of destruction in the upper or lower portions of the lungs. 
Homogenous disease produced a flat RA curve (as in figure 3.5c).  
In heterogeneous disease, the lung with the greater degree of heterogeneity was treated first, on 
the assumption that this would represent the better potential improvement in lung function.  
Similarly, in homogeneous disease, the lung with the higher degree of destruction was treated 
first.  If a patient was shown to have one lung with a heterogeneous distribution of disease and 
one with a homogeneous distribution, the heterogeneous lung was treated first, owing to the 
greater body of evidence for lung volume reduction in this group.   
In terms of inclusion and exclusion based on degree of lung destruction, patients with 
homogenous distribution were recruited if they had a plateau level of destruction below a 
threshold of 50% of parenchyma with density of -950HU. A higher level of destruction was 
accepted in heterogeneous disease provided the healthier portion of the lung had much lower 
levels of destruction (<25%).  Large bullae or blebs excluded subjects from this trial as these 
will negatively impact on the LVRC’s ability to tension the lung. The tension created by the coils 
will distort the blebs/bullae without significant retensioning of the surrounding parenchyma, as 
all the force is transmitted to the more compliant bullae. The axial slices of the CT were 
individually examined looking for blebs larger than 2cm in diameter (the size of a 50p coin). 
This was aided by Pulmo-CMS CT density reconstructions with a purple-scale (darker 
representing more destruction) as in figure 4.6. More than one dark purple bleb of this size 
excluded subjects from enrolment onto this trial. Data presented as a poster at the ERS 
conference in Barcelona 2010 (132) suggested that the ‘ideal’ heterogeneous lung has a 
percentage area destruction at the top 25th centile axial slice being more than twice as bad as at 
the 75th centile axial cut. 
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Figure 3.5: CT density graphical output of quantitative results using Pulmo-CMS. (a) Heterogeneous 
upper lobe predominant disease bilaterally. (b) Upper lobe predominant heterogeneous disease in right 
lung, homogenous disease in the left lung. (c) Homogenous disease bilaterally.  
 
a a 
(a) 
(c) 
(b) 
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Figure 3.6: Pulmo-CMS images. (a) each lung is delineated and major blood vessels excluded from 
analysis. (b,c) axial images with density mapping; darker purple represents worse parenchymal damage.    
 
3.2.9  6 MINUTE WALKING DISTANCE  
The 6 minute walking distance (6MWD) is a well validated test of exercise capacity in patients 
with COPD, and is commonly used both in clinical practice and in research. In this study patients 
had their 6MWD measured as per schedule summarised in tables 3.3 and 3.4. The American 
Thoracic Society criteria(128) for the 6MWD were followed. All tests were performed in the 
same 30 metre long corridor at the Royal Brompton Hospital.  
 
3.2.10  ST. GEORGE’S RESPIRATORY QUESTIONNAIRE 
The St. George’s Respiratory Questionnaire (122) is a 76-item health status survey specific for 
COPD and other respiratory disease. It is designed to measure impact of the disease on overall 
health, daily life, and perceived well-being. The participants answered the questions considering 
the preceding 4 weeks on visits as per schedule summarised in tables 3.3 and 3.4. 
 
3.2.11  MRC DYSPNOEA SCORE 
Participants in this trial completed an mMRC score as per schedule summarised in tables 3.3 
and 3.4. 
b c a 
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3.2.12  BRONCHOSCOPIC PROCEDURE 
The participant was given a bronchoscopy information leaflet to review with relevant 
instructions at least 24 hours in advance of the procedure. Departmental pre-procedure and 
post-procedure protocols for routine bronchoscopy were followed for patients in the treatment 
arm. Subjects were consented and 5mg salbutamol with 500mcg ipratropium bromide was 
administered via nebuliser before the procedure. Subjects were sedated using midazolam (2-
5mg) and fentanyl (50-200mcg), or general anaesthesia as per anaesthetist preference. 
Lignocaine 2% topical spray (4-6 mls) was used to anaesthetise the pharynx, vocal cords and 
airways as per usual protocol for bronchoscopy. Once sedated, the subject was intubated using 
size 8-8.5 cuffless endotracheal tube. A diagnostic bronchoscopy was performed before the 
target lobe was approached.  
The guide wire was carefully passed into the target subsegment and advanced under 
fluoroscopic guidance, avoiding sharp changes of direction, to a distance still safely away from 
the pleural edge (>35mm). The delivery catheter was then advanced over the guide wire. A 
measurement of the length of the guide wire was made by counting how many 25mm markers 
(visible on fluoroscopy) exist between the distal end of the bronchoscope and the tip of the 
guide wire (figure 3.7c). The LVR coil was sized by adding 50mm to the measured distance 
(over-sizing by 50mm). During our early experience of coil deployment we observed that the 
proximal end of the coil tended to recoil away from sight, prompting over-sizing to keep the 
proximal end of the coil within reach in case there is a need for removal in the future. The guide 
wire was then removed carefully ensuring that the delivery catheter remained in the same 
position. The appropriate sized coil was then prepared for deployment by extracting it from its 
casing directly into a straight deployment cartridge using forceps (figure 3.8a-c). The cartridge 
was coupled to the delivery catheter and the coil advanced through the bronchoscope and into 
the target subsegment. Under fluoroscopic guidance, coils were advanced until the distal tip 
reached the distal end of the delivery catheter (figure 3.7e). The sheath was then slowly pulled 
back (figure 3.7f). The nitinol coil regained its pre-determined shape as it was released from 
within the sheath, and gentle advancement of the coil and pulling back of the sheath was 
continued until the forceps was seen to exit from the distal end of the sheath. Under 
bronchoscopic vision, the forceps were then opened releasing the coil (figure 3.7g), with the 
proximal end of the sheath ideally visible in the target subsegment (figure 3.7h).  
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Figure 3.7(a-h): Coil deployment process. (a) the guide wire is inserted into the target subsegment, (b,c) 
the catheter is advanced until the distal tip aligns with the distal end guidewire, and measurement of 
required coil made by the number of visible 25mm markers, (d) the guidewire is removed and replaced 
by the coil, (e-h) the catheter is withdrawn and the coil released from the forceps in the proximal 
subsegmental airway.  
 
Figure 3.8: Coil preparation for deployment. (a) The proximal end of the coil is grasped with forceps 
whilst inside the packaging and (b-c) is then pulled into the straight loading cartridge ready for 
deployment through a delivery catheter. 
a c b 
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The coil can be removed by reversing the deployment procedure: re-capturing the proximal end 
of the implant with the forceps and then advancing the catheter distally over the implant while 
maintaining the relative position of the implant to the bronchoscope. 
In patients with heterogeneous disease, the worst affected lobes were treated by inserting a coil 
into every visible distinct subsegment whilst avoiding concentration of too many coils in one 
region and achieving a broad “spread” of coils on fluoroscopy (figure 3.9). Between 8 and 12 
coils are generally required for lobar treatment. Patients with homogenous disease had coils 
inserted into all major accessible subsegmental airways in the upper and lower lobes (avoiding 
the lingua/right middle lobe), evenly distributed and up to a maximum of 14 coils per lung.  
Post-procedure care is identical to routine post-bronchoscopy care, with added vigilance 
regarding the risk of hypoventilation secondary to sedation with opiates and benzodiazepines. 
None of our patients have required non-invasive ventilation (but it was used in recovery until 
sedation wore off in patients already on long-term domiciliary nocturnal non-invasive 
ventilation). A chest radiograph was performed one hour post procedure to rule out a 
pneumothorax. The subject was then transferred to the respiratory ward for overnight 
observation, and discharged the next morning if well. A 7 day course of prednisolone and 
suitable antibiotics was prescribed and started on the day of the procedure as procedure/coil 
induced bronchospasm has been reported in the early pilot studies.(103) 
 
Figure 3.9: Chest radiographs of a patient with lower lobe predominant heterogeneous disease one hour 
after the first and second treatments. The coils are evenly spread throughout the treated lobes. The shape 
of the right hemidiaphragm is already altered one hour after the procedure. 
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3.2.13  STATISTICAL ANALYSIS 
An intention to treat analysis was conducted for the primary endpoint, secondary endpoints and 
non-endpoint outcomes up to the 3 month time point. For subjects whose last recorded values 
were less than 3 months from the final treatment, their last recorded value was carried forward.   
Secondary and non-endpoint analysis for 6 and 12 month follow-up data (uncontrolled) was 
performed using the available data.  
Two-tailed unpaired t-tests were performed on the between group differences in mean change 
in outcomes, except for unpaired changes in mMRC score, where the Mann Whitney test was 
used. Two-tailed paired t-tests and repeated measures ANOVA with Bonferroni’s multiple 
comparison test were performed on data at visits from 1 month post treatment visit 1 through 
12 months post final treatment against baseline data within each group, except for paired 
changes in mMRC score where the Wilcoxon signed rank test and Friedman’s test with Dunn’s 
multiple comparison test were used.  
 
3.2.14  ROLE OF THE SPONSOR AND CONFLICT OF INTEREST DECLARATION 
The study sponsor and funder was PneumRx Inc., the manufacturer of the LVRCs. The 
sponsor assisted the chief investigator Dr. Pallav Shah with the trial design and financed 
the study, reimbursing my institutions for trial expenses. The sponsor facilitated 
independent safety and monitoring audit, as well as central data collation and 
appointed an independent statistician for data analysis. The data presented here was 
collated separately by the author who performed independent statistical analysis of 
data from patients recruited at this institution. The author received travel grants for the 
purposes of attending international conferences and presenting trial data. 
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3.3   RESULTS 
 
3.3.1  BASELINE DATA 
36 patients were recruited at our institutions, 18 randomised to the treatment arm and 18 to 
the control arm. Another 10 patients were recruited at a second site(Gartnavel Hospital, 
Glasgow, UK) as part of this trial. In this thesis, only data from patients recruited at our 
institutions are presented. All control subjects crossed over to the treatment arm after their 3 
months post control treatment 2 follow-up visit. Therefore control baseline data are available 
on 18 subjects and treatment baseline data on 36 subjects.  For control arm subjects who 
crossed over to the treatment arm, the 3 month post 2nd control treatment follow-up visit data 
was considered their treatment baseline data.  Baseline demographics and lung function data 
are illustrated in table 3.3. 
 
 
Table 3.5: Baseline characteristics and lung function for participants of the coil study. 
 Treatment Control p value 
Number 36 18 - 
Age (y) 64.6 (8.52) 63.6 (8.05) 0.67 ∆ 
Male (%) 58% 67% 0.77 ∞ 
BMI 24.2 (4.38) 24.4 (4.64) 0.46 ∆ 
FEV1 % predicted 27.3 (7.31) 28.6 (7.44) 0.58 ∆ 
FVC % predicted 82.8 (17.6) 87.4 (17.5) 0.18 ∆ 
RV % predicted 231.9 (48.7) 241.7 (70.6) 0.70 ∆ 
RV/TLC 63.5 (6.4) 62.8 (7.6) 0.72 Ŧ 
TLco % predicted 33.4 (10.2) 34.7 (11.1) 0.81 Ŧ  
mMRC 2.53 (0.7) 2.33 (0.49) 0.32 Ŧ 
SGRQ 59.1 (13.1) 53.2 (12.8) 0.09 ∆ 
6MWD (m) 305.4 (15.1) 338.6 (26.3) 0.24 ∆ 
Presented as mean (SD) 
∆ Unpaired t-tests 
∞ Fisher’s exact test 
Ŧ   Mann-Whitney test 
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3.3.2   PROCEDURE DETAILS AND FOLLOW-UP DATA AVAILABILITY 
The flow diagram in Figure 3.10 illustrates subject numbers in the trial at each data collection 
time point. Data on 18 control subjects and 32 treatment subjects were available at the 3 month 
primary endpoint visit. One subject improved sufficiently after his first LVR coil treatment to be 
able to return to full time work, and was unable to commit to further follow-up visits. He 
declined contralateral treatment and withdrew from the study. Two subjects died before their 3 
month follow-up visits (details in adverse events section below). One further data set from the 3 
month post 2nd treatment primary endpoint visit was not available owing to a prolonged 
hospital admission. For the intention to treat analysis, data from three subjects’ latest 1 month 
post treatment visit and the baseline data of the patient who died before any follow-up visits 
were performed, were carried forward. 
At the 6 month post final treatment time point, data was available for 33 subjects. At the 12 
month time point, data was available for 29 subjects; Two subjects passed away, one subject 
moved home and was lost to follow-up, and one patient withdrew from the trial as she needed 
to focus her energy on caring for her husband who had been recently diagnosed with cancer.  
A total of 68 treatment procedures were performed in 36 patients as part of this trial (one death  
and one drop out before the 2nd procedure, and two did not have a 2nd treatment for medical 
reasons). In one case the patient suffered from recurrent exacerbations and was not well 
enough for a sustained period to proceed with a second bronchoscopy, and the research team 
did not wish to perform a procedure which could trigger further exacerbations. Another patient 
had an extended hospital admission locally due to multiple unrelated medical conditions 
including urinary tract infections, severe urinary retention eventually requiring suprapubic 
catheter insertion, and later rectal bleeding requiring colonoscopy. The research team felt that it 
would not be in the patient’s best interest to subject her to further bronchoscopy. The 3 month 
post 1st (and final) treatment visit data was used as the primary end point data for these two 
patients.  
Sixty two of 68 bronchoscopic procedures were performed at the Chelsea and Westminster 
Hospital endoscopy unit using moderate sedation as day case procedures (mean (SD) dose of 
midazolam and fentanyl administered was 3.9 (1.6) mg and 86.3 (27.4) mcg, respectively). 
Three patients were known not to have tolerated bronchoscopy under moderate sedation in the 
past and had their procedures performed in the Royal Brompton Hospital operating theatres 
under general anaesthesia. The mean (SD) time from the final treatment to the 3 month 
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endpoint visit was 93.9 (15.2) days. Two subjects had died before attending any follow-up visits 
after final treatment.   
 
Figure 3.10: Flow diagram of subjects’ journey through the coil study. LVRC, Lung Volume Reduction 
Coils); IECOPD, Infective exacerbation of COPD; CVA, Cerebrovascular accident. 
#1 data set not available due to extended hospital admission covering follow-up visit timeframe.  
&1 lung function set of results not available as subject refused to perform lung function during the visit.  
A further 10 subjects were recruited at another site as part of this trial – not illustrated. 
 
3.3.3  PRIMARY ENDPOINT 
3 months following the final treatment there was a clinically and statistically significant mean  
(SD) reduction in the SGRQ of 6.32 points (11.4), p=0.0017 in the LVRC group compared to 
baseline. There was no significant change in the SGRQ in the control arm (∆ +2.59 (12.2), 
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p=0.38). The primary end point between group difference in the mean change in SGRQ was 
clinically and statistically significant at Δ-8.91 points, (95% CI -15.6 to -2.24), p=0.0097 (figures 
3.11 and 3.12).  
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Figure 3.11: Boxplot analysis of the primary endpoint change in SGRQ in the intent-to-treat population.  
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Figure 3.12: Change in SGRQ from baseline.  
Unpaired t-tests between the LVRC and control groups at time points T1 1m (1 month post 1st treatment), 
T2 1m (1 month post 2nd treatment), and T2 3m (3 months post final treatment). ** <0.01 
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3.3.4  SECONDARY ENDPOINTS 
 
1) Between group differences 3 months post final treatment in the change from baseline: 
 
 Percentage change in FEV1: 3 months following the final treatment there was a 
clinically and statistically significant mean (SD) percentage increase in the FEV1 of 15.2 
(16.8) %, p<0.001 in the LVRC group. There was no significant change in the FEV1 in the 
control arm (∆ +0.097 (0.11) %, p=0.77). The between group difference in the mean 
change in FEV1 was clinically and statistically significant at Δ15.2%, (95% CI 5.03 to 
23.4), p=0.0031 (mean absolute volume 110mls) (figures 3.13 and 4.14).  
 Percentage change in FVC: There was a significant between group difference in the % 
change in FVC 1 month after the second treatment (Δ13.1% (95%CI 5.42 to 20.1) 
p=0.0012) and 3 months after the final treatment (Δ9.35% (95%CI 2.8 to 15.9) 
p=0.006), but not 1 month after the 1st treatment (figures 3.13 and 4.14). 
 Change in RV: The LVRC treatment group had a mean (SD) reduction in the residual 
volume of 0.386 (0.59) litres, p=0.0004 3 months post final treatment compared to 
baseline. There was no significant change in the RV in the control group 3 months post 
final control treatment as compared to baseline (Δ-0.027 (0.33) litres, p=0.74). The 
between group difference in the mean change in RV was statistically and clinically 
significant at Δ-0.359 litres (95% CI -0.66 to -0.059), p=0.019 (figures 3.13 and 4.14). 
 Change in TLC: There was no significant change in the TLC in either group (LVRC group 
-0.130 (0.43) litres, control group 0.040 (0.20) litres), with a between group difference 
of Δ-0.172 litres (95% CI -0.131 to 0.107) p =0.17 (figures 4.12 and 4.13). 
 Change in the 6MWD: The LVRC treatment group had a mean (SD) increase in the 
6MWD of 69.2 (60.8) m, p<0.0001 3 months post final treatment as compared to 
baseline. There was no significant change in the 6MWD in the control group at 3 months 
post final treatment compared to baseline (Δ-10.8 (44.6) m, p=0.32). The between group 
difference in the mean change in the 6MWD was statistically and clinically significant at 
Δ+80.0 meters, (95% CI 47.5 to 112.5), p<0.0001 figures 3.13 and 4.14). 
 Change in mMRC dyspnoea score: The LVRC treatment group had a mean (SD) 
reduction in the mMRC score of 0.44 (0.84) points p=0.003, 3 months post final 
treatment as compared to baseline. There was no significant change in the mMRC score 
in the control group 3 months post final treatment as compared to baseline (Δ-0.06 
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(0.73) points, p=0.75. There was no statistically significant difference between the 
medians of the change in mMRC score between the 2 groups (medians (range) 0 (-2 to 
1) in the treatment arm, 0 (-1 to 2) in the control arm, p=0.17) (figures 3.13 and 4.14). 
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Figure 3.13: Between group differences in the secondary outcome measures.  
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Presented as mean with error bars. Unpaired t-tests except for mMRC (Mann Whitney test). 
Statistically significant differences identified where they occur with: * p<0.05, **p<0.01, *** 
p<0.001  
 Responder analysis: Using an intention to treat analysis, a statistically significantly 
higher proportion of subjects met the responder criteria for reduction in SGRQ in the 
LVRC treatment arm compared to the control arm, both at the 4 point and 8 point 
minimally clinically important difference (MCID) thresholds (table 3.4). The responder 
analysis at the 8 point threshold was conducted alongside the accepted 4 point MCID 
threshold for this patient population (133) as this was an unblinded study and the 
primary outcome is a patient reported measure. There were significant differences in 
the responder rates between the 2 groups in reduction in RV below 0.35 litres (134) and 
improvements in the 6MWD above 26m,(126) but not in the FEV1 increase of >12% 
MCID (135) (though if we adopt a 10% FEV1 MCID threshold the difference between the 
groups is significant (58% in the LVRC arm vs 28% in the control arm, p=0.045) (Table 
3.4). 
 
 
 
Table 3.6: Responder Analysis of Efficacy Outcomes in the LVRC treatment and control arms -change 
from baseline at 90 days post final treatment. 
 
LVRC Treatment 
 (n= 36) 
Control  
(n=18) p-value * 
Primary outcome 
SGRQ- 4 Point improvement 
(133) 
60.0% (22/36) 22.2%  (4/18) 
0.0096 
SGRQ- 8 Point improvement  50.0% (18/36) 16.7%  (3/18) 0.0209 
Secondary outcomes 
RV - 0.35 L improvement (134) 55.6% (20/36) 11.1%  (2/18) 0.0027 
6-minute Walk Test- 26m 
improvement (126) 
77.8% (28/36) 16.6% (3/18) 
<0.0001 
FEV1- 12% improvement (135) 52.8% (19/36) 27.8% (5/18) 0.145 
*p-value determined by Fisher’s exact test. 
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Predictors of Response: 
Univariate linear regression comparing baseline measures with outcomes has identified only 
one significant relationship: RV% predicted at baseline and change in RV (fig 3.14). Our data 
suggests that subjects with RV <190% predicted at baseline are less likely to respond to 
treatment in terms of reduction in RV. However there was no similar correlation with changes 
in exercise capacity or quality of life. There were no other significant correlations comparing 
FEV1 % predicted, 6MWD, SGRQ and TLco with all other outcome measures suggesting our 
inclusion criteria were otherwise appropriate. 
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Figure 3.14:  Correlation of baseline RV  % predicted versus change in RV post LVRC treatment 
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2) Change in outcome measures  6 and 12 months post treatment: 
 
The 6 and 12 month outcome data is detailed in Table 3.7 and illustrated in Figure 3.15. 
Repeated measures ANOVA and Bonferroni’s multiple comparison tests were performed for 
statistical analysis for all outcomes except mMRC, where Friedman’s test with Dunn’s 
comparison of all pairs of columns was performed. For the subjects remaining in the study 6 and 
12 months post final treatment, the SGRQ remained statistically and clinically significantly 
lower than baseline 6 months (Δ-11.7 (15.0) points) and 12 months (Δ-8.9 (13.2) points) 
following treatment.  FEV1 was statistically significantly higher than baseline at 6 months (Δ10.1 
(20.7) %), and non-statistically significantly higher at 12 months (Δ10.7 (23.5) %); below the 
MCID of 12%. Similarly, the RV was statistically lower than baseline at 6 but not 12 months, at 
means under the MCID of -0.35 litres. The statistically and clinically significant benefits in the 
6MWD seen at 3 months were maintained at 6 and 12 months though smaller in magnitude 
(Δ61.7 (52.6) and Δ47.9 (52.4) at 6 and 12 months, respectively). Reductions in the mMRC score 
of 0.64 (0.84) and 0.48 (0.74) point at 6 and 12 months, respectively, were in keeping with 
improvements in the SGRQ. 
 
 A responder analysis of subjects 6 and 12 months post treatment for the available data at these 
time points (table 3.5) shows small falls in the responder rates in the measured outcomes. 
Twelve months after treatment 55%, 46%, 62% and 43% of subjects still had significant 
benefits exceeding the MCIDs in the SGRQ, RV, 6MWD and FEV1, respectively. 
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Figure 3.15: Continued with legend overleaf. 
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Figure 3.15: Change in outcome measures from baseline at each time point (1 month after 1st (T1 1m) 
and final (T2 1m) treatments, and 3 months (T2 3m), 6 months (T2 6m) and 12 months (T2 12m) after 
the final treatment. Repeated measures ANOVA performed with Bonferroni’s multiple comparison test, or 
Friedman’s test with Dunn’s comparison of all pairs of columns as appropriate. Statistical differences 
from baseline marked at each time point where they occur, and highlighted with connecting bars when 
significant between time points. * p=<0.05, ** p=<0.01, *** p=<0.001. 
 
 
 
 
 
 
3 months post T2 
(n) 
6 months post T2 
(n) 
12 months post T2 
(n) 
Primary outcome  
SGRQ- 4 Point improvement 
(133) 
60.0% (22/36)      66.7%  (22/33)       
55.2% (16/29) 
SGRQ- 8 Point improvement  50.0% (18/36)      54.5.7%  (18/33)       41.4% (12/29) 
Secondary outcomes 
RV - 0.35 L improvement (134) 55.6% (20/36)             33.3%  (11/33)             46.4% (13/28) 
6-minute Walk Test- 26m 
improvement (126) 
77.8% (28/36)           75.8% (25/33)       
62.1% (18/29) 
FEV1- 12% improvement (135) 52.8% (19/36)  42.4% (14/33)  42.9% (12/28) 
Table 3.7: Responder analysis of efficacy outcomes in the LVRC treatment arm 3,6 and 12 months post 
final treatment.  
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3) Adverse Events: 
Table 3.6 represents the adverse events in both the treatment and control arms by 
interval. In the immediate post-treatment period and up to 3 months following the final 
treatment, there was no difference in the rate of infective and non-infective 
exacerbations of COPD between the 2 study arms. From 3 months post treatment up to 
the final 12 month follow-up visit, 20 patients suffered from an average of 3 infective 
exacerbations each, whilst 16 patients did not suffer any. Five patients suffered from 
minor haemoptysis (less than 10mls per day for more than 4 days). 
 
Deaths: One subject developed a severe infective exacerbation secondary to H1N1 
influenza during the 2009 epidemic, and passed away due to a haemorrhagic stroke 
whilst ventilated on the intensive care unit. One subject developed a severe infective 
exacerbation of his COPD approximately 10 weeks after his second treatment and 
passed away from respiratory failure refractive to ventilatory therapy via endotracheal 
tube at the end of a 2 week hospital admission. One subject died secondary to a severe 
infective exacerbation of COPD 7 months after his final treatment. In all three cases the 
LVRCs did not appear to play a role in the subject’s death. One subject died from severe 
urinary sepsis 11 months after her treatment. 
Pneumothoraces: There were eight pneumothoraces following 68 procedures (11.7%) 
in the treatment recovery period. Six of these occurred within 2 hours of the procedure 
and were picked up on the routine post-procedure chest X-ray, and one confirmed 
before discharge the next morning. Six of these seven patients were treated with small 
bore chest tube drainage and all were discharged within 72 hours. Two patients had 
overnight chest tube drainage and did not have a delayed discharge, hence the 
pneumothorax in these two cases was not considered an SAE as per the a priori 
definition of SAE set in the protocol.  One subject was diagnosed with a pneumothorax 
during his 1 month follow-up visit (he had been symptomatic for 10 days and self 
medicated with antibiotics and prednisolone suspecting an infective exacerbation). He 
had a 14 day admission and required large bore surgical chest drain insertion and 
attachment to wall suction to treat a bronchopleural fistula. He proceeded with his 
contralateral treatment 6 weeks later without complication. One subject had a 
recurrence of his immediate post-procedure pneumothorax 3 months later, and was 
managed with small bore chest tube drainage and suction for 7 days. He was reviewed 
by thoracic surgeons who did not feel intervention was necessary. He remains problem 
free 3 years after his second pneumothorax. 
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Table 3.8:  Adverse Events (Serious Adverse Events (SAEs)) by interval. 
Adverse 
 Events 
(SAEs) 
LVRC Treatment 
(n=68 procedures) 
Control 
(n=36 procedure equivalents) 
p-value* 
Events, 
n 
Patients, 
 n 
Incidence 
(%) 
Events, 
n 
 Patients, 
 n 
Incidence 
(%) 
Treatment Recovery Period (up to day 28 post procedure)  
Non-IECOPD 4 (0) 3 (0) 5.8 2 (0) 2 (0) 5.6 0.69 
IECOPD  15 (1) 8 (1) 22.1 7 (0) 7 (0) 19.4 0.81 
Haemoptysis 5 (0) 5(0) 7.4 0 0 0 0.16 
Pneumothorax 8 (6) 8(6) 11.7 0 0 0 0.052 
Death 1 (1) 1 (1) 1.5 0 0 0 0.99 
Adverse 
 Events 
(SAEs) 
LVRC Treatment 
(n=36 patients) 
Control 
(n=18 patients) 
p-value* 
Events, 
n 
Patients, 
 n 
Incidence 
(%) 
Events, 
N 
Patients, 
 n 
Incidence 
(%) 
Day 29 post each procedure up to next procedure or 90 day follow-up visit 
Non-IECOPD 3 (0) 3 (0) 8.3 2 (0) 2 (0) 11.1 0.99 
IECOPD  15 (2) 12 (2) 41.7 9 (1) 7 (1) 50.0 0.58 
Haemoptysis 0 0 0 0 0 0 0.99 
Pneumothorax 1 (1) 1 (1) 2.8 0 0 0 0.99 
Death 1 (1) 1 (1) 2.8 0 0 0 0.99 
90 days  to 12 months  post final treatment visits  
Non-IECOPD 12 (1) 4 (1) 33.3     
IECOPD  60 (5) 20 (2) 166.7     
Haemoptysis 1 (0) 1 (0) 2.8     
Pneumothorax 0 0 0     
Death 2 (2) 2 (2) 5.6     
Event incidence for treatment recovery period calculated by n events/n procedures (or n procedure 
equivalents), and for subsequent periods by n events/n subjects. 
*p-value calculated using Fisher’s exact test comparing number of events.  
Includes pneumonia 
 
Table 3.9:  LVRC treatment arm primary, secondary and non-endpoint measures 
Data for visits 1 month after 1st (T1 1m) and final (T2 1m) treatments, and 3 months (3m), 6 months (6m) and 12 months (12m) after the final treatment, presented 
as mean (SD) or median (range) as appropriate. Change from baseline compared using repeated measures ANOVA with Bonferroni’s multiple test comparison, or 
Friedman’s test with Dunn’s multiple test comparison, as appropriate. * p=<0.05, ** p=<0.01, *** p=<0.001. 
Outcome Baseline T1 1m P value T2 1m p value 3 months p value 6 months p value 12 months 
p-
value 
SGRQ 
(points) 
59.6 (12.8) 50.9 (16.4) *** 49.74 (17.3) *** 53.3 (16.0) * 48.1 (17.7) *** 50.9 (14.8) ** 
FEV1 (L) 0.72 (0.17) 0.79 (0.20) ** 0.83 (0.20) *** 0.83 (0.21) *** 0.79 (0.21) * 0.79 (0.22) ns 
FVC (L) 2.77 (0.61) 2.89 (0.63) ns 3.04 (0.68) *** 3.02 (0.63) *** 2.98 (0.59) * 3.08 (0.59) * 
RV (L) 5.13 (1.19) 4.93 (1.11) ns 4.77 (1.06) *** 4.75 (1.09) *** 4.82 (1.03) * 4.94 (1.03) ns 
TLC (L) 8.03 (1.35) 8.01 (1.41) ns 8.00 (1.29) ns 7.97 (1.28) ns 7.89 (1.21) ns 8.03 (1.29) ns 
6MWD (m) 305 (91) 346 (110) *** 360 (109) *** 375 (106) *** 365 (100) *** 349 (89) *** 
mMRC 
(points) 
2 (1-4) 2 (1-4) ns 2 (1-3) * 2 (1-4) ns 2 (1-4) * 2 (1-4) ns 
FRC (L) 6.18 (1.28) 6.04 (1.18) ns 7.36 (8.76) ns 5.80 (1.19) ns 5.97 (1.07) ns 6.09 (1.18) ns 
RV/TLC (%) 63.5 (6.41) 61.2 (6.7) * 59.5 (7.0) *** 59.5 (6.4) *** 60.9 (6.7) * 60.4 (6.3) ns 
TLco 2.74 (0.83) 2.73 (0.75) ns 2.72 (0.74) ns 2.72 (0.47) ns 2.67 (0.76) ns 2.67 (0.87) ns 
PaO2 (kPa) 9.21 (1.24)     9.14 (1.16) ns 9.26 (1.13) ns 9.20 (1.39) ns 
PaCO2 (kPa) 5.23 (0.65)     5.09 (0.63) ns 5.08 (0.84) ns 5.08 (0.77) ns 
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Table 3.10: Control arm primary, secondary and non-endpoint measures 
Outcome Baseline T1 1m p value T2 1m p value 3 months p-value 
SGRQ 
(points) 
53.2 (12.8) 54.0 (15.3) ns 53.2 (13.7) ns 55.8 (14.8) ns 
FEV1 (L) 0.75 (.019) 0.76 (0.19) ns 0.74 (0.16) ns 0.75 (0.19) ns 
FVC (L) 2.89 (0.70) 2.90 (0.71) ns 2.77 (0.57) ns 2.88 (0.68 ns 
RV (L) 5.01 (1.01) 4.94 (1.03) ns 5.00 (1.21) ns 4.98 (0.94) ns 
TLC (L) 7.96 (1.24) 7.90 (1.25) ns 7.95 (1.40) ns 8.00 (1.24) ns 
6MWD (m) 339 (112) 326 (102) ns 340 (113) ns 328 (97) ns 
mMRC 
(points) 
2 (2-3) 2 (1-3) ns 2 (1-3) ns 2 (1-4) ns 
FRC (L) 6.11 (1.19) 6.06 (1.14 ns 6.08 (1.43) ns 6.10 (1.17) ns 
RV/TLC (%) 62.8 (7.7) 62.4 (7.3) ns 62.4 (7.1) ns 62.2 (6.2) ns 
TLco 2.84 (0.98) 2.86 (0.94) ns 2.94 (0.88) ns 2.83 (0.93) ns 
PaO2 (kPa) 9.48 (1.17)     9.16 (1.17) ns 
PaCO2 (kPa) 5.24 (0.52)     5.13 (0.52 ns 
Data for visits 1 month after 1st (T1 1m) and final (T2 1m) treatments, and 3 months (3m) after the final 
treatment, presented as mean (SD) or median (range) as appropriate. Change from baseline compared 
using repeated measures ANOVA with Bonferroni’s multiple test comparison, or Friedman’s test with 
Dunn’s multiple test comparison, as appropriate. * p=<0.05, ** p=<0.01, *** p=<0.001 
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Table 3.11: Between group differences in the mean change from baseline of primary, secondary and non-
endpoint measures 
Between Group 
Difference 
T1 1m p value T2 1m p value 3m p-value 
Change in SGRQ 
(points) 
-9.5 (3.1) ** -9.8 (3.4) ** -8.9 (3.3) ** 
% Change in FEV1 8.4 (5.5) ns 14.7 (4.6) ** 14.2 (4.6) ** 
% change in FVC 4.4 (3.9) ns 13.1 (3.8) ** 9.4 (3.3) ** 
Change in RV (L) -0.137 (0.113) ns -0.3608 (0.190) ns 
-0.359 
(0.149) 
* 
Change in TLC (L) -0.054 (0.146) ns -0.096 ( 0.132) ns 
-0.172 
(0.107) 
ns 
Change in 6MWD (m) 53.2 (17.0) ** 53.2 (15.6) ** 80.0 (16.2) *** 
Change in mMRC 
(points) 
-0.17 (0.22) ns -0.2 (0.26) ns -0.39 (0.23) ns 
Change in FRC (L) -0.091 (0.108) ns 1.210 (2.030) ns 
-0.368 
(0.164) 
* 
Change in RV/TLC (%) 1.9 (1.0) ns 3.3 (1.5) * 3.4 (1.2) ** 
Change in TLco -0.10 (0.11) ns -0.10 (0.13) ns -0.01 (0.12) ns 
Change in PaO2 (kPa)     0.28 (0.25) ns 
Change in PaCO2 (kPa)     -0.04 (0.13) ns 
1 month after the 1st (T1 1m) and final (T2 1m) treatments, and 3 months (3m) after the final treatment. 
Presented as mean (SD). Comparison of the means performed using unpaired t-test or Mann Whitney test 
as appropriate. * p=<0.05, ** p=<0.01, *** p=<0.001 
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3.4 DISCUSSION 
 
In our cohort, treatment with LVRCs resulted in significant improvements in the primary 
outcome measure 3 months following treatment compared to controls. The data presented here 
is, however, comparing groups in a 2:1 assignment (36 LVRC subjects versus 18 controls), 
rather than the required 21 LVRCs versus 21 controls in the sample size calculation. The final 
independently audited and source verified results of 46 subjects randomised in 2 centres (1:1 
assignment and inclusive of additional patients recruited at a different centre and not reported 
in this thesis) have been analysed by an independent statistician and the data was presented by 
the author as a late-breaking abstract at the American College of Chest Physicians Chest 
conference 2012 (136) and later published.(94) The results are very similar to those of our 
cohort which includes cross over patients at the 3 month primary time point. In this thesis I 
report medium term data from our cohort including cross over treatments, which reveal 
statistically and clinically significant improvements in quality of life and exercise capacity 
measures persisting up to 12 months following treatment as compared to baseline. 
Improvements in the FEV1 and RV at 6 months, though statistically significant, slipped just 
below what is considered to be clinically significant, and lost statistical significance by 12 
months post treatment (at a similar magnitude to 6 months post treatment, likely due to 
missing data from drop outs). 
The use of a patient reported qualitative outcome measure as the primary outcome in an 
unblinded study is a major weakness of this trial. I was not personally involved in the study 
design phase of this trial, which took place soon after the VENT trial(82) results were published 
showing statistically significant but not clinically meaningful improvements in the primary 
outcome measure of % change in FEV1. Therefore an outcome measure directly examining 
patient’s quality of life was preferred, in keeping with requirements by the Food and Drug 
Administration (FDA) for a large randomised controlled trial of the intrabronchial valves (84) to 
include change in SGRQ as a co-primary endpoint along with CT measured volume change. 
Responder analyses using both the 4-point and 8-point MCID thresholds were thus performed 
to compensate for the unblinded nature of this study. The 8-point threshold was used in the 
NETT trial, chosen somewhat arbitrarily, to “represent a degree of improvement that would be 
appropriate to justify the high risks associated with surgery in patients with severe 
emphysema”(66). Fifty four % and 49% of LVRS patients in the NETT trial had a >8 point 
reduction in SGRQ 6 and 12 months post- surgery, respectively. In comparison, our cohort had a 
50% and 33.3% responder rate at these time points (to allow a like for like comparison, patients 
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with missing data were considered non-responders, explaining the discrepancy from figures in 
table 3.7). Nevertheless, the changes in the outcome measures (qualitative and quantitative) 
experienced by subjects in the LVRC treatment arm are all consistent in the direction of benefit, 
with no significant change in the control arm, suggesting that the improvements in the SGRQ are 
a real treatment effect.  Nevertheless, the placebo effect of unblinded intervention on patients 
with end stage disease with a naturally fluctuating symptomatic course is sizable and will not be 
accounted for by the measures taken here. There is disagreement as to which is the best 
endpoint measure to assess lung volume reduction interventions. The FDA have tended to 
favour % change in FEV1 with an MCID of 12% in this population, however many feel recurrent 
infections and natural variations in this measure over time, as well as the small FEV1 values in 
this patient population bringing this magnitude of change close to the limits of test accuracy, 
make it an imperfect endpoint. Furthermore, changes in FEV1 do not necessarily correlate with 
changes in patient symptoms. Measures of exercise capacity are preferred by some but are 
dependent on factors beyond patients’ respiratory status and are difficult to standardise and 
perform, being highly dependent on patient motivation. The 6MWD has the best guidance and 
evidence base in COPD and LVR, and has indeed been approved by the FDA as the primary 
endpoint in a new randomised controlled trial of the LVRCs. There is, however, a wide range of 
proposed MCIDs (section 2.7.1). The residual volume has also been proposed as a good measure 
of gas trapping but is subject to similar limitations to those discussed for FEV1 above, and an 
MCID has not been determined. Co-primary endpoints including a test of exercise capacity and 
lung function would be ideal, however population size for studies employing such an approach 
is likely to be prohibitively large. 
Another criticism of the study design is the absence of a sham procedure. The LVRCs are 
radiographically striking and the target patient population suffer from recurrent infections and 
frequently attend local hospitals acutely unwell when they are likely to have chest radiographs 
as part of their assessment. The chance of unblinding by a surprised and/or intrigued junior 
doctor or radiographer is therefore very high, minimising the scientific merit of a sham 
procedure. Furthermore, 8 of our 36 patients (22%) suffered from a pneumothorax (from 68 
procedures). In a 1:1 randomised controlled trial with similar pneumothorax rates, 
pneumothorax alone could unblind between a fifth and a quarter of the treatment arm.  
Three months controlled follow-up is arguably too short and perhaps should have extended to 6 
months at the earliest. This is, however, the first randomised controlled trial of this device and 
was not designed to be a pivotal one. It is the largest treated cohort of patients with LVRCs to 
date. It has informed on a variety of aspects of this novel treatment approach and on the design 
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of a future pivotal trial. Comparison of 6 and 12 month follow-up data with baseline shows 
gradual return to baseline in lung function (FEV1, RV), though improvements in exercise 
capacity and quality of life remained stable. In fact, there was a further improvement in the 
SGRQ between 3 and 6 months post treatment. This probably reflects the time needed to 
recover fully from the procedure and to increase regular activity levels. This in turn leads to 
further improvements in general conditioning and muscle strength driving further 
improvements in exercise capacity and quality of life. Emphysema is a progressive disease and a 
gradual deterioration in lung function is the norm. The VENT trial (82) reported data on a 
randomised, controlled population of severe emphysema patients with similar baseline 
characteristics, undergoing optimal medical care, providing an estimate of functional decline 
expected in this patient group. In these patients, median change from baseline to 6 months in 
6MWD was -10·7m, and mean change in SGRQ score was +0·6 (p=0·04).(82) These small but 
significant reductions are expected given the compromised status of patients at randomisation 
and the progressive nature of the disease, and highlight the need for longer-term controlled 
studies to establish the true magnitude of benefit of endoscopic treatment in this patient group.  
More robust guidance to ensure that recruited subjects were on optimal medical therapy would 
have been preferable, with clear definition of what this includes and for how long (I would 
recommend a minimum period of three months period prior to screening). Adding pulmonary 
rehabilitation within six months as an inclusion criteria is, in my opinion, an essential 
requirement. This was stipulated in the NETT trial and therefore not having had this as an 
inclusion criteria will limit from the ability to compare with this most validated form of LVR. 
More importantly, however, is that pulmonary rehabilitation is a categorically and incontestably 
one of the main pillars of optimal medical care of patients in COPD, and this should be a pre-
requisite within a reasonable timeframe before considering any LVR technique, whether 
clinically or as part of a trial. 
The SAE pneumothorax rate per procedure at our site was 8.8%, which is higher than reported 
in the literature and by the manufacturer’s database. Our trial is the biggest to date and this may 
represent a more accurate representation of the true risk of pneumothorax, different patient 
selection criteria, or indeed a technique issue at our site. The pneumothoraces were evenly 
spread out amongst early, middle and late recruits, making a “learning” effect an unlikely cause.  
Nevertheless, taken in context, 100% of LVRS patients have a chest drain post operatively for 
several days, and the pneumothorax rate for successfully treated patients with endobronchial 
valves is likely to be higher than 20% (discussed in section 1.3.8.3.2). Pneumothorax in this 
patient population can be particularly serious if it occurs outside of the hospital setting or if the 
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patient is unable to get to hospital rapidly. The majority of the pneumothoraces (7 of 9) in our 
cohort occurred within 12 hours of the procedure and were therefore quickly and easily treated. 
Of particular concern are delayed pneumothoraces, though these did not lead to severe or life 
threatening situations in both episodes in our cohort. We carefully educate our patients about 
pneumothorax, instruct them on what symptoms to look out for, to urgently attend their local 
emergency department should they develop any of these symptoms, and provide a detailed 
information sheet with emergency contact details. It was in fact the case that subjects who 
suffered from a pneumothorax had better improvements in lung function than the group as a 
whole with a mean (SD) 16.6 (19.6) % increase in FEV1, -0.67 (0.75) litre reduction in RV, and 
66.8 (81) m improvement in the 6MWD 3 months after treatment. Pneumothorax is a reflection 
of successful tension of the coils within the lung, and once treated this tension and compression 
should lead to the benefits in lung function as seen. 
There was no increased risk of infective or non-infective exacerbations in the treatment 
recovery period or the subsequent 12 months as a result of the LVRCs. We were concerned 
about atypical bacterial, fungal, and non-tuberculous mycobacterial infections related to the 
presence of foreign bodies in a cohort already susceptible to recurrent infections. This has not 
been an issue in the vast majority our patients. Two patients cultured pseudomonas species for 
the first time, more than 6 months after treatment. Eradication was successful in one patient, 
and unsuccessful in another. The latter was a frequent exacerbator prior to his LVRC treatment 
and continues to suffer from recurrent exacerbations. Pseudomonas is a recognised coloniser in 
COPD and it is not possible to say whether these episodes are directly related to the LVRCs. One 
other patient developed an upper lobe pneumonia 8 months after treatment, leading to 
cavitation and ultimately an aspergilloma. There are no LVRCs in or around this cavity. He 
recovered fully following a 10 day admission. He continues to culture aspergillus but is 
otherwise well, and has not developed allergic bronchopulmonary or invasive aspergillosis. We 
have not seen any incidences of non-tuberculous Mycobacterial infection in this LVRC treated 
cohort. 
Although the manufacturer states that the LVRC deployment process is reversible and the 
LVRCs are removable, our experience suggests that they are not. It is indeed possible (but not 
easy) to grasp the proximal end of a coil and advance the sheath over it, however the reality is 
that the vast majority of the LVRCs recoil distally once released, out of site of the bronchoscope. 
This makes it impossible to remove these coils with existing bronchoscope sizes. In over 200 
treated patients, there was one case in Germany where an LVRC needed to be removed due to 
persistent coughing. It was not possible to pull the LVRC back into a catheter so it was simply 
pulled out, fortunately without injury. To my knowledge, there has not been another situation 
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where a coil needed to be removed. The LVRCs should not preclude lung transplantation should 
this become an option for patients as the whole lung is resected, however LVRCs may be 
problematic if lung volume reduction surgery is to be considered. It is likely that LVRCs will 
cross the intended staple line and possibly interrupt the staple gun action. The LVRCs, which are 
not removable endobronchially, will therefore need to be removed by dissecting the lung prior 
to stapling. This should not be technically difficult to perform however it would certainly 
require an open thoracotomy rather than a video assisted thoracoscopic surgical (VATS) 
procedure, according to Mr Simon Jordan, thoracic surgeon. One subject from this trial, a non-
responder, was referred for LVRS two years after his LVRC treatment. A lobar resection 
approach to LVRS was adopted case in this case as there was very little remaining healthy 
parenchyma in the resected lobe. However we made attempts to staple over the LVRCs ex vivo 
post explantation and the staple gun could not successfully accomplish this.  
Whereas a unilateral treatment approach has been adopted for endobronchial valve lung 
volume reduction, bilateral treatment has been used for LVRCs. When comparing paired data in 
our LVRC treatment cohort, there was no statistically significant difference in any of the 
outcome measures between 1 month post 1st treatment and 1 or 3 months post 2nd treatment, 
other than a difference between the 6MWDs 1 month post 1st treatment and 3 months post 2nd 
treatment. However, the between group difference for change in RV, % change in FEV1 and % 
change in FVC as compared to baseline where not significant after the first treatment but 
significant 3 months post 2nd treatment. The small number of patients studied makes comment 
difficult, however it may be the case that the largest improvements occur after the first 
treatment as the worst affected lung was targeted first. It may be that some “retensioning” effect 
is transferred across the mediastinum towards the contralateral lung as gas trapping is reduced 
in the treated lung. It may also be the case that there is a reduction in benefit after an early peak 
after which the lung or LVRCs remodel to absorb the new tension. It may therefore be more 
optimal to spread out treatments over a longer time period (for example 3-4 months). This 
would also allow a longer period for recovery from any adverse events associated with the first 
procedure.  
The optimal number of LVRCs per lung to achieve maximal benefit is not known. The first-in-
man studies of the LVRCs treated each lung with six LVRCs leading to small clinical 
benefits.(103) The following feasibility study aimed to treat each lung with 10 coils, and results 
were encouraging. Inserting more than 10 LVRCs into a single lobe is technically difficult; 
accessing more than 10 subsegmental airways leading into distinct airways in different parts of 
the lobe is challenging with the required size bronchoscope. Therefore the number of LVRCs is 
dictated by practical issues and knowledge of the minimum number of coils needed to effect a 
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positive change (probably ~8 LVRCs).  There was no relationship between outcomes and 
number of LVRCs in our cohort. Different subjects or indeed lungs probably respond differently 
to LVRCs and a standardised number of LVRCs for all subjects may not be appropriate. It is now 
possible to measure compliance endobronchially using a dedicated pressure balloon, and 
studies examining the effect of each individual additional LVRC on lung compliance are required 
to better understand the effects of the LVRCs on the lung and tailor therapy for each lung.   
In our study, subjects with homogeneous emphysema were treated with LVRC implantation to 
both the upper and lower lobes. Unpublished data from one centre in the Netherlands, where a 
small number of patients with homogenous emphysema were treated with LVRCs to the upper 
lobe, showed benefits in outcomes on a par to patients with heterogeneous emphysema 
(personal communication, Dr. D-J Slebos and PneumRx representatives).  It remains unclear 
which approach is best, and it is unfortunately difficult to make any conclusions from our cohort 
as only five subjects  had upper and lower lobe treatments bilaterally, whilst 4 others had one 
homogenous and one heterogeneous lung and therefore had “mixed” distribution of treatment. 
The five patients with bilateral upper and lower lobe LVRC treatment had a mixed response 
with a mean (SD) change in the SGRQ of -2.7 (7.7) points, a reduction in the RV of -0.44 (0.71) 
litres, no change in FEV1 (+0.6 (12.2)%), and an increase in the 6MWD of 52.6 (54.1) metres 3 
months after treatment. Although some localised atelectasis surrounding LVRCs developed in 
some (but by no means all) patients on their CT scans, there was no significant volume loss in 
the treated lobes. This is consistent with the absence of change in TLC following LVRC 
treatment. Hence there was no “volume reduction” per se, and therefore the reduction in gas 
trapping is attributed primarily to retensioning of the lung and the resultant small airway 
splinting and prevention of expiratory airway collapse.  Crucially for patients, this leads to 
reductions in dynamic hyperinflation during exertion, which may explain the improvements in 
exercise capacity and quality of life which are proportionally larger than the changes in lung 
function. The target, therefore, is reducing gas trapping (RV) and it would seem sensible to 
deploy coils throughout the damaged lung parenchyma and not to restrict treatment to one 
particular lobe.  
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3.5  CONCLUSION 
 
Treatment with LVRCs results in improvements in quality of life, exercise tolerance and lung 
function which are sustained up to 12 months following treatment. Overall, the safety profile is 
acceptable particularly in view of the magnitude of benefit experienced by our cohort and in 
comparison with surgical and other bronchoscopic lung volume reduction techniques. A larger 
randomised controlled trial with longer follow-up to assess longer term durability and safety of 
the LVRCs is required. Spreading out the sequential  treatments might extend the benefits, and 
further studies informing on optimal LVRC number and location will help maximise the patients’ 
response. 
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Chapter 4 
Endobronchial autologous blood to reduce 
hyperinflation in advanced emphysema 
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4.1  BACKGROUND 
Lung volume reduction surgery (LVRS) is successful at improving quality of life, exercise 
capacity and mortality in a subgroup of patients with severe emphysema however it is 
associated with high morbidity and a5.5% mortality.(66) A variety of less invasive techniques to 
replicate the effects of LVRS have therefore been evaluated with mixed results. Bronchoscopic 
lung volume reduction using endobronchial valves, lung volume reduction coils, airway bypass 
stents, transpleural pneumonostomy, bronchial thermal vapour and biological gels are 
expensive techniques costing many thousands of pounds per treatment. They require extensive 
training of both primary and support staff, as well as substantial technical skill and experience 
to execute safely and successfully. For these reasons, access to these techniques is likely to be 
very limited even when a solid evidence base develops to support their use. These techniques 
require leaving foreign material in the airways in the form of foreign implants or biological gels 
and sclerosants. This predisposes to a theoretical risk of infection, trauma, bleeding, device 
migration or expectoration, and device failure. Furthermore, it is likely that each of these 
techniques, similar to LVRS, will be suitable to treat small subgroups of the emphysema 
population depending on phenotype.  
Biological lung volume reduction is based on the concept of inducing scarring of hyperinflated 
lung parenchyma, leading to tissue contraction and hence volume loss. In early animal studies, 
endobronchial trypsin-based solutions followed by fibrinogen and thrombin solutions were 
used to stimulate fibroblast attachment, proliferation and collagen expression, inducing scar 
organisation.(137) Human pilot studies of this technique followed (138, 139) and the solution 
has since been revised and patented as Aeris Polymeric lung volume reduction. Data from 28 
patients treated with this solution demonstrate changes on cross-sectional imaging in keeping 
with volume loss.(101) A pivotal trial of this technique is currently underway. 
Using a similar strategy Kanoh and colleagues trialled the use of autologous blood admixed a 
thrombin solution to achieve volume reduction, and have demonstrated significant reductions 
in static lung volumes and dyspnoea in a 59 year old man after infusion of a pre-prepared 
mixture of autologous blood with thrombin and fibrinogen into a large bulla.(105) The same 
group also published encouraging results in one patient with lymphangioleiomyomatosis and 
two with advanced heterogeneous emphysema.(140) Kanoh and colleagues suggested that 
blood has “potential bioadhesive properties”, and added thrombin solution to “enhance this blood 
effect”(140). They bronchoscopically injected 4 mls of blood with 2mls of thrombin solution in 
up to 5 subsegments per treated lung (maximum 20mls of blood per treatment), and repeated 
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this treatment twice weekly for up to four treatments. The amount of thrombin used per 
treatment was 20,000 iu.  
I investigated what volume of whole unaltered blood would contain equivalent amounts of 
thrombin. Discussions with Louise Tillier, consultant haematologist, and Simon Davidson, 
clinical scientist at our institution, informed that after a lag phase of up to 1 minute following 
venesection when no thrombin is measurable, thrombin generation peaks at approximately 2-4 
minutes. The thrombin concentration varies between individuals and is somewhere between 
200-1000nmol/ml (there is approximately 10nmol to 1iu). Therefore 180mls of whole blood 
contains anywhere between 36000 to 180000 iu of thrombin.  
In addition to the effects of clotting factors, the induction of oxidation and reduction reactions 
by extracellular haeme-bound iron contained within blood, an airway and alveoli irritant, also 
plays an important role in triggering an inflammatory response.(141) Therefore we propose 
that, if delivered in sufficient quantities, unaltered autologous blood contains sufficient amounts 
of fibrinogen, thrombin and extracellular haeme-bound iron to induce similar effects to the 
Biological LVR solutions or Kanoh et al.’s reconstituted blood mixture. If safe and efficacious, 
this inexpensive single treatment strategy has the potential for dramatic cost savings and 
widespread uptake. Theoretically, it can be offered to patients with a wide variety of patterns of 
emphysema including bullous disease, and not only restricted to heterogeneous upper lobe 
emphysema. We have therefore studied this treatment approach in two phenotypes of 
emphysema: heterogeneous emphysema and giant bulla. Crucially, we did not manipulate the 
blood following venesection with 180-240mls of blood instilled within 60 seconds of being 
withdrawn from the subject during the procedures (up to ~10 multiples of the volumes used by 
Kanoh et al).  
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4.2  A RANDOMISED DOUBLE-BLIND SHAM CONTROLLED 
TRIAL OF AUTOLOGOUS BLOOD INSTILLATION IN UPPER LOBE 
HETEROGENEOUS EMPHYSEMA 
 
4.2.1  METHODS 
 
4.2.1.1 Study Design 
This was a randomised double-blind sham-controlled study examining the safety and efficacy of 
autologous blood instilled bronchoscopically into the most emphysematous lobe in subjects 
with heterogeneous disease. Research ethics committee and NHS Trust R&D approval was 
obtained and all patients provided written informed consent. Patients were recruited between 
January 2010 and June 2012.  
 
4.2.1.2 Study outcomes 
Primary Endpoint 
 Between group difference in the change in Residual Volume (RV) 8 weeks post- procedure 
Secondary Endpoints 
1) Between group difference in the percentage change in FEV1 8 weeks post- procedure  
2) Between group difference in the change in the 6MWD 8 weeks post-procedure 
3) Between group difference in change in the SGRQ 8 weeks post procedure 
4) Between group difference in change in the mMRC score 8 weeks post procedure 
5) Evidence of new atelectasis on HRCT 8 weeks post- procedure. 
6) Difference in the adverse event profiles between the two groups. 
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4.2.1.3 Patient Selection 
Subjects with GOLD stage III-IV emphysema were recruited from the respiratory clinics at the 
Royal Brompton and the Chelsea and Westminster Hospitals, after discussion in the appropriate 
multidisciplinary meeting. Patients with severe airflow obstruction, significant hyperinflation, 
heterogeneous emphysema and limiting breathlessness who have no contraindications 
prohibiting bronchoscopy were considered. The inclusion and exclusion criteria are listed 
below.  
Inclusion Criteria: 
 Age 40-80 years. 
 Moderate to severe airflow obstruction FEV1 <50% Predicted. 
 Significant dyspnoea – mMRC  ≥2. 
 Hyperinflation – TLC ≥100% predicted, RV  ≥150% predicted. 
 Heterogeneous upper lobe predominant emphysema in at least one lung 
 Optimum COPD treatment for at least 6 weeks. 
 No COPD exacerbation for at least 30 days. 
 Fewer than 3 hospital admissions for COPD exacerbations in the preceding 12 months. 
Exclusion Criteria: 
 Patient unable to provide informed consent. 
 TLco <15% predicted or FEV1 <15% predicted. 
 PaO2 on air <6.0kPa or PaCO2 on air >8.0kPa. 
 Other major medical illness that will limit participation. 
 No contraindications to bronchoscopy. 
 Clinically significant bronchiectasis. 
 Large bulla more than 1/3 of hemithorax volume on CT scan. 
 Maintenance oral steroids greater than 10mg prednisolone daily. 
 Prior LVRS or lobectomy. 
 Participated in a study of investigational drug or device in prior 30 days 
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4.2.1.4 Study schedule 
Baseline/screening visit: 
 Full Informed consent. 
 Full medical history and clinical examination. 
 Static and dynamic lung volumes and gas transfer measurements. 
 Arterial blood gas tensions. 
 HRCT scanning of the chest. 
 6MWT. 
 SGRQ. 
 mMRC dyspnoea score. 
Bronchoscopic Procedures: 
The bronchoscopic procedure was performed at the earliest opportunity following fulfilment of 
the trial entry criteria. Subjects were randomised to either bronchoscopic autologous blood LVR 
or sham bronchoscopic LVR using 0.9% saline.  Randomisation, blinding and the procedure are 
discussed in more detail below.  
8 week evaluation: 
Participants underwent a repeat of all the examinations, investigations and health related 
quality of life questionnaires performed at baseline as listed above. Assessments were 
performed by an investigator blinded to the patient’s treatment allocation. Participants were 
unblinded only after completion of this 8 week assessment. 
4.2.1.5 Static and dynamic lung volumes and gas transfer measurements 
Lung function testing was performed at baseline and 8 weeks post- treatment. The lung function 
physiologists at the Royal Brompton Hospital lung function department perform all testing 
using the Compact Master Lab system (Jaeger, Germany). The European Coal and Steel Workers 
cohort is used to obtain standardised reference values(120).  
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4.2.1.6 Arterial blood gases 
ABG analysis was performed at baseline and 8 weeks post procedure by the lung function 
department physiologists at the Royal Brompton Hospital. End capillary blood samples from the 
participant’s earlobe were used.  Analysis for pH and for partial pressures of O2 and CO2 was 
performed using the Rapidlab 348 analyser (Bayer, Germany).   
4.2.1.7 HRCT of the chest  
HRCT scanning was performed at baseline and 8 weeks post procedure. A Siemens Sensation 64, 
a 32 detector scanner with a rotation time of 0.33 seconds was used. Volumetric spiral 
acquisition with contiguous slices (1mm slice thickness on 1mm for lung windows, and 10mm 
on 10mm mediastinal windows) was taken with the participant in the supine position at full 
inspiration. 
Baseline HRCTs were studied and heterogeneity independently assessed visually by two 
investigators using thin slice axial, sagittal and coronal reconstructions. The most 
heterogeneous lobe was identified for treatment. Subjects were excluded from the trial if both 
lungs were considered homogeneous. A joint review of the HRCT by the two investigators was 
performed and a consensus reached in case of disagreement between investigators. Interlobar 
fissures in the treated lung were considered intact if >90% of the fissure was in clear continuity 
in at least one axis.  
For post-trial analysis, HRCT scans at baseline and 8 weeks post treatment were directly 
compared by an independent, blinded, radiologist asked to state whether new atelectasis had 
developed, and in which lobe.  
4.2.1.8 6 minute walking distance 
The 6MWD is a well validated test of exercise capacity in patients with COPD, and is commonly 
used both in clinical practice and in research. In this study patients had their 6MWD measured 
at baseline and at 8 weeks post-procedure. The American Thoracic Society criteria(128) for the 
6MWD were followed. The test was performed in the same 30 metre long corridor at the Royal 
Brompton Hospital by the same blinded investigator.  
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4.2.1.9 St. George’s Respiratory Questionnaire 
The SGRQ (122) is a 76-item health status survey specific for respiratory conditions. It is 
designed to measure impact of the disease on overall health, daily life, and perceived well-being. 
The participants answered the questions considering the preceding 4 weeks at baseline and 8 
weeks post procedure.  
4.2.1.10 mMRC dyspnoea score 
Participants in this trial completed an mMRC score at baseline and 8 weeks post procedure. 
4.2.1.11 Randomisation and blinding 
Subjects were randomly allocated in a one-to-one ratio to either blood LVR (treatment arm) or 
sham procedure using 0.9% Saline (control arm). The randomisation sequence was computer 
generated in random permuted blocks of 10. The generated codes were placed in sequentially 
numbered opaque sealed envelopes and opened in sequence in the bronchoscopy suite after the 
patient was sedated, by a staff member who was not part of the research team. The six 60ml 
syringes used during each procedure were pre-wrapped in opaque tape making the contents of 
the syringe unknown on external examination. Treatment and control arm patients had 
venesection of 180 mls of blood. At the time of instillation of solution, the staff member with the 
randomisation information handed the investigators a wrapped syringe containing either blood 
or 0.9% saline solution as per randomisation. At the end of the procedure, 5 mls of blood were 
injected down the bronchoscope channel in the main trachea in all subjects, such that subjects 
in both treatment arms had the possibility of having minor haemoptysis post- procedure. The 
bronchoscopists were therefore blinded throughout the procedure, as was the patient. As the 
instilled solution was released 4cm distal to the tip of the bronchoscope, we anticipated that the 
contents of the syringe will not be made known to the bronchoscopist in most cases. We were 
unexpectedly pleased that in none of the subjects treated with autologous blood did any blood 
leak or flow back proximally after instillation.  The follow-up investigations (6MWD, PFTs) were 
performed by assessors who were blinded as to which trial arm the subject was in. 
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4.2.1.12 Bronchoscopic Procedures and venesection 
The bronchoscopic procedures were performed at the Chelsea and Westminster Hospital 
endoscopy unit using moderate sedation (intravenous Midazolam and Fentanyl) as day case 
procedures. The participant was given a bronchoscopy information leaflet to review and 
relevant instructions at least 24 hours in advance of the procedure. Departmental pre-
procedure and post-procedure protocols for routine bronchoscopy were followed for patients in 
both treatment arms.  
Once in the bronchoscopy suite and sedated, a pre-sealed envelope was opened by a member of 
staff who was not part of the research team. This informed on the patient’s randomisation to 
receive either blood or 0.9% saline solution. A diagnostic bronchoscopy was performed before 
the target segment was approached. This was determined by the investigators based on HRCT 
assessment as described above. An extended working channel was advanced 4 cm distally from 
the tip of the bronchoscope into one sub-segment (figure 4.1).   Venesection of 60 mls of blood 
was then performed using syringes wrapped in opaque tape and the syringe handed to the 
assistant who opened the randomisation envelope. The bronchoscopist was then handed back a 
syringe (contents unknown to the bronchoscopist) by the unblinded assistant. The treatment 
solution was instilled within 60 seconds of venesection through the extended working channel 
followed by a 10mls 0.9% saline flush. After a period of 120 seconds, the extended working 
channel was repositioned into the next sub-segment and the process repeated. Three 
subsegments of the target lobe were treated. 
At the end of all procedures, 5mls of blood were injected into the trachea via the bronchoscope 
working channel, aiming to even out the risk of minor haemoptysis post-procedure between 
both study arms.  The rest of the blood retrieved during the procedure was discarded in 
accordance with infection control policies.  
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Figure 4.1: The extended working channel advanced 4cm beyond the tip of the bronchoscope. 
4.2.1.13 Statistical analysis and sample size 
The VENT endobronchial valve study,(82) which recruited a similar patient population, is the 
only published randomised controlled trial from which data for calculation of sample size can be 
utilised. The change in RV at 6 months in the VENT trial responder sub-group (subjects with 
high heterogeneity, intact fissures, and successful lobar occlusion) was ∆-56.8%. Changes in RV 
at earlier time-points were not published. For 80% power and a significance of 0.05, assuming a 
more conservative reduction in RV of 40% in the treatment arm to be clinically significant and 
no change in RV in the control arm, a study of 14 patients in each arm would be required. 
Therefore in such a pilot trial with little data to support a sample size calculation, recruiting 35 
patients (assuming 20% drop outs) was sensible to pick up any signal in outcomes and safety. 
An efficacy and safety analysis after recruitment of approximately half the cohort was 
performed. 
Qualitative data is presented as percentages and comparisons of these variables will be 
performed using Chi squared or Fishers exact test. Quantitative data was checked for normality. 
Data that are normally distributed are presented as mean (standard deviation) and 
comparisons done using the 2 sample t test. Data that are not normally distributed are 
presented as median (Inter quartile range) and comparisons done using the Wilcox rank-sum 
test.  
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4.2.2   RESULTS – INTERIM ANALYSIS (17 PATIENTS RECRUITED) 
 4.2.2.1 Baseline data, procedure details and follow-up data availability 
An interim analysis was conducted after 17 patients were recruited. One patient withdrew 
consent before randomisation. One subject died before his procedure (sudden cardiac event) 
and two withdrew consent before their procedures (one no longer wished to take part, and the 
other was offered entry into a novel inhaler device trial). Of the remaining 14 patients, seven 
were randomised to the treatment arm with autologous blood LVR, and seven to the control 
(sham) arm using 0.9% saline.  
Baseline demographics and lung function data are illustrated in table 4.1. No differences were 
observed between the two groups. There were no differences in procedure time, sedation 
requirements or target treatment lobes.  
 
Table 4.1: Baseline and procedure data for the endobronchial blood LVR study 
 Treatment Control p value Ŧ 
Number 7 7 - 
Age (yr.) 64.9 (4.9) 65.4 (7.9) 0.85 
Male (%) 57 71 1.0 ¥ 
BMI 24.3 (4.4) 22.5 (4.5) 0.46 
FEV1 % predicted 28.9 (8.1) 26.9(10.2) 0.99 
FVC % predicted 87.3 (14.3) 76.7(19.8) 0.54 
RV % predicted 229.4 (31.6) 223.3 (46.9) 0.44 
TLC % predicted 135.7 (7.1) 127.1(14.0) 0.26 
RV/TLC 63.7 (7.0) 64.2 (9.7) 0.80 
TLco % predicted 32.4 (14.8) 31.1(10.7) 0.90 
PaO2 (kPa) 8.8 (1.3) 8.8 (1.3) 0.54 
PaCO2 (kPa) 5.1 (0.8) 5.1 (0.8 0.17 
mMRC (points) 2.6 (0.5) 2.6 (0.5) 0.94 
SGRQ (points) 55.4 (14.0) 57.1 (12.6) 0.90  
6MWD (m) 264.0 (76.6) 274 (131) 0.71 
Procedure data 
Procedure time (min) 23.9 (4.0) 22.6 (3.2) 0.52 
Right upper lobe (%) 43 57 1.0 ¥ 
Midazolam (mg) 2.0 (0.58) 1.86 (0.4)  0.66 
Fentanyl (mcg) 28.6 (9.5) 21.4 (9.5) 0.21 
Ŧ All Mann-Whitney test except ¥ where Fisher’s exact test was used.  
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4.2.2.2 Primary Endpoint 
The primary endpoint visit took place 49.3 (8.9) and 50.7 (17) days following the procedure in 
the treatment and control arms, respectively. Tables There was a mean (SD) increase in the RV 
in the treatment arm of 0.384L, and a mean (SD) reduction in the control arm of  0.333L. The 
between group difference in the change in RV was 0.719 L (95% CI 0.019 to 1.41, p=0.011) to 
the detriment of the treatment arm (figure 4.2, tables 4.2 - 4.4). 
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Figure 4.2: Primary outcome change in RV 8 weeks post procedure – Autologous blood LVR study. Top: 
Box plot; and bottom: individual and group average data. 
 
 
4.2.2.3 Secondary Endpoints 
Data discussed below is illustrated in figure 4.3 and detailed in tables 4.2 – 4.4.  
1) Percent change in FEV1: 8 weeks following the procedure, there was a 13.2 (5.8) % 
reduction in FEV1 in the treatment arm, and a 2.4 (8.2) % increase in FEV1. The between 
group difference was a non-statistically significant 15.8 (10.3) % change in favour of the 
control arm (p=0.15).  
2) Change in the 6MWD: 8 weeks following the procedure, there was a 32.9 (40.3) m 
reduction in the 6MWD in the treatment arm, and a 4.7 (51.1) m increase in the control arm. 
The between group difference was a non-statistically significant 37.6 (24.6) m in favour of 
the control arm (p=0.25).  
3) Change in SGRQ: 8 weeks following the procedure, there was a 3.4 (7.9) point increase in 
the SGRQ in the treatment arm, and a 2.5 (5.0) point increase in the control arm. There was 
no significant difference between the groups (∆ 0.88 (3.4) points).  
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4) Change in the mMRC dyspnoea score: There was no change in the mMRC score in any of 
the treatment arm patients, and a mean 0.29 (0.49) increase in the mMRC score in the 
control arm patients (2 subjects had a 1 point increase).  
5) Evidence of new atelectasis on HRCT: Zero of seven subjects in the treatment arm and zero 
of seven subjects in the control arm had CT evidence of development of new atelectasis in 
the treated lobe 8 weeks post procedure. 
6) Safety Analysis: Three of seven subjects in the treatment arm and one of seven in the 
control arm experienced mild infective exacerbations of COPD which resolved fully 
following treatment with the rescue pack of an appropriate antibiotic and 30mg daily of 
Prednisolone for seven days provided on discharge. None required hospital admission or 
medical review. Only one study patient (in the treatment arm) experienced minor 
haemoptysis post-procedure. There were no adverse events related to venesection of 180ml 
of blood in these subjects. 
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Figure 4.3: Change in secondary endpoint outcome measures 8 weeks autologous blood LVR post-
procedure. 
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Table 4.2: Treatment arm outcome measures at baseline and 8 weeks following autologous blood LVR 
treatment. 
 
 
 
 
 
 
 
Mean (SD) or median (range); ¥ Wilcoxon sign rank test. 
 
Table 4.3: Control arm outcome measures at baseline and 8 weeks following sham bronchoscopy. 
 
 
 
 
 
 
 
Mean (SD) or median (range); ¥ Wilcoxon sign rank test. 
 
 
Outcome Baseline 8 weeks Change p-value¥ 
RV (L) 5.24 (1.36) 5.62 (1.50) 0.38 (0.42) 0.03 
FEV1 (L) 0.76 (0.19) 0.66 (0.20) -0.10 (0.10) 0.48 
FVC (L) 2.90 (0.46) 2.52 (0.53) -0.37 (0.29) 0.03 
TLC (L) 8.14 (1.46) 8.32 (1.52) 0.18 (0.28) 0.16 
SGRQ (points) 55.4 (14.0) 58.8 (12.3) 3.39 (7.51) 0.30 
6MWD (m) 264 (77)) 231 (68) -33 (40) 0.11 
mMRC (points) 3 (2-3) 3 (2-3) n/a n/a 
RV/TLC (%) 63.7 (6.95) 66.8 (8.23) 3.1 (3.4) 0.08 
TLco 2.67 (1.33) 2.47 (1.22) -0.20 (0.28) 0.18 
pO2 (kPa) 9.21 (1.24) 8.83 (1.29) -0.37 (1.23) 0.47 
pCO2 (kPa) 5.10 (0.84) 5.36 (0.87) 0.26 (0.51) 0.22 
Outcome Baseline 8 weeks Change p-value¥ 
RV (L) 5.49 (1.57) 5.16 (1.27) -0.33 (0.53) 0.22 
FEV1 (L) 0.81 (0.30) 0.80 (0.27) -0.01 (0.16) 0.80 
FVC (L) 2.93 (0.68) 3.13 (0.76) 0.20 (0.30) 0.16 
TLC (L) 8.44 (1.27) 8.47 (1.19) 0.02 (0.38) 0.94 
SGRQ (points) 57.1 (12.6) 59.6 (11.5) 2.51 (5.02) 0.22 
6MWD (m) 273 (131) 278 (103) 4.71 (51.2) 0.87 
mMRC (points) 3 (2-3) 3 (2-4) n/a 0.35 
RV/TLC (%) 64.2 (9.69) 60.5 (8.56) -3.74 (2.90) 0.03 
TLco 2.72 (0.80) 2.94 (0.99) -0.22 (0.55) 0.38 
pO2 (kPa) 8.30 (1.18) 8.60 (1.16) -0.30 (1.19) 0.69 
pCO2 (kPa) 5.67 (0.89) 5.48 (1.06) -0.19 (0.53) 0.38 
Zaid Zoumot 
CID: 00541359      
 122 
 
Table 4.4: Between group differences in the mean change from baseline of primary, secondary and non-
endpoint measures 8 weeks post- treatment. 
Outcome 8 weeks following treatment p value¥ 
Change in RV (l) 0.713 (0.225) 0.011 
% Change in FEV1  15.8 (10.2) 0.13 
% change in FVC 20.4 (5.4) 0.002 
Change in TLC (l) 0.156 (0.177) 0.53 
Change in 6MWD (m) 37.6 (24.6) 0.26 
Change in mMRC (points) 0.29 (0.48) n/a 
Change in SGRQ (points) 0.88 (3.4) 0.71 
Change in RV/TLC (%) 6.8 (1.7) 0.002 
Change in TLco 0.43 (0.23) 0.08 
Change in PaO2 (kPa) 0.67 (0.65) 0.38 
Change in pPaCO2 (kPa) 0.45 (0.28) 0.097 
Mean (SD) or median (range); ¥ Mann Whitney test. 
 
4.2.3  STUDY DISCONTINUATION 
The study was discontinued after the interim efficacy and safety review conducted by the study 
team led by the chief investigator, Dr. Pallav Shah. This decision was later discussed at the 
advanced COPD MDT at the Royal Brompton Hospital and there was consensus that this was an 
appropriate course of action. The primary reason was that there  did not appear to be any 
signal to suggest a positive response clinically, radiologically or on lung function to LVR 
using endobronchial segmental instillation of autologous blood. It also became apparent 
that the primary endpoint was inappropriate, with eight weeks too short a period for a 
fibrotic process to manifest, nor for full recovery from post procedure exacerbations. 
After commencement of the trial, data was published from other techniques utilising a 
similar mechanism of action (vapour(87) and PLVR(86)) showing optimal benefit at six 
months following treatment. We also had safety concerns with data suggesting a 
deterioration in the status of the treatment arm patients with a statistically significant 
worsening in gas trapping (RV) despite small patient numbers.  
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4.3  A PILOT STUDY OF BRONCHOSCOPIC INTRABULLOUS 
AUTOLOGOUS BLOOD INSTILLATION (BIABI) FOR THE TREATMENT 
OF GIANT BULLAE  
 
4.3.1  METHODS 
 
4.3.1.1 Study Design 
This trial was a small single arm open label proof of concept pilot study examining the safety 
and efficacy of autologous blood instilled bronchoscopically directly into giant bullae. Subjects 
who were not suitable for, or had declined the offer of, surgical bullectomy and had no 
alternative treatment options were recruited. Research ethics committee and NHS Trust R&D 
approval was obtained and all patients provided written informed consent. Patients were 
recruited between October 2011 and May 2012.  
4.3.1.2  Study Endpoints 
Primary Endpoint 
 Change in the RV 3 months following treatment. 
Secondary Endpoints 
1) Percentage change in FEV1 3 months following treatment. 
2) Change in SGRQ 3 months following treatment. 
3) Change in 6MWD 3 months following treatment. 
4) CT evidence of change in bulla volume 3 months following treatment. 
5) Adverse event rate. 
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4.3.1.3 Patient Selection 
Subjects with giant bullae who were not suitable for, or had declined the offer of, surgical 
bullectomy and had no alternative treatment options were recruited from the respiratory clinics 
at the Royal Brompton and the Chelsea and Westminster Hospitals, after discussion in the 
appropriate multidisciplinary meeting. Patients with a giant bulla, airflow obstruction, 
significant hyperinflation, and limiting breathlessness who have no contraindications 
prohibiting bronchoscopy were considered. The inclusion and exclusion criteria are listed 
below.  
Inclusion Criteria: 
 Age > 40 years.  
 Hyperinflation – TLC ≥100% predicted, RV ≥150% predicted. 
 Giant bulla (>30% of hemithorax). 
 Exertional breathlessness (mMRC ≥1). 
 Bullectomy contraindicated or is actively avoided. 
 Optimum COPD treatment for at least 6 weeks. 
 No COPD exacerbation for at least 6 weeks. 
 Fewer than 3 admissions for infective exacerbations in the preceding 12 months.  
Exclusion Criteria: 
 Inability to obtain informed consent  
 Co-morbidities that would render bronchoscopy or sedation unsafe. 
 Anaemia or other reasons precluding venesection. 
 pO2 on air <6.0kPa or pCO2 on air >8.0kPa. 
 Clinically significant bronchiectasis. 
 Subject taking clopidogrel, warfarin, or other anticoagulants and unable to stop. 
treatment for 5 days pre-procedure. 
 Maintenance oral steroids greater than 10mg prednisolone a day. 
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4.3.1.4 Study schedule 
The study schedule is summarised in table 4.5. 
Baseline/screening visit: 
 Full Informed consent. 
 Full medical history and clinical examination. 
 Static and dynamic lung volumes and gas transfer measurements. 
 Arterial blood gas tensions. 
 High resolution computed tomography (HRCT) scanning of the chest. 
 6 minute walking test (6MWT). 
 St. George’s Respiratory Questionnaire (SGRQ). 
 Modified Medical Research Council (mMRC) dyspnoea score. 
 
Table 4.5: Summary of BIABI trial study schedule 
 Baseline Procedure 3 months post 
treatment 
Clinical History X  X 
Examination X  X 
PFTs X  X 
mMRC X  X 
SGRQ X  X 
HRCT scan X  X 
6MWT X  X 
Bronchoscopy  X  
 
Bronchoscopic Procedures: 
The bronchoscopic procedures were performed at the Chelsea and Westminster Hospital 
endoscopy unit as day case procedures using mild sedation (intravenous Midazolam). The 
participant was given a bronchoscopy information leaflet to review and relevant instructions at 
least 24 hours in advance of the procedure. Departmental pre-procedure and post-procedure 
protocols for routine bronchoscopy were followed.  
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A diagnostic bronchoscopy was performed before the bronchial segment containing the giant 
bulla was approached. This was determined by the investigators based on careful examination 
of the bronchial anatomy on HRCT along with real time fluoroscopic imaging. An extended 
working channel was passed bronchoscopically into the giant bulla and fluoroscopy was used to 
guide and confirm the positioning of the tip of the extended working channel inside the giant 
bulla (figure 4.4).  Venesection of 60 mls of blood was then performed and the blood was 
instilled through the extended working channel within 60 seconds of being withdrawn, followed 
by a 10ml normal saline flush. The process was repeated and a total of 180mls-240mls of the 
patient’s blood was instilled.  
 
Figure 4.4: Fluoroscopic image exhibiting the tip of an extended working channel inside a giant bulla. 
 
3 month evaluation: 
Participants underwent a repeat of the examinations, investigations and health related quality 
of life questionnaires performed at baseline as listed above.  
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4.3.1.5-9 Static and dynamic lung volumes and gas transfer measurements, 
arterial blood gases, 6MWD, SGRQ, and mMRC 
As in sections 4.2.1 
4.3.1.10 HRCT of the chest 
HRCT scanning was performed at baseline, 3 and 6 months following treatment. A Siemens 
Sensation 64, a 32 detector scanner with a rotation time of 0.33 seconds was used. Volumetric 
spiral acquisition with contiguous slices (1mm slice thickness on 1mm for lung windows and 
10mm on 10mm for mediastinal windows) was taken with the participant in the supine position 
at full inspiration. 
HRCT scans were studied and the presence of a giant bulla was independently assessed visually 
by two investigators using thin slice axial, sagittal and coronal reconstructions. Fissures in the 
treated lung were considered intact if >90% of the fissure was in clear continuity in at least one 
axis. The location of the bulla and the sub-segmental airways leading into it were noted.  
For post-trial analysis, HRCT scans at baseline and 3 months post treatment were directly 
compared by an independent, blinded, radiologist who were asked to state whether there is 
bullae volume change of >20%, and whether there is evidence of scarring/fibrosis in the bullae 
lining. 
 
4.3.2  RESULTS 
 
4.3.2.1 Baseline data and procedure details 
Five subjects (three male and two female) were recruited (age range 43 – 78 years). Table 4.6 
details the baseline demographics, lung function, CT characteristics, and procedure specifics. 
The cohort had severe airway obstruction (mean (SD) FEV1 36.4 % (6.8) predicted) with severe 
gas trapping and hyperinflation (mean RV 218 % (53.3) predicted). Mean (SD) procedure time 
was 25 (6.6) minutes. There was successful deposition of the blood with no back-spill seen in 
any of the cases. The mean dose of Midazolam required for the procedures was 2.25 (0.62) mg.  
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4.3.2.2 Primary Endpoint 
The primary endpoint visit took place 95.4 (5.8) days following the procedure. The cohort 
experienced a clinically significant reduction in the primary outcome measure of change in RV 
of ∆-0.73 (0.50) L three months following BIABI treatment (p=0.06) (figure 4.6, table 4.6). 
4.3.2.3 Secondary Endpoints 
The secondary endpoints are illustrated in figure 4.6 and detailed in table 4.7.  
1) There was a mean (SD) % increase in FEV1 of 17.3 (17.8) % 3 months post treatment. 
2) There was a mean (SD) reduction in SGRQ of 11.1 (13.3) points 3 months post treatment. 
3) There was a mean (SD) increase in the 6MWD of 88 (69.9) m 3 months post treatment. 
4) There was significant reduction in the CT size of the bulla as evidenced by displacement of 
the interlobar fissures and the development of new scarring within the bulla lining in 3 of 5 
subjects (60%) as determined by an independent blinded radiologist 3 months following 
treatment.  
5) Adverse events: discussed in section 4.2.3.4 below. 
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Table 4.6: Baseline demographics, lung function, CT characteristics (including fissure integrity), and 
procedure details of subjects in the BIABI study.  
 Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Mean SD 
Sex F M M M F - - 
Age (yr.) 61 60 68 43 78 63.7 8.7 
FEV1 (% predicted) 39 41 13 30 59 36.4 16.8 
FVC (% predicted) 102 69 39 96 91 79.4 25.8 
TLco (% predicted) 32 48 - 68 26 43.6 18.8 
RV (% predicted) 214 185 283 253 149 216.7 53.3 
TLC (% predicted) 146 104 127 144 118 127.8 17.7 
RV/TLC (%) 57.8 59.2 79.2 52.6 57.9 61.3 10.3 
PaO2 (kPa) 8.62 9.88 6.98 10.3 6.75 8.51 1.62 
PaCO2 (kPa) 4.58 4.32 5.61 4.79 3.85 4.63 0.65 
mMRC (points) 3 2 4 1 4 2.8 1.3 
SGRQ (points) 74.9 56.4 72.6 28 66 59.6 19.1 
6MWD (m) 90 144 - 411 63 177 160 
Fissures >90% intact 
(treated lobe) 
Yes No Yes No Yes - - 
Treated bullae 
RLL apical 
segment 
RUL 
anterior 
segment 
RML 
LUL apical 
segment 
LLL apical 
segment 
- - 
Procedure time (min) 25 19 33 30 18 25.0 6.6 
RLL, right lower lobe; RUL, right upper lobe; RML, right middle lobe; LUL, left upper lobe; LLL, left lower lobe. 
 
Table 4.7: Change in efficacy outcomes three months after treatment. 
Subject number 1 2 3 4 5 
No. of 
Responders 
Mean change SD 
RV (L) -1.23 -0.98 -0.23 -1.06 -0.17 3/5 -0.73 & 0.50 
FEV1        
(%change) 
27.1 33.1 -11.1 22.4 14.9 4/5 17.30 17.28 
SGRQ (points) 0.9 -22.5 2.2 -8.8 -27.5 3/5 -11.1 13.25 
RV/TLC ratio 
(%) 
-12.1 -19.3 3.6 -14.9 0.9 3/5 -8.39 10.39 
6MWT (m) 53 177 - 106 16 3 /4 88 69.90 
Number of MCID 
endpoints 
4/5 5/5 0/4 5/5 2/5    
Change on HRCT Yes No No Yes Yes    
&p=0.06 Wilcoxon matched pair test. Improvements beyond the minimal clinically important differences (MCIDs) of 
FEV1 improvement of >12%,(135) RV reduction of >0.35L,(134) SGRQ reduction of >4 points,(133) increase in the 
6MWD of >26m,(126) and RV/TLC ratio reduction >10% highlighted in bold/italics) 
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Figure 4.5: Primary and secondary outcomes before and 3 months following BIABI treatment. 
6MWD was not available for one subject. 
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4.3.2.4 Safety Analysis 
Subject 1 was admitted to her local hospital eight days after her procedure with symptoms and 
chest radiograph appearances of pneumonia. She improved with nebulised bronchodilators and 
intravenous antibiotics for three days and was discharged home five days after admission, with 
subsequent complete resolution of the adverse event. Two of the other four patients 
experienced infective exacerbations of their COPD at days 4 and 9 following their procedures, 
respectively. Both took their seven day rescue pack of antibiotics and prednisolone provided to 
them on discharge, after discussion with the research team. Both episodes fully resolved. No 
other adverse events were reported by the subjects.  There were no adverse events noted 
related to venesection of 180-240mls of blood in these subjects. 
 
4.4  DISCUSSION 
These two pilot studies demonstrate the safety of bronchoscopically instilled endobronchial 
autologous blood using moderate sedation in patients with severe COPD. The adverse event 
profile was acceptable with the only adverse events experienced involving an inflammatory 
reaction – a desired outcome in terms of inflammation leading to scarring.  
The optimal volume of blood instilled to cause the desired effect is unclear, and likely depends 
on the location and method of instillation. Our data reveals that 180-240mls is sufficient to 
trigger a response when concentrated inside a confined space (a bulla), but probably not when 
instilled in 60mls aliquots as in subsegmental airways of emphysematous parenchyma. This 
volume of venesected blood was not sufficiently large to cause side effects of hypotension in our 
studies. Venesection of 440mls is routinely undertaken for blood donation and other medical 
reasons.  
The patients with heterogeneous disease having lobar blood instillation had a significant 
deterioration in lung function compared to the sham control group 8 weeks following treatment 
in this small cohort. Mean reduction in FEV1 of 13% and increase in RV of 380mls are above the 
MCIDs for these outcomes, but these are likely skewed by one subject in the treatment arm who 
had recovered from an exacerbation only 3 days before her follow-up visit and had a 40% 
reduction in FEV1 and 1.16L increase in her RV. Similarly, the control group had a mean 330ml 
increase in the RV, driven by one subject’s 1.3L reduction 8 weeks following a sham 
Zaid Zoumot 
CID: 00541359      
 132 
 
bronchoscopy. This highlights a major limitation of such small underpowered trials from which 
one should not draw conclusions.  
It may be that there remains subtle parenchymal inflammation in the treated lobes 8 weeks 
following lobar blood instillation, and that the patients had not fully recovered from post-
procedure exacerbations. The follow up period may be inadequate to detect a benefit as trials 
with Ariseal and thermal ablation with steam have shown that maximal benefit occurs after six 
months.(85, 142) However five of the seven patients in the treatment arm group (two received 
other non-medical therapy soon after completing trial follow-up) did not demonstrate any 
symptomatic or lung function improvements at routine clinical review 9 - 12 months following 
treatment. It may be that a more concentrated instillation of the full volume of blood in one 
subsegment or repeated treatments would be more effective at inducing scarring, rather than 
small volumes of blood interspersed throughout the treated lobe. 
Stopping randomised controlled trials early for apparent benefit or lack thereof is controversial 
and may have ethical considerations. Conducting frequent or unplanned interim analyses runs a 
risk of capturing the data at a time of a random extreme, usually representing an overestimation 
of benefit, though an underestimation is equally possible but less likely to be acted upon in 
terms of stopping a trial early.(143)  In an explanation and elaboration to the  CONSORT 2010 
statement on guidelines of reporting parallel RCTs,(144) possibilities why trials may be stopped 
early are reviewed: “RCTs can stop earlier than planned because of the result of an interim 
analysis showing larger than expected benefit or harm on the experimental intervention. Also RCTs 
can stop earlier than planned when investigators find evidence of no important difference between 
experimental and control interventions (that is, stopping for futility). In addition, trials may stop 
early because the trial becomes unviable: funding vanishes, researchers cannot access eligible 
patients or study interventions, or the results of other studies make the research question 
irrelevant”. Whatever the cause, RCTs must clearly indicate why trials came to an end and who 
made the decision,  disclosing extrinsic factors including the funding sponsor’s role in the 
decision to stop the trial. Section 4.2.3 details this information for the autologous blood LVR 
study, and several of the reasons reviewed by Moher et al. contributed to the decision to 
discontinue this trial. However one must comment on the fact that there was no pre-appointed 
safety and data monitoring committee for this interventional study and the decision was made 
by the chief investigator and study team. This was a small single centre study with very limited 
funding nevertheless it would have been preferable to have an independent committee in a trial 
involving an intervention which risks serious adverse events. The decision was later discussed 
with members of the COPD MDT to obtain a consensus, but this was not mandated in the 
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protocol. The timing of the interim analysis was appropriate as the follow up period was short 
such that follow-up data was available for all patients enrolled onto the study at the time of the 
decision to discontinue the trial. This meant there was no unblinding of patients still awaiting 
follow-up at the time of trial discontinuation, and no “relaxation” of the best medical care 
offered to patients in both study arms. However as discussed previously there is little data in 
the literature to give an accurate sample size calculation and patient numbers were small with 
data skewed by patients with outlying results. There are ethical obligations to trial participants 
who provided informed consent at the time of recruitment, and all subjects were informed of 
the trial discontinuation and offered other treatments if suitable. It is important that results of 
this trial are published as this may guide other researchers to adjust trial protocols avoiding 
other patient exposure to this unsuccessful technique. The results have been submitted to 
several respiratory journals but unfortunately editors did not find the study of sufficient 
interest for publication. We hope to successfully publish this data in an open access journal in 
the near future. 
The post-BIABI treatment data are very encouraging and show large improvements in lung 
function, exercise capacity, and respiratory related quality of life in 3 out of 5 patients. Crucially, 
this was accompanied by clear reduction in bullae size on CT in 3 of the 5 patients. Subjects 1, 2 
and 4 had dramatic and almost universal improvements across the outcome measures, 
exceeding the minimally clinically important differences (MCIDs) by large margins (table 4.6).  
All three described their symptomatic improvements as “life-changing”. Subject 5 had strong 
responses in 2 of the 5 outcome measures with trends in the direction of benefit in RV change. 
CT scans performed at the follow-up visit demonstrated noticeable reductions in the size of the 
bullae in subjects 1, 4 and 5, with evidence of new fibrotic reactions in the bullae lining (figure 
4.6). The patients had further follow-up assessments six months post- BIABI treatment outside 
the trial protocol, and the mean reduction in RV diminished slightly but was still improved 
compared to baseline (∆-0.27 (0.47)L), whilst improvements in FEV1 (∆+16.4 (23.7)%), 6MWD 
(∆+60.5 (42.4) m), and SGRQ (∆- 11.7 (10.7) points) were maintained. FVC increased further as 
compared to baseline (∆+16.2 (30.2)%). These encouraging results after five treated patients 
informed the design of a larger feasibility and safety study of BIABI treatment for giant bullae in 
patients unsuitable for bullectomy. The protocol was written by the author and favourable 
Ethics and local Research and Development opinions obtained (NCT 01727037). Ten of a target 
30 patients have already been treated and early results are thus far consistent with  data 
presented in this thesis. 
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The health and symptom status of the BIABI cohort was relatively heterogeneous, with two of 
the three “responders” suffering from end-stage inoperable disease with very poor exercise 
tolerance, whilst the third subject was relatively young and active but had declined the offer of a 
bullectomy. Nevertheless all three had similarly large benefits from this minimally invasive 
treatment. Subject 3, the non-responder in this cohort, had had two previous pleurodeses for 
pneumothoraces which may have restricted lung remodelling explaining his lack of response.  
 
 
Figure 4.6: Coronal HRCT scan images from subject 2 at baseline, 3, and 6 months following BIABI 
treatment. There is a reduction in bulla size 3 months after treatment and new thickening and fibrosis of 
the inferior bulla lining can be appreciated. No subsequent change was seen between 3 and 6 months 
following treatment. 
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We also observed that, when successful at instigating an inflammatory reaction, remodelling 
and scarring continues to develop beyond three months. Figure 4.7 illustrates images from 
subject 1’s HRCT scans at baseline, 3, 6 and 12 months following treatment. The shrinking of the 
bulla is progressive and dramatic. This subject’s lung function and quality of life score 
improvements have been maintained 12 months following treatment. Trials with other 
sclerosants and profibrotic agents such as Aeriseal and thermal ablation with steam have shown 
that maximal benefit occurs after six months.(85, 142) 
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Figure 4.7: Axial CT scan images of Subject 1 at the levels of the T4 (carina) and T6 vertebrae at baseline, 
3, 6 and 12 months following BIABI treatment. There is progressive and dramatic shrinking in the size of 
the bulla. 
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It is likely that repeat intrabullous blood instillation (perhaps 3-6 months after the first 
treatment) can lead to further shrinkage of bullae. However this was not necessary in subject 1 
as described above. We repeated subject 5’s BIABI treatment as she showed a partial response 
three months after her first treatment. Three months after her second BIABI treatment (nine 
months after the first treatment) the patient had further improvements in lung function, quality 
of life, exercise capacity (table 4.7), along with a major reduction in bulla size on HRCT scanning 
(figure 4.8). Repeat treatment decisions should be made on an individual basis.  
 
Table 4.8: Outcome measures for subject 5 three months after the first and second treatments. 
 Baseline 
3 months post 
1st treatment 
Change 
(%change) 
from baseline 
3 months post 
2nd treatment 
Change 
(%change) from 
baseline 
RV (L) 3.07 2.90 -0.17 (-5.5%) 2.45 -0.62 (-20.2%) 
FEV1 (L) 0.94 1.08 0.14 (14.9%) 1.41 0.47 (50.0%) 
SGRQ (points) 66 38 -28 37 -29 
RV/TLC ratio (%) 57.9 52.4 -5.51 (-9.5) 46.1 -11.8 (-20.3) 
6MWT (m) 63 79 16 (25.4) 101 101 (60.3) 
 
Although essential for successful lung volume reduction using endobronchial valves,(82, 83) 
success of techniques which reduce lung volume by inducing scarring and fibrosis should not be 
influenced by the presence or absence of collateral ventilation. Hence fissure integrity (as a 
surrogate for the absence of collateral ventilation) is not a factor in the success of these 
treatment approaches.(101, 145)  We can therefore deduce that fissure integrity should not 
influence the success of bronchoscopic intrabullous autologous blood instillation. In our cohort, 
two of the five patients BIABI patients had incomplete fissures in the treated lobe, both being 
strong responders.  
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Figure 4.8: HRCT scan images for subject 5 at the levels of the aortic arch, the carina and T7 vertebra, as 
well as coronal views 3 months after the first, and 3 and 6 months after the second treatment (10 months 
after the first treatment). These demonstrate shrinkage of the giant bulla with re-expansion of the upper 
lobe and shifting of the mediastinum towards the treated lung. 
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4.5  CONCLUSION 
The results from these studies using endobronchially instilled autologous blood suggest that 
BIABI treatment into giant bullae can induce shrinkage of the bullae leading to clinically 
meaningful improvements in lung function, exercise capacity and quality of life in some patients. 
This treatment represents a cheap, minimally invasive and safe technique to reduce bulla 
volume. It may serve as an adjunct to surgical bullectomy, by postponing the need for surgery or 
indeed as a precursor to surgery. It may also be considered in the treatment of frail patients on 
maximal medical therapy who are not fit for surgical intervention when no other treatment 
options are available. Further basic science research is required but the patient responses in the 
BIABI pilot study are sufficiently impressive to warrant a larger clinical trial. 
Autologous blood instilled in aliquots of 60mls per lobar segment is ineffective at inducing 
atelectasis and reducing lung volumes. Success of autologous blood instillation in giant bullae 
suggests that, in principle, the technique may be successful but the technique requires 
refinement and further study is required. 
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Chapter 5 
Optoelectronic Plethysmography in the assessment of 
advanced emphysema and the effects of lung volume 
reduction 
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5.1  BACKGROUND 
Optoelectronic plethysmography (OEP) is a system for indirectly measuring lung volumes based 
on an automatic motion analyser which detects 89 passive markers composed of a thin film of 
retro-reflective paper on plastic hemispheres (5-10mm diameter). Six-eight cameras 
surrounding the patient record non-invasively real time breath-by-breath images of the 
markers and their movement (figure 1.8). Dedicated software uses the data received from the 
cameras to compute 3-dimentional co-ordinates of the markers by stereo-photogrammetric 
techniques. The principles, history, validation and applications of OEP were discussed in Section 
1.4.  
A particularly useful characteristic of OEP is that the software can be programmed to divide 
chest wall volumes into any desired combination of different compartments or subdivisions 
once the raw data has been accrued. This technology has not been used to study the effect of 
lung volume reduction in the treatment of emphysema, and in particular I was interested to 
examine the effect of unilateral treatment on changes in chest wall measured lung volumes with 
a view to informing physiological mechanisms of benefit following lung volume reduction. 
Specifically, does reduction in hyperinflation lead to changes in chest wall movements? Is any 
improvement limited to the treated side or is there bilateral change? In which compartment 
does this change in chest wall volumes predominate (pulmonary rib cage (RC,p), abdominal rib 
cage (RC,a) or abdomen(Ab))?   
In health, the expansion and contraction of the rib cage and abdominal compartments during 
inspiration and expiration occurs in tandem as the straightened diaphragm pushes abdominal 
contents downwards (and thus abdominal wall outwards), and the intercostal and accessory 
muscles of respiration work to expand the ribcage. The diaphragm apposed part of the rib cage 
(RC,a) is subjected to different pressures than the upper rib cage (RC,p) which is apposed to the 
visceral pleurae. The flattened straightened diaphragm in COPD alters this dynamic and 
uncoordinated or asynchronous expansion of the rib cage compartment can occur, with 
negative impacts on ventilatory mechanics.(146, 147) Aliverti and colleagues used 
ultrasonography to delineate the area of apposition of the diaphragm to the chest wall, and then 
to measure diaphragm fibre length.(109) They demonstrated a linear relationship between OEP 
measured abdominal compartment volume displacement and diaphragm length, and concluded 
that this highly repeatable measure can be used to estimate diaphragm length. The same group 
used OEP to demonstrate the effect of within breath asynchrony on dynamic hyperinflation in 
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patients with COPD, with lower rib cage paradox associated with earlier dynamic hyperinflation 
than in COPD patients without chest wall asynchrony at baseline.(119) This did not influence 
exercise capacity or dyspnoea, but leg fatigue was higher in early hyper inflators.  In contrast, 
Bruni et al. did not find that rib cage paradox influenced exercise capacity or the degree of 
dynamic hyperinflation in 10 COPD patients.(148) It has been proposed that returning the 
length of the diaphragm back to a more natural shape is one of the mechanisms of benefit of 
LVRS (section 1.3.8.3.1), but this has not been quantified. Here, the author hypothesised that 
OEP can demonstrate that reductions in hyperinflation and the accompanied return of the 
diaphragm to a more normal physiological length results in improvements in chest wall 
asynchrony or diaphragmatic paradox. Whether the presence of asynchrony at baseline can 
predict the response to lung volume reduction was also of interest.  
In terms of direct comparison of volumes obtained with spirometry and those using OEP, small 
discrepancies were reported during quiet tidal breathing,(108)  slow expiratory 
manoeuvres,(149) tidal breathing during submaximal (150, 151) and peak exercise (152)  in 
patients with COPD and healthy controls. However there is general agreement that OEP 
measured dynamic chest wall volumes during forced or maximal manoeuvres are different to 
the volumes of air being expired from the mouth. This is due to factors relating to changes in 
intrathoracic pressures (blood shift out to the extremities and gas compression),(153) and 
increased movement artefact.(151)  In patients with severe airflow obstruction, the author 
hypothesised that gas compression may play a leading role in the discrepancy between 
spirometric  and OEP measured volumes during forced expiratory manoeuvres as exit out of the 
thorax through narrowed and collapsible airways is severely restricted, compared to patients 
without airflow obstruction. Do improvements in airflow obstruction lead to reduction in 
discrepancies between spirometric and OEP measured volumes during forced expiratory 
manoeuvres? 
Thus the aims of this study are to: 
1) Assess compartmental chest wall volume changes following lung volume reduction in 
patients with emphysema. 
2) Assess whether improvements in airways obstruction following LVR lead to reduction in 
the discrepancy between spirometry and OEP measured volumes during forced 
expiratory manoeuvres. 
3) Assess changes in chest wall asynchrony following lung volume reduction. 
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I also included in the study protocol cardiopulmonary exercise testing to examine whether OEP 
can be used, reliably and non-invasively (without a mouth piece), to assess the effect of lung 
volume reduction on dynamic hyperinflation in patients with severe COPD, though this was 
beyond the scope of this thesis. 
 
5.2  METHODS 
 
5.2.1  STUDY DESIGN 
This was a prospective study recruiting patients with COPD undergoing lung volume reduction 
procedures at the Royal Brompton Hospital as part of routine clinical care or clinical trials. This 
included patients having both LVRS and BLVR (LVR coils, endobronchial valves, and 
endobronchial/intrabullous autologous blood instillation). Research ethics committee and NHS 
Trust R&D approval was obtained and all patients provided written informed consent. Patients 
were recruited between July 2011 and March 2013. After fulfilling the enrolment criteria, 
subjects had baseline assessments and these were repeated 3 months following treatment.  
This is a pilot study with no data in the literature to guide a sample size calculation. We 
obtained ethics committee approval to assess 20 patients undergoing lung volume reduction, 
aiming to study 8-10 LVRS and 10-12 BLVR subjects, as well as 20 control COPD patients 
preferably undergoing a sham bronchoscopy as part of a clinical trial. 
 
5.2.2  STUDY ENDPOINTS 
1) Change in static and dynamic compartmental chest wall volumes 3 months post LVR, 
compared to controls. 
2) Change in FEV1 and FVC measured by OEP post LVR, and the change in the difference 
between OEP and spirometry measured values after LVR compared to baseline. 
3) Change in chest wall asynchrony 3 months post lung volume reduction compared to 
controls. 
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5.2.3  PATIENT ENROLMENT 
Participants were recruited at the Royal Brompton Hospital. Patients already scheduled to 
undergo LVRS as part of routine clinical care where identified from the thoracic surgical 
outpatient clinics, the advanced COPD MDT and ward admissions lists. Patients enrolled onto 
BLVR clinical trials were identified from the advanced COPD MDT and research fellows in our 
department. BLVR trials ongoing at time of recruitment for this study included randomised 
controlled trials of endobronchial valves, lung volume reduction coils, and autologous 
endobronchial blood instillation. Subjects were also recruited from a single arm pilot study of 
bronchoscopic intrabullous autologous blood instillation for giant bullae. The control phase of 
the endobronchial valve and the endobronchial autologous blood instillation trials involved a 
sham bronchoscopic procedure. 
The enrolment criteria were as follows: 
Inclusion Criteria 
 COPD patient scheduled for a lung volume reduction procedure 
 Age > 18 years  
 Written informed consent 
Exclusion Criteria 
 Inability to obtain informed consent  
 Contraindications or inability to perform cycle ergometry  
 
5.2.4  SUBGROUP DEFINITIONS 
Not all patients are expected to have a positive outcome following BLVR, and the implication 
this has on possible OEP findings is clear; if there is no “lung volume reduction” then we do not 
expect to find any change on OEP measured chest wall volumes. In this study, we sought to 
identify changes in thoraco-abdominal chest wall movements as a result of successful lung 
volume reduction, specifically compartmental volume change and chest wall asynchrony after 
unilateral procedures. Therefore those with a positive outcome were separated from those with 
unsuccessful treatment for the purpose of data analysis. BLVR patients were divided into 
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subgroups depending on whether lung volume reduction was achieved or not; termed 
“responders” and “non-responders”. Patients were deemed to be responders if there was: 
(1) Clear radiological evidence of significant volume reduction (i.e. lobar or segmental collapse 
with displacement of the interlobar fissures on HRCT, or significant reduction in the size of a 
giant bullae causing interlobar fissure displacement or adjacent parenchyma re-expansion); and  
(2) Improvements in spirometry or hyperinflation on pulmonary function testing exceeding the 
MCIDs in % change in FEV1 of reduction in RV. 
 
 
5.2.5  STUDY SCHEDULE 
Baseline assessments were performed within 2 weeks of the planned procedure, and in 
conjunction with other assessments if treatment was performed as part of another clinical trial. 
The data collected included: 
 Demographic data 
 Pulmonary function tests (static and dynamic lung volumes and gas transfer) 
 SGRQ 
 mMRC Dyspnoea Score 
 HRCT of the thorax 
 6MWD 
 Arterial blood gas analysis 
 Incremental cycle ergometry to maximum achievable workload. 
 Endurance submaximal cycle ergometry exercise test at 75% of maximal workload 
achieved during the Incremental test. 
 OEP recordings were made simultaneously during spirometry and endurance cycle 
ergometry. 
Three months after the procedure (LVR or sham), subjects had a repeat assessment as listed 
above without repeating the incremental cycle ergometry test.  
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5.2.6  OEP: TECHNICAL ASPECTS AND PATIENT TESTING 
The OEP system at the Royal Brompton Hospital is the latest from BTS Bioengineering (2011) 
and uses eight cameras. This maximises reflective yield from the markers and improves stability 
of the geometric model, especially if there is excessive movement during the recording. After the 
first few cases and a couple of system “crashes”, we operated the infrared cameras at 30Hz 
rather than 60 Hz to minimise the chance of system malfunction and loss of data from 
excessively large data files.  
This study was the first to utilise the OEP system at the Royal Brompton Hospital. Simon Ward, 
head of the lung function department at the Royal Brompton, and Chris Nelson, senior 
physiologist, had received training on how to calibrate and use the OEP system by BTS 
Bioengineering engineers upon installation of the system. They in turn kindly trained me, and 
Chris and I performed the first 20 patient assessments together. A steep learning curve and 
technical difficulties were expected in the early stages. The majority of OEP tests were 
performed by both operators present together to ensure consistency, and I was personally 
present for all but two patient assessments. 
5.2.6.1  Room preparation 
Before each test, the cameras were mounted on their dedicated tripod stands or wall brackets 
and connected in the correct numbered order to the OEP system (the equipment is kept secure 
when not in use). Blinds were closed as natural light (but not indoor incandescent light) can 
disturb infrared light detection. All reflective material in the room was covered with drapes (e.g. 
metal taps, oxygen cylinders, coat hooks, computer screens, PhD candidate’s belt buckle) and 
the patient and other staff instructed to remove watches, rings, necklaces and any item that can 
reflect light.  
5.2.6.2  Infrared cameras 
Experience following the first few cases suggested that the optimal camera positioning when 
patients are on a cycle ergometer (often leaning forwards and with arms out straight on the 
handlebar) is not the standard setup with eight cameras on wall brackets at head height. For 
subsequent tests we placed six of the cameras on wall mounted brackets at a height of 2.5m and 
the other two cameras were positioned on tripods at chest level (Figure 5.1). This enabled 
Zaid Zoumot 
CID: 00541359      
 147 
 
marker detection from an angle below the outstretched arms. Before each OEP assessment, the 
camera positions were adjusted for every patient with the patient sitting on the cycle ergometer 
seat after adjusting the seat height. The camera views on the computer screen guided camera 
positioning ensuring that the whole torso is within each camera’s the field of vision (Figure 5.1). 
 
Figure 5.1: OEP system setup at the Royal Brompton. Top panel, camera positioning anteriorly;  Bottom 
panel, reflective marker positioning; camera view for optimisation of camera positioning and focus level 
to ensure all markers are within view and detectable by each infrared camera.  
 
5.2.6.3  Calibration 
A triangular shaped calibration tool (“Reference Frame Assembly” including a “wand”) with 
inbuilt reflective material was used to perform a two part calibration of the system (Figure 5.2). 
The tool was placed on the cycle ergometer seat, and 3-dimensional positions in the x, y, and z 
axes were calculated during a 5-10 second recording. Each camera has to recognise all three 
axes in the first part of the calibration process. In the second part, the wand is moved around 
within the space above the cycle ergometer seat which the subject will occupy for 
approximately 90 seconds. The calibration is complete and accurate when the cameras are able 
to detect the wand as it moves through the given space. If the wand is not detected, part 1 of the 
Zaid Zoumot 
CID: 00541359      
 148 
 
calibration needs to be repeated, and the cameras may need to be manipulated. Once calibration 
is complete, the system is immediately ready to measure breath by breath volumes.  
 
Figure 5.2: Step 1 of the OEP system calibration using the Reference Frame Assembly tool.  
 
5.2.6.4  Reflective markers 
With the cameras and cycle seat position optimised and the OEP system calibrated, OEP 
recordings may commence. The 89 reflective markers were carefully positioned on the subject’s 
torso in a grid following a specific protocol (BTS biomedical engineering handbook 2001, see 
figure 5.3). This was done using two-sided hypoallergenic circular adhesive tape. Anteriorly, the 
grid consists of seven horizontal rows between the clavicles and the anterior superior iliac crest 
with additional bilateral columns in the mid-axillary line. Posteriorly there are also seven 
horizontal rows between the C7 vertebra and the posterior axillary lines. All markers were 6mm 
in diameter. Guidance is for 79 hemi-spherical markers and the 10 markers in the mid-axillary 
lines being spherical protruding off their base to improve detection by the cameras which are 
positioned anteriorly and posteriorly relative to the cycle ergometer. However we found that, 
due to the camera views being restricted by outstretched arms holding the cycle ergometer 
handlebar, as well as other equipment in a relatively small room, views of the lower left anterior 
abdominal markers were frequently lost. Our solution was to place spherical markers in these 
positions, and also at the horizontal line at the level of the xiphisternum, to improved marker 
detection and accuracy.  
Zaid Zoumot 
CID: 00541359      
 149 
 
 
 
Figure 5.3: 89 marker configuration setup.  
 
5.2.6.5  OEP patient testing 
Before the start of each OEP recording, the subject was positioned optimally with all markers 
facing each camera completely within the camera’s field of vision.  The OEP screen was then 
switched from “camera view” to “3D view” and the “refresh” command used to prompt the OEP 
system to automatically connect the 89 markers matching the predefined geometric model, thus 
assigning each marker a label (1-89). The system can only create a model if all 89 markers are 
detected, and additional transient “phantom” markers from reflections off other objects in the 
room are common. If the resultant geometric model was incorrect, the system was refreshed 
repeatedly whilst subtle changes in the rotation and angulation of the torso were made until the 
geometric model was recognised by the OEP system. Labels can be re-tracked after the 
recordings are made and so if the automatic labelling system is not “connecting the dots” 
perfectly, this could be corrected at a later stage provided there is no error in marker placement 
on visual inspection of the model in the 3-D view. On occasions, repositioning of some markers 
was necessary to improve image capture. Once happy with a stable geometric model, recording 
was commenced. For each OEP test, two sets of OEP recordings were performed: 
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 Three forced expiratory manoeuvres were performed with the patient seated on the 
cycle ergometry seat with simultaneous recording of spirometry via a pneumotacograph 
with a mouthpiece and a nose clip applied. 
 OEP measurements were then obtained simultaneously whilst cycle ergometry testing 
took place, including a five minute rest phase with inspiratory capacity manoeuvres 
performed every minute, as detailed in section 2.7.2.  
The OEP and the metabolic cart recordings were started simultaneously to synchronise 
timelines and allow breath by breath lung volume measurement comparisons between the two 
systems.  
Standing or sitting up straight provides the best views and putting arms out to the side or on 
one’s hips kept them from interfering with the cameras’ marker capture. During cycling, 
however, subjects were asked to grab hold of the handlebars to enable them to cycle effectively 
and safely. Leaning forward alters thoraco-abdominal chest wall shape and volume, and the 
outstretched arms in particular interfered with the camera views especially of the lower 
anterior abdominal markers. Layton et al. reported difficulties ensuring all their healthy study 
subjects maintained adequately upright torso position and they were unable to analyse 3 of 30 
studies due to impeded camera views. (152) However, cycling upright is not the natural cycling 
position and likely influences exercise tolerance which is particularly limited in patients with 
severe emphysema. Therefore we asked patients to cycle holding the handlebars and, only if 
safe to do so, subjects were asked to sit up straight with their arms out to the side or on their 
hips supported by investigators for the 10 seconds before and 5 seconds after each inspiratory 
capacity manoeuvre (figure 5.4). 
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Figure 5.4: Arm positioning during inspiratory capacity manoeuvres to optimise marker detection by the 
infrared cameras.  
Early experience of cycle ergometry testing with OEP recording revealed that ECG electrodes 
were problematic, with limited room on the chest wall for the electrodes and 10 wires 
repeatedly impeding camera views of the markers markedly diminished the quality of the OEP 
recordings. Having had an incremental cycle ergometry test to maximal workload without 
cardiovascular strain, we took the view that it was safe to perform submaximal steady state 
exercise without ECG monitoring,  and subsequently the ECG electrodes were placed either on 
the forearms or lower back below the level of the lowest reflective markers (required for 
cardiac pulse rate measurements) (figure 5.1). 
It became clear early on that performing reliable OEP recordings of women is much more 
challenging, specifically with maintaining adequate camera vision of markers below the breast 
line. In fact it was near impossible particularly during cycling with the patients leaning forward. 
Furthermore, following strict anatomical guidelines for marker positioning is essential in this 
study of measuring compartmental chest wall volumes and chest wall asynchrony, and several 
studies of female patients were thus technically inadequate for analysis. However recruitment 
was dictated by patient availability and I continued to recruit females having LVRS (limited 
numbers) but restricted female recruits to those with a normal/low BMI.  
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5.2.6.6  Thoraco-abdominal chest wall volume analysis 
The standard OEP software protocol divides thoraco-abdominal lung volumes (Vcw) 
measurements into three compartments: pulmonary rib cage (Vrc,p), abdominal rib cage (Vrc,a) 
and abdomen (Vab). The upper border of Vrc,p is at the clavicles and jugular notch and 
terminates inferiorly at the horizontal line at the level of the xiphoid. This line is the superior 
border of Vrc,a which has its inferior borders at the lower costal margins. Vab extends from the 
lower costal margin to the level of a horizontal line connecting the anterior superior iliac crests 
(figure 5.5). For the purpose of our study and with the assistance of the technical department at 
the manufacturer BTS Bioengineering and the team at the Politecnico di Milano (Andrea Aliverti 
and Antonella Lo Mauro), we devised protocols to divide the chest wall volumes into six 
compartments; i.e. left and right for each of Vrc,p, Vrc,a and Vab. 
 
 
 
 
 
Figure 5.5: Thoraco-abdominal chest wall volumes (Vcw) and its separation into six compartments. 
(Adapted from the BTS Bioengineering OEP handbook 2011). 
After raw data accrual, the following process was followed: 
 For each recording, dedicated OEP software (OEPtracker, OEPanalyzer, and 
OEPtdfInspector (BTS Bioengineering, Milan)) enabled frame-by-frame review of all 
markers for correction of anomalous reflections, re-labelling of markers, and 
reconstruction of missing markers if feasible, to create a geometric model as complete as 
possible (ideally 89 markers for the duration of the recording) (figure 5.6). Some cycle 
ergometry recordings were very long (lasting up to 20 minutes at 30 or 60 
frames/second) and the resultant OEP files being extremely large (>300MB). Splitting 
these recordings into smaller and easier to manage parts was performed to facilitate 
analysis. 
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 Once marker tracking was completed and the models “cleaned up”, the OEPtracking 
software was used to calculate the frame by frame volumes of the recordings. 
 The volume data files were then viewed by dedicated software kindly provided by 
Andrea Aliverti and the team from the Politecnico di Milano (DIAMOV). A protocol 
splitting volumes into six compartments, as well as the standard three compartments 
(Vrc,p, Vrc,a and Vab) and Vcw was devised specifically for this study (figure 5.7). 
 The volume traces on DIAMOV were then used to identify points of interest on the time-
volume trace, and these were saved in the appropriate format: (1) for forced spirometry 
manoeuvres, the FRC, TLC, and RV points were highlighted for the largest of the three 
manoeuvres (figure 5.7).(2) For chest wall volume and asynchrony measurements, a run 
of between 5-10 stable tidal volume breaths was identified and the end expiratory (FRC) 
and maximum volumes of these tidal breaths (TV) was highlighted (figure 5.8). For the 
IC manoeuvre, TLC was highlighted and the end expiratory (FRC) volume obtained from 
the 5-10 tidal breaths (figure 5.8). The Vcw trace was used to identify the start and end 
of each breath or manoeuvre (rather than compartmental traces). 
 Matlab (version 7.11.0.584, Mathworks, Naticks, Massachusetts, USA), a mathematical 
analysis software, was then used to extract and export the data from the highlighted 
points of interest using DIAMOV, calculating volumes for each compartment and 
transferring this to a Microsoft Excel spreadsheet for analysis. 
 
Figure 5.6: Geometric model marker labelling using OEPtracker software.  
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Figure 5.7:    Volume-time trace of 9 compartments (labelled on right of screen), with the points of 
interest during the forced expiratory manoeuvre (FRC, TLC, RV) highlighted (red dots) for data 
extraction. A transient expansion of the chest wall compartments was seen in most patients within the 
first second of the forced expiratory manoeuvres in our cohort (green arrows), despite continuous 
expulsion of air from the mouth. 
 
Figure 5.8: Volume-time trace of Vcw, Vrc,p, Vrc,a and Vab during quiet breathing and an inspiratory 
capacity manoeuvre. Tidal volumes and IC points of interest highlighted (green and yellow dots) for 
extraction. 
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5.2.6.7   Analysis of thoraco-abdominal wall asynchrony  
Five to 10 stable tidal breaths during quiet breathing were averaged to obtain a typical 
respiratory cycle during quiet breathing (figure 5.8). This and the best of five resting IC 
manoeuvres were used to measure compartmental chest wall asynchrony using an approach 
first used to assess asynchrony by Bloch et al., and later by other groups (78, 148, 154-156) as 
follows:  
The time courses of the change in volume of the two compartments being examined for phase 
shift Ɵ (see below) were plotted against each other creating a Lissajou figure (figure 5.9). The 
degree of opening of the Lissajou figure corresponds to the phase shift angle(Ɵ). Ɵ was 
determined by the ratio of the distance delimited by the intercepts of the two compartmental 
volumes’ dynamic loops on a line parallel to the x-axis at 50% of the tidal volume of the first 
compartmental volume (m), divided by the second compartmental tidal volume (s) (figure 5.9), 
as:      
     Ɵ = sin-1 (ms-1)    
In this system, a phase angle of zero represents a completely synchronous movement of the 
compartments and 180˚ total asynchrony. The phase shift angle Ɵ was calculated separately for 
both quiet breathing and inspiratory capacity manoeuvres.  
Aliverti et al. (154) and Bruni et al. (148) both examined asynchrony between the pulmonary 
and abdominal rib cages in their respective studies of COPD patients during exercise.  However 
there are other possible asynchronous chest wall movements particularly when investigating 
the effect of unilateral interventions. Therefore, a Matlab protocol was kindly prepared by 
Antonella Lo Mauro of the Politecnico di Milano to extract the phase shift angles between the 
following compartments to enable the assessment of these various potential forms of chest wall 
asynchrony: 
 ƟRC;   Phase shift angle between RC,p and RC,a. 
 ƟDIA;  Phase shift angle between RCa and Ab.  
 ƟRC and ƟDIA for the treated (or worst affected side in sham treated patients) and non-
treated sides. 
 ƟRC,p;   Phase shift angle between treated and untreated sides of RC,p. 
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 ƟRC,a;  Phase shift angle between treated and untreated sides of RC,a 
 ƟAb;  Phase shift angle between treated and untreated sides of Ab 
 All phase shift angles above were calculated during tidal breathing and inspiratory 
capacity manoeuvres. 
 
 
Figure 5.9: (a-c) Time courses of Vrc,p, Vrc,a, Vab and Vcw during two consecutive breaths at rest. (d-f) 
Lissajou figures of the dynamic loops of ∆Vrc,p versus ∆Vrc,a during quiet breathing, averaged in 
respiratory cycle time of a (d) healthy subject, (e) a patient with COPD without asynchrony between Vrc,p 
and Vrc,a, and (f) a patient with COPD and asynchronous rib cage movement.     Period of inspiratory 
paradoxical movement; m, line parallel to the x-axis at 50% of RCp tidal volume; s; RCa tidal volume. 
Phase shift is calculated as Ɵ = sin-1 (ms-1). Adapted from (119) and reproduced with permission of the 
European Respiratory Society © Eur Respir J 2009 33:49-60;2008 (see appendix for permission letter). 
 
Aliverti et al. studied 14 normal subjects and used a difference of at least 2 standard deviations 
above the mean value in normal subjects (99% confidence interval) to obtain a threshold for the 
upper limit of normal of 14˚ for ƟRC.(154) Bruni et al. used in the same method to obtain a 
threshold for the upper limit of normal of 18˚ for ƟRC (this is mentioned in their manuscript 
(148) but not formally reported in the literature).  The upper range of normality for ƟDIA is not 
known, but is likely higher than ƟRC in view of the much more compliant abdominal wall as 
compared to the rib cage. Using an upper limit of normal of 18˚ for both ƟRC and ƟDIA in this 
study is conservative and reasonable based on the limited available evidence. 
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5.2.7  STATISTICAL ANALYSIS 
Data are presented as mean (1 standard deviation(SD)) or mean ± SD in tables for continuous 
variables. The normality test applied was the Shapiro-Wilk test.  The differences between 
groups for continuous variables were studied using either unpaired T-tests or the Mann-
Whitney U test depending on the normality of their distribution, or when comparing more than 
one group the one way analysis of variance with bonferroni’s multiple comparison test or 
Kruskal-Wallis test with Dunn’s multiple comparison test depending on normality of 
distribution. The differences between groups for categorical variables were tested using the Chi-
square test. Comparisons of repeated measures were performed using paired T-tests or 
Wilcoxon matched pairs test depending on normality of distribution. Between group 
comparisons were presented as mean change with 95% confidence intervals (CIs). A level of 
p<0.05 was considered significant.  
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5.3  RESULTS 
 
5.3.1  OVERVIEW  
The technical quality of the first 10-12 recordings was poor, and most were inadequate for 
analysis. We were still in the process of identifying the optimal camera positions for the purpose 
of our recordings, and had lost several recordings at the “save recording” stage due system 
malfunction as some data files were too large. The body habitus of some patients made 
detection of markers in certain positions (e.g. under the breast line in women) very poor. 
Improvements were made in our technique and also in patient selection, and advice sought 
from BTS Bioengineering. Recording quality and efficiency improved as we became more 
experienced. Thus to  account for technically inadequate studies and subjects who did not 
proceed to have a treatment or follow-up assessment, we continued recruitment beyond the 
initial target of 40 patient and ultimately 52 patients were recruited and assessed at baseline, 
with 43 having follow-up assessments. The flow diagram in figure 5.10 illustrates subject 
numbers in the trial and reasons for drop outs. Nine patients had LVRS, 12 LVR with 
endobronchial valves, eight LVR coils, eight sham bronchoscopy and five autologous blood LVR.  
A total of 104 OEP assessments were performed (LVR coil and two BIABI subjects had two 
treatments and hence two follow-up OEP assessments each).  The primary follow-up 
assessment visit for LVR coil patients was the one after the first treatment as our interest is in 
unilateral changes. Mean (SD) time between baseline and the primary follow-up assessment 
was 107 (50) days.  
For the purpose of data analysis, patients were categorised in the following groups: 1) LVRS 
(n=9); 2) BLVR responders (n=9); 3) Controls (sham controls (n=8) and BLVR non-responders 
(n=9)); and 4) LVR coils (n=8). 
The reasons for unsuccessful treatment in the BLVR non-responders were as follows: two 
expectorated valves; three had positive interlobar collateral ventilation and would thus not be 
expected to benefit from valve treatment; one had endobronchial anatomy which precluded 
complete lobar exclusion; and three had no response to autologous blood LVR.  It is reasonable 
to consider this group as effectively having had the equivalent of sham procedures for the 
purpose of this study, and thus their data was used with that of the sham bronchoscopy patients 
in the group labelled “controls”.  
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All eight LVR coil patient assessments where in the first 12 tests performed, and five were 
female. As a result only two subjects have technically satisfactory assessments.  This was 
disappointing as this group was the only cohort to have bilateral sequential treatments, of great 
interest from a unilateral assessment perspective. Although some had positive responses 
clinically the mechanism of benefit does not involve volume reduction per se, rather restoring 
lung elasticity and reductions in dynamic airway collapse (Chapter 3). Therefore responders 
from this cohort were not added to the BLVR responder group. 
 
Figure 5.10: Flow diagram of subjects in the OEP study 
For measurements of TVs, ICs and chest wall asynchrony, both baseline and 3 month OEP 
studies of sufficiently good technical quality for assessment were available for 9 LVRS patients, 
7 BLVR responders, and 10 controls. For forced expiratory manoeuvres, pre- and post- studies 
of adequate quality for assessment were available for 8 LVRS patients, 7 BLVR responders, and 
11 controls.  
Recruited and had 
baseline OEP 
assessment 
52 patients 
LVRS 
(9 patients) 
LVRS 
(9 patients) 
Endobronchial valves 
(12 patients)  
Responders – 6 patients 
Non-responders – 6 patients 
BLVR Responders 
(9 patients) 
Valves - 6 patients 
BIABI - 3 patients 
Blood LVR 
(6 patients) 
3 BIABI responders 
2 BIABI non-responders 
1 Endobronchial blood LVR non- 
responder 
Sham treatment  
(8 patients) 
Controls 
(17 patients) 
Sham - 8 patients 
Valves - 6 patients 
Blood LVR - 3 patients 
LVR coils  
(8 patients) 
Responders – 4 patients 
Non-responders – 4 patients 
No follow-up OEP assessment  
(9 patients) 
- RIP before treatment – 1 patient 
- RIP before follow-up assessment – 2 patients (1 
LVRS, 1 endobronchial valves) 
- Withdrew consent for treatment – 2 patients 
- Withdrew consent for follow-up OEP assessment – 2 
patients (both sham BLVR) 
- Surgical decision not to operate – 2 patients.  
Subgroups for analysis 
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5.3.2  CLINICAL CHARACTERISTICS AND VALUES AT BASELINE 
Baseline characteristics for the whole cohort and the subgroups are detailed in Table 5.1.  There 
was no significant difference between the any of the groups. 
Table 5.1: Baseline characteristics of all subjects and the different subgroups. 
 
All 
subjects 
(n=52) 
LVRS 
(n=9) 
BLVR 
respon
ders 
(n=9) 
BLVR 
non-
respond
ers (n=9) 
Sham 
(n=8) 
Control 
(n=17) 
Coils 
(n=8) 
No 
follow-
up 
(n=9) 
p-
value 
¥ 
Age 
(years) 
mean 62.7 58.6 62.2 62.4 64.0 63.2 65.4 63.8 
ns 
SD 7.6 9.2 10.1 5.7 5.4 5.5 6.0 7.9 
BMI 
(kg/m2) 
mean 24.8 23.0 27.4 24.9 25.5 25.2 24.8 23.3 
ns 
SD 4.0 4.5 2.9 3.4 3.9 3.5 4.0 4.2 
Males  (%)  83 89 78 100 75 88 38 89 n/a 
FEV1 (L) 
mean 0.94 1.07 1.04 0.94 0.97 0.95 0.76 0.85 
ns 
SD 0.30 0.39 0.26 0.29 0.23 0.26 0.20 0.34 
FEV1  % 
predicted 
mean 34.6 46.4 42.4 29.3 32.1 30.6 29.6 27.1 
ns 
SD 17.7 33.4 14.0 11.5 7.5 9.6 9.6 7.6 
FVC (L) 
mean 3.40 3.57 3.55 3.49 3.59 3.54 2.87 3.27 
ns 
SD 0.88 1.18 0.91 0.76 0.95 0.83 0.57 0.79 
FVC % 
predicted 
mean 95.2 103.0 113.4 85.3 97.3 90.9 87.9 83.8 
ns 
SD 33.6 47.9 53.4 26.2 18.5 23.0 12.8 13.2 
RV % 
predicted 
mean 217.8 214.3 194.3 229.5 229.0 229.3 212.3 227.9 
ns 
SD 41.8 43.1 40.4 53.6 23.4 41.0 47.6 35.6 
TLC % 
predicted 
mean 139.5 140.5 137.8 134.3 144.5 139.1 149.8 132.0 
ns 
SD 26.5 31.5 21.8 10.2 10.4 11.2 52.3 13.6 
FRC % 
predicted 
mean 182.2 181.1 170.4 192.2 190.0 191.1 195.8 167.6 
ns 
SD 36.2 32.6 20.8 23.3 19.9 21.1 31.3 65.9 
Raw % 
predicted 
mean 406.3 291.5 329.5 350.5 439.3 392.2 524.9 519.0 
ns 
SD 192.0 151.6 138.7 108.1 195.9 157.2 212.0 232.2 
TLcoc % 
predicted 
mean 36.4 33.1 39.1 35.5 43.1 39.3 37.6 30.6 
ns 
SD 11.0 11.7 12.1 10.2 7.1 9.3 11.1 11.3 
RV/TLC 
(%) 
mean 60.2 58.1 56.7 60.7 60.0 60.4 63.6 62.8 
ns 
SD 6.9 7.1 5.1 9.3 4.9 7.3 5.7 7.4 
SGRQ 
(points) 
mean 59.3 59.1 64.4 56.7 59.2 57.8 58.8 57.2 
ns 
SD 15.1 12.1 16.1 17.8 13.9 15.7 17.5 15.7 
6MWD 
(m) 
mean 330.1 390.6 297.9 350.0 353.3 351.6 317.4 281.4 
ns 
SD 101.2 82.7 137.3 82.7 94.3 85.7 53.0 114.4 
mMRC 
(points) 
mean 2.6 2.7 2.9 2.8 2.3 2.6 2.4 2.6 
ns 
SD 0.8 0.7 0.6 1.0 0.8 0.9 0.9 0.5 
PaO2 
(kPa) 
mean 9.3 10.0 9.1 9.0 9.7 9.4 8.9 9.0 
ns 
SD 1.2 1.4 1.3 1.1 0.7 0.9 1.4 1.1 
PaCO2 
(kPa) 
mean 5.1 5.0 4.9 4.7 5.3 5.0 5.4 5.3 
ns 
SD 1.0 0.7 1.0 0.6 1.7 1.1 0.8 1.0 
¥ Kruskal-Wallis test with Dunn’s multiple comparison test. 
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5.3.3  CLINICAL OUTCOMES 
LVRS patients and the BLVR responders had clinically and statistically significant improvements 
in lung function, exercise capacity and quality of life as detailed in table 5.2, which accompanied 
the radiological evidence of volume loss. Controls (patients who had sham bronchoscopy and 
patients who did not derive benefit from BLVR) did not exhibit any significant change in the 
clinical outcome measures. 
 
Table 5.2: Change from baseline in clinical outcome measures in the whole cohort and subgroups. 
 
All 
subjects 
(n=43) 
LVRS 
(n=9) 
BLVR 
responders 
(n=9) 
Coils 
(n=8) 
All LVR 
responders 
(n=18) 
Controls 
(n=17) 
p-
value¥ 
∆FEV1 
(L) 
mean 0.16 0.38 0.25 0.07 0.32 0.02 
0.01 
SD 0.33 0.61 0.21 0.10 0.43 0.14 
FEV1 
%change 
mean 15.3 33.6 26.9 9.8 30.3 1.6 
0.003 
SD 28.0 48.1 19.9 14.6 34.9 14.4 
∆FVC 
(L) 
mean 0.25 0.21 0.58 0.20 0.39 0.11 
ns 
SD 0.59 0.82 0.36 0.26 0.63 0.66 
∆RV 
(L) 
mean -0.49 -0.77 -1.16 -0.34 -0.96 -0.03 
<0.0001 
SD 0.66 0.71 0.32 0.61 0.55 0.42 
∆FRC 
(L) 
mean -0.34 -0.50 -0.82 -0.31 -0.66 0.05 
<0.0001 
SD 0.54 0.47 0.36 0.60 0.43 0.42 
∆TLC 
(L) 
mean -0.29 -0.57 -0.79 0.23 -0.68 -0.13 
0.001 
SD 0.69 0.58 0.52 1.10 0.53 0.36 
∆RV/TLC 
mean -5.1 -6.3 -9.3 -3.4 -7.8 0.5 
0.0004 
SD 11.0 10.5 2.8 3.6 7.4 4.3 
TLCOc 
%change 
mean 3.9 10.1 9.8 0.8 10.0 -0.9 ns 
(0.057) SD 15.9 20.0 17.6 11.9 17.8 13.4 
∆SGRQ 
(points) 
mean -7.4 -15.7 -12.4 -8.3 -14.1 0.1 
0.01 
SD 16.0 13.5 19.0 8.6 15.6 16.1 
∆6MWD 
(metres) 
mean 40.9 30.5 60.6 85.5 46.4 6.8 
ns 
SD 70.8 49.4 41.6 49.9 47.3 82.9 
∆mMRC 
(points) 
mean -0.40 -0.78 -0.67 -0.25 -0.72 -0.18 
ns 
SD 0.86 0.83 0.87 0.71 0.82 0.95 
¥Unpaired t-tests or Mann Whitney test comparing the change from baseline between all LVR responders 
(LVRS and BLVR responders) vs. controls. No significant difference was seen between LVRS and BLVR 
responder groups. 
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5.3.4   OEP RESULTS 
 
5.3.4.1  Static chest wall volumes 
5.3.4.1.1  Baseline 
Five to ten continuous stable tidal breaths during quiet breathing at rest with the patient sitting 
on the cycle ergometer were used to extract the end expiratory lung volume (Vcw at FRC), and 
the volume at the end of the inspiratory capacity manoeuvre was used to calculate the maximal 
total thoraco-abdominal chest wall volume (Vcw at TLC), and their compartments.  
There was no significant difference between the groups in static Vcw at TLC or at FRC at 
baseline, though there is a 7.7 L difference between the mean Vcw at TLC of the LVRS and BLVR 
responder groups at baseline. This may in be attributable to the difference in the mean BMI 
(23.0 (4.5) kg/m2 in the LVRS group vs. 27.4 (2.9) kg/m2 in the BLVR responder group).  Vcw of 
the treated (or worst affected in the control arm) side as a proportion of the total Vcw was 
similar between the groups at both TLC and FRC. 
 
Table 5.3: Baseline OEP measured static thoraco-abdominal chest wall volumes. 
 
All 
subjects 
(n=26) 
LVRS 
(n=9) 
BLVR 
responders 
(n=7) 
Controls 
(n=10) 
p-
value¥ 
Vcw at TLC 
(L) 
mean 31.30 28.10 35.80 31.03 
ns 
SD 6.47 6.03 6.53 5.43 
Vcw at TLC treated side 
(L) 
mean 14.73 13.11 16.80 14.73 
ns 
SD 3.26 2.89 3.41 2.88 
Vcw TLC treated side % of 
total Vcw 
mean 46.94 42.52 46.83 47.34 
ns 
SD 1.55 18.77 1.50 1.70 
Vcw at FRC 
(L) 
mean 29.47 26.21 33.66 29.47 
ns 
SD 6.47 6.01 6.29 5.80 
Vcw at FRC treated side 
(L) 
mean 14.79 13.13 16.91 14.79 
ns 
SD 3.27 2.90 3.40 2.86 
Vcw FRC treated side % of 
total Vcw 
mean 50.20 50.21 50.16 50.23 
ns 
SD 1.15 0.93 0.92 1.54 
¥ Kruskal-Wallis test with Dunn’s multiple comparison test. 
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5.3.4.1.2 Change in static total chest wall volumes at 3 months 
There were non-statistically significant reductions in Vcw at TLC of 0.71(2.89) L and at FRC of 
0.79 (2.7) L in the LVRS group 3 months following treatment (table 5.4). The reduction was 
evenly distributed between the treated and non-treated sides. There were no changes seen in 
the BLVR responder or control groups at 3 months (Table 5.4).  Between group comparisons in 
the change in Vcw at both FRC and TLC at 3 months did not reveal any significant between 
group differences. 
 
Table 5.4: Change in Vcw at TLC and FRC and change in proportion of Vcw from treated side. 
 
LVRS 
(n=9) 
BLVR 
responders 
(n=7) 
Controls 
(n=10) 
Change in Vcw at TLC 
(L) 
mean -0.71 0.35 0.06 
SD 2.89 1.91 2.80 
% change in Vcw at TLC 
(L) 
mean -2.6 0.97 0.89 
SD 9.3 5.05 8.76 
Change in proportion of treated 
side to total Vcw at TLC (%) 
mean -0.52 -0.18 -0.25 
SD 1.18 1.44 1.41 
Change in Vcw at FRC 
(L) 
mean -0.79 -0.02 0.51 
SD 2.7 2.70 7.92 
% change in Vcw at FRC 
(L) 
mean -0.39 0.78 -0.07 
SD 1.27 8.43 2.53 
Change in proportion of treated 
side to total Vcw at FRC (%) 
mean -0.97 0.36 0.32 
SD 1.28 0.91 0.86 
Wilcoxon matched pairs test comparing baseline and 3 months for each group, all non-significant. Kruskal 
Wallis with Dunn’s multiple comparison comparing change between the groups, non-significant. 
 
5.3.4.1.3  Static compartmental chest wall volumes and proportions to Vcw 
There was no significant change in compartmental volumes nor to their contribution to Vcw at 
TLC or FRC at 3 months in any of the groups (figure 5.12, table 5.5), though there was a trend 
towards a small reduction in Vrc,a post LVRS on the treated side (∆Vcw at TLC - 0.17L , p=0.08; 
Vcw at FRC -0.17L, p=0.09). There was no between group difference in the change in 
compartmental chest wall volumes at 3 months. 
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Table 5.5: Static compartmental lung volumes at baseline and 3 months post procedure. 
 
LVRS 
pre 
LVRS 
post 
p-
value¥ 
BLVR 
pre 
BLVR 
post 
p-
value¥ 
Control 
pre 
Control 
post 
p-
value¥ 
Vcw 
at 
TLC 
(L) 
 
 
 
Vrc,p Tr 7.47 7.29 0.48 8.54 9.15 0.17 8.14 7.96 0.65 
Vrc,a Tr 1.87 1.70 0.08 2.34 2.19 0.66 2.16 2.17 0.97 
Vab,Tr 3.77 3.67 0.68 5.92 5.90 0.91 4.42 4.54 0.62 
Vrc,p unTr 8.17 8.01 0.48 9.16 10.03 0.17 8.56 8.49 0.65 
Vrc,a unTr 2.36 2.35 0.55 3.07 2.95 0.66 2.70 2.63 0.97 
Vab, unTr 4.45 4.35 0.68 6.77 6.69 0.91 5.04 5.30 0.62 
 
 
Vcw 
at 
FRC 
(L) 
Vrc,p Tr 7.49 7.35 0.58 8.58 9.20 0.17 8.19 8.00 0.63 
Vrc,a Tr 1.87 1.70 0.09 2.32 2.18 0.64 2.17 2.18 0.98 
Vab,Tr 3.77 3.70 0.73 6.02 5.90 0.80 4.43 4.56 0.63 
Vrc,p unTr 7.35 7.29 0.58 8.33 9.23 0.17 8.01 7.89 0.63 
Vrc,a unTr 1.87 1.79 0.09 2.41 2.23 0.64 2.18 2.15 0.98 
Vab, unTr 3.86 3.59 0.73 6.00 6.00 0.80 4.49 4.59 0.63 
¥Wilcoxon matched pairs test. Tr, treated (or worst affected) side; unTr, untreated side. LVRS n=9, BLVR 
responder n=7, controls n=10. 
 
  
 
Figures 5.11 and 5.12: Compartmental contribution to Vcw at TLC (Fig 5.11 top) and FRC (Fig 5.12 
bottom). Tr, treated (or worst affected) side; unTr, untreated side. 
0%
20%
40%
60%
80%
100%
LVRS
pre
LVRS
post
BLVR
pre
BLVR
post
Control
pre
Control
post
Compartmental contribution to Vcw at TLC 
Vab, unTr
Vrc,a unTr
Vrc,p unTr
Vab,Tr
Vrc,a Tr
Vrc,p Tr
0%
20%
40%
60%
80%
100%
LVRS
pre
LVRS
post
BLVR
pre
BLVR
post
Control
pre
Control
post
Compartmental contribution to Vcw at FRC 
Vab, unTr
Vrc,a unTr
Vrc,p unTr
Vab,Tr
Vrc,a Tr
Vrc,p Tr
Zaid Zoumot 
CID: 00541359      
 165 
 
5.3.4.2  Dynamic chest wall volumes (TV, IC, FEV1, FVC) 
There was a reduction in the change in Vab during quiet breathing (TV) on the non-treated side 
in the LVRS group, and an increase in Vrc,a on the treated side in the BLVR responder group 
(table 5.6). No changes were seen in chest wall volumes during quiet breathing in the control 
group, and there were no significant between group differences in the above mentioned changes 
when comparing with the change in the control group. There were no changes in any of the 
groups in the compartmental volumes during inspiratory capacity manoeuvres (table 5.6). 
Table 5.6: Compartmental contributions to volume change during quiet breathing (TV) and IC at baseline 
and at 3 months. Presented as means. 
 
LVRS 
pre 
LVRS 
post 
p-
value¥ 
BLVR 
pre 
BLVR 
post 
p-
value¥ 
Control 
pre 
Control 
post 
p-
value¥ 
TV 
(L) 
Vrc,p Tr 0.152 0.127 0.21 0.090 0.050 0.14 0.062 0.098 0.08 
Vrc,a Tr 0.023 0.052 0.13 0.005 0.017 0.01 0.018 0.012 0.57 
Vab,Tr 0.200 0.214 0.52 0.353 0.304 0.53 0.359 0.367 0.38 
Vrc,p unTr 0.149 0.138 0.53 0.205 0.157 0.27 0.185 0.226 0.13 
Vrc,a unTr 0.067 0.064 0.56 0.070 0.107 0.50 0.119 0.104 0.51 
Vab, unTr 0.222 0.148 0.04 0.207 0.186 0.29 0.224 0.251 0.89 
IC 
(L) 
Vrc,p Tr 0.413 0.287 0.24 0.305 0.350 0.95 0.201 0.205 0.81 
Vrc,a Tr 0.110 0.142 0.91 0.186 0.234 0.52 0.150 0.157 0.54 
Vab,Tr 0.420 0.296 0.18 0.320 0.184 0.28 0.196 0.317 0.11 
Vrc,p unTr 0.425 0.476 0.36 0.548 0.516 0.79 0.372 0.414 0.51 
Vrc,a unTr 0.383 0.408 0.22 0.471 0.486 0.83 0.376 0.402 0.88 
Vab, unTr 0.167 0.513 0.10 0.571 0.497 0.39 0.343 0.498 0.95 
¥Wilcoxon matched pair test. LVRS n=9, BLVR responder n=7, controls n=10. 
Table 5.7: Compartmental contributions to FEV1 and FVC at baseline and at 3 months. 
 
LVRS 
pre 
LVRS 
post 
p-
value¥ 
BLVR 
pre 
BLVR 
post 
p-
value¥ 
Control 
pre 
Control 
post 
p-
value¥ 
FEV1 
(L) 
 
 
Vrc,p Tr 0.20 0.19 ns 0.19 0.16 ns 0.16 0.19 ns 
Vrc,a Tr 0.18 0.19 ns 0.19 0.25 ns 0.25 0.20 ns 
Vab,Tr 0.25 0.35 ns 0.35 0.25 ns 0.25 0.37 ns 
Vrc,p unTr 0.23 0.21 ns 0.21 0.17 ns 0.17 0.17 ns 
Vrc,a unTr 0.21 0.22 ns 0.22 0.22 ns 0.22 0.20 ns 
Vab, unTr 0.30 0.36 ns 0.36 0.23 ns 0.23 0.36 ns 
Vcw 1.37 1.58 ns 1.50 1.42 ns 1.40 1.47 ns 
 
 
FVC 
(L) 
Vrc,p Tr 0.71 0.44 ns 0.44 0.51 ns 0.51 0.52 ns 
Vrc,a Tr 0.43 0.36 ns 0.36 0.48 ns 0.48 0.42 ns 
Vab,Tr 0.72 0.86 ns 0.86 0.66 ns 0.66 0.86 ns 
Vrc,p unTr 0.70 0.45 ns 0.45 0.51 ns 0.51 0.48 ns 
Vrc,a unTr 0.40 0.40 ns 0.40 0.46 ns 0.46 0.39 ns 
Vab, unTr 0.73 0.90 ns 0.90 0.62 ns 0.62 0.82 ns 
Vcw 3.69 1.35 ns 3.50 1.25 ns 3.29 3.37 ns 
¥Wilcoxon matched pair test. LVRS n=8, BLVR responder n=7, controls n=11. 
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In terms of the forced expiratory manoeuvres, there were no significant changes at 3 months in 
OEP measured chest wall volumes of FEV1 or FVC in any of the groups compared to baseline. 
None of the compartments, treated or non-treated sides, had a statistically significant change at 
3 months as compared to baseline (table 5.7). 
 
5.3.4.3  Correlation between spirometry and OEP measured volumes 
As expected and for the reasons discussed in section 5.1, the correlation between spirometry 
and OEP measured volumes during forced respiratory manoeuvres was moderate at best. 
(figure 5.13). Bias was small but 95% limits of agreement were wide for both FEV1 and FVC. 
FEV1 measured by spirometry was lower than OEP measured FEV1 (Bland Altman FEV1 figure 
5.13) due to gas compression and blood shift. Total chest wall volume should equal the sum of 
volume at mouth (spirometry), volume of compressed gas and volume of blood shifted out of 
trunk to the extremities.(151) As expected this was less pronounced for FVC. For FEV1, the 
relationship between OEP and spirometry measurements is stronger when looking at the 
change at 3 months compared to baseline with r2 value of 0.58, p<0.001. There was no 
significant reduction in the discrepancy between OEP and spirometry measured forced 
expiratory volumes following LVR which may have suggested reduction in gas compression 
following LVR due to reduced airways obstruction. In this context, OEP measured expiratory 
volumes should be higher than spirometry measured volumes, but this was not always the case 
with some OEP measures smaller than spirometry measured values. 
Agreement in the % change in the FEV1/FVC ratio measured by spirometry and that measured 
by  OEP  was  poor (r2 value of 0.02), with  a  bias  of  4.4%  and  95%  limits  of  agreement from 
-99.1% to 107.8%.  The change in OEP measured forced expiratory volumes 3 months post-
treatment did not correlate with clinical and functional outcome assessments.  
During quiet breathing, agreement between OEP and spirometry measured TV was strong (r2 
value of 0.62, p<0.001), though there was a relatively wide 95% limit of agreement (-0.50 to 
0.60 L) (figure 5.14). Much stronger agreement was reported in the literature (r2 values >0.90 
for measurements of tidal volume at rest (154) as well as during exercise (148) in patients with 
COPD. The patterns are similar for IC and minute ventilation (VE) (figure 5.14) 
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Figure 5.13: Agreement between spirometry and OEP measured volumes during forced respiratory 
manoeuvres. 
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Figure 5.14: Agreement between spirometry and OEP measured volumes during quiet 
breathing and inspiratory capacity manoeuvres. 
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5.3.4.4  Chest wall compartmental asynchrony 
5.3.4.4.1  Baseline Phase shift angles (Ɵ) 
There was no difference in phase shift angles between any of the groups at baseline, in any of 
the phase shifts angles measured as detailed in table 5.7. The following phase angle shifts were 
assessed: ƟRC, ƟDIA, ƟRC treated and non-treated, ƟDIA treated and non-treated ƟRC,p, ƟRC,a, 
ƟAb. 
 
Table 5.8: Phase shift angles at baseline  
Tidal breathing 
All 
subjects 
(n=26) 
LVRS 
(n=9) 
BLVR 
responders 
(n=7) 
Controls 
(n=10) 
p-
value¥ 
ƟRC (˚) 
 
mean 31.3 28.2 50.1 20.9 
ns SD 38.4 31.5 42.2 40.3 
ƟRC Treated (or worst 
affected) side (˚) 
mean 34.2 36.2 51.6 20.2 
ns SD 39.9 33.8 47.4 38.2 
ƟRC Untreated side(˚) 
mean 29.6 24.0 46.1 23.1 
ns SD 37.3 30.6 35.7 43.6 
ƟDIA (˚) 
mean -38.7 -36.2 -54.4 -30.1 
ns SD 36.3 29.7 44.7 35.4 
ƟDIA Treated (or worst 
affected) side (˚) 
mean -38.8 -42.1 -51.4 -27.0 
ns SD 36.8 31.1 45.3 35.4 
ƟDIA Untreated side (˚) 
mean -39.6 -32.8 -55.7 -34.3 
ns SD 36.1 28.5 42.6 37.5 
IC manoeuvre      
ƟRC (˚) 
 
mean 5.1 9.9 -25.0 22.0 
ns SD 58.0 55.1 44.8 65.2 
ƟRC Treated (or worst 
affected) side (˚) 
mean -5.4 9.7 -8.7 -10.1 
ns SD 55.3 60.6 43.7 53.8 
ƟRC Untreated side(˚) 
mean 35.3 13.8 67.0 32.6 
ns SD 59.2 41.1 64.1 65.2 
ƟDIA (˚) 
mean -1.0 8.3 -33.8 13.6 
ns SD 57.9 49.8 52.6 64.1 
ƟDIA Treated (or worst 
affected) side (˚) 
mean 24.0 17.9 65.0ʱ 0.7ʱ 
ns SD 58.5 15.0 54.3 73.4 
ƟDIA Untreated side (˚) 
mean 23.7 18.7 54.8≠ 6.5≠ 
ns SD 47.0 10.1 45.6 59.7 
¥ Kruskal-Wallis test with Dunn’s multiple comparison test. ≠ p=0.09; ʱp=0.08 Mann Whitney test; ƟRC, 
phase shift angle between RC,p and RC,a; ƟDIA, phase shift angle between RCa and Ab.  
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5.3.4.4.2  Change in Phase shift angles (Ɵ) at 3 months 
In the LVRS group, there was a significant improvement in ƟDIA from -36.2 (31.5)˚ to -7.3 
(16.1)˚ 3 months after surgery (p=0.004) during quiet breathing (Table 5.9). The change in 
ƟDIA was statistically significant in the treated but not untreated side. The BLVR responders 
saw a mean 28 (30.1)˚ reduction in ƟDIA during tidal breathing but this change did not reach 
statistical significance.  
ƟRC reduced from 50.1 (42.2) ˚ to 7.7 (17.1) in the BLVR responders 3 months after the 
procedure (p=0.002) during quiet breathing. The improvement was statistically significant in 
the treated but not untreated side. The LVRS group also saw improvements in ƟRC but these did 
not reach statistical significance (Table 5.9). 
When assessing change at 3 months from baseline of all successful LVR patients as a single 
group, there were statistically significant improvements in ƟRC and ƟDIA, as well is in ƟRC and 
ƟDIA on the treated sides (but not untreated sides) during quiet breathing (table 5.9). The 
changes in ƟDIA and ƟRC seen here can be considered clinically relevant as it brings the all LVR 
group means of ƟDIA and ƟRC to within the presumed “normal” ranges (based on published 
data on ƟRC) of within 0 to 18˚ (-44.1 (36.8) ˚ to -15.7 (16.5) ˚, p=0.002 for ƟDIA; and 37.8 (37.0 
to 9.5 (17.8) ˚, p=0.004 for ƟRC).  
There were no differences in ƟRC or ƟDIA during inspiratory capacity manoeuvres at 3 months 
in any of the groups, though there was less asynchronous chest wall movement at baseline 
during these manoeuvres (table 5.10). There was no change in ƟRC,p, ƟRC,a or ƟAb before and 
3 months after the intervention in any of the groups. 
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Table 5.9: Phase shift during quiet breathing (TV). 
Wilcoxon matched pair s test. ƟRC, phase shift angle between RC,p and RC,a; ƟDIA, phase shift angle between RCa and Ab. 
 
Ɵ during Quiet 
Breathing 
ƟRC 
(˚) 
ƟRC Treated (or worst affected) side 
(˚) 
ƟRC Untreated side 
(˚) 
Pre Post change 
p-
value 
Pre Post change 
p-
value 
Pre Post change 
p-
value 
LVRS 
mean 28.2 11.0 -17.3 
0.10 
36.2 10.8 -25.4 
0.13 
24.0 12.1 -11.9 
0.43 
SD 31.5 19.1 40.5 33.8 19.3 42.5 30.6 21.6 41.1 
BLVR 
mean 50.1 7.7 -42.4 
0.02 
51.6 2.0 -49.6 
0.02 
46.1 20.8 -25.3 
0.22 
SD 42.2 17.1 30.3 47.4 14.0 36.2 35.7 35.5 47.0 
All LVR 
mean 37.8 9.5 -28.2 
0.004 
42.9 6.9 -36.0 
0.005 
33.6 15.9 -14.7 
0.10 
SD 37.0 17.8 37.5 39.6 17.2 40.5 33.7 27.8 42.8 
Control 
mean 20.9 36.9 16.1 
0.16 
20.2 38.0 17.8 
0.16 
23.1 35.4 12.3 
0.77 
SD 40.3 37.5 45.1 38.2 36.5 38.1 43.6 40.2 54.9 
 
ƟDIA 
(˚) 
ƟDIA Treated (or worst affected) side 
(˚) 
ƟDIA Untreated side 
(˚) 
Pre Post change 
p-
value 
Pre Post change 
p-
value 
Pre Post change 
p-
value 
LVRS 
mean -36.2 -7.3 28.9 
0.004 
-42.1 -9.3 32.8 
0.004 
-32.8 -19.4 13.5 
0.25 
SD 29.7 16.1 24.1 31.1 20.7 22.6 28.5 31.2 51.2 
BLVR 
mean -54.4 -26.4 28.0 
0.11 
-51.4 -21.4 30.0 
0.11 
-55.7 -39.4 16.4 
0.47 
SD 44.7 10.0 38.6 45.3 10.1 45.3 42.6 27.9 44.7 
All LVR 
mean -44.1 -15.7 28.5 
0.002 
-46.1 -14.6 31.6 
0.003 
-42.9 -28.1 14.8 
0.16 
SD 36.8 16.5 30.1 36.9 17.6 33.1 36.0 30.6 46.9 
Control 
mean -30.1 -36.0 -6.0 
0.49 
-27.0 -38.2 -11.2 
0.32 
-34.3 -39.6 -5.4 
0.38 
SD 35.4 36.4 51.9 35.4 40.8 47.7 37.5 38.6 59.1 
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Table 5.10: Phase shift during inspiratory capacity manoeuvre. 
Ɵ during IC 
manoeuvre 
ƟRC 
(˚) 
ƟRC Treated (or worst affected) side 
(˚) 
ƟRC Untreated side 
(˚) 
Pre Post change 
p-
value 
Pre Post change 
p-
value 
Pre Post change 
p-
value 
LVRS 
mean 9.9 -23.3 -33.1 0.16 
 
9.7 -5.6 -15.4 
0.51 
13.8 22.7 8.9 
0.15 
SD 55.1 42.8 52.9 60.6 36.8 67.3 41.1 54.8 50.1 
BLVR 
mean -25.0 8.4 33.4 0.11 
 
-8.7 11.8 20.5 
0.38 
67.0 -17.3 -84.3 
0.06 
SD 44.8 14.3 42.3 43.7 21.6 36.4 64.1 79.5 88.4 
All LVR 
mean -5.4 -9.4 -4.0 
0.93 
-10.1 -17.3 -7.2 
0.84 
1.7 2.0 -0.3 
0.62 
SD 52.4 36.3 58.1 53.8 48.4 68.8 53.0 31.5 57.3 
Control 
mean 22.0 17.1 -4.0 
0.85 
-16.7 18.6 35.3 
0.19 
32.6 24.2 -8.3 
0.92 
SD 65.2 60.2 52.2 59.8 59.5 78.1 65.2 59.8 64.6 
 
ƟDIA 
(˚) 
ƟDIA Treated (or worst affected) side 
(˚) 
ƟDIA Untreated side 
(˚) 
Pre Post change 
p-
value 
Pre Post change 
p-
value 
Pre Post change 
p-
value 
LVRS 
mean 8.3 -35.7 -44.0 
0.16 
17.9 19.2 1.3 
0.93 
18.7 14.9 -3.7 
0.78 
SD 49.8 58.4 59.1 15.0 48.7 42.7 10.1 37.1 41.0 
BLVR 
mean -33.8 6.4 40.2 
0.08 
65.0 39.2 -25.8 
0.69 
54.8 40.6 -14.2 
0.79 
SD 52.6 12.0 50.3 54.3 80.0 126.3 45.6 89.7 130.9 
All LVR 
mean 38.5 28.0 -10.6 
0.45 
37.1 5.2 -31.9 
0.46 
34.5 26.2 -8.3 
0.39 
SD 43.4 62.7 86.7 57.3 67.5 81.2 35.1 64.2 88.2 
Control 
mean 13.6 5.0 -8.6 
0.77 
0.7 9.5 8.8 
0.70 
6.5 -4.7 -11.2 
0.56 
SD 64.1 60.8 48.8 73.4 70.1 57.0 59.7 56.7 63.4 
Wilcoxon matched pairs test. ƟRC, phase shift angle between RC,p and RC,a; ƟDIA, phase shift angle between RCa and Ab.
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5.3.4.4.3  Between group comparisons in the change in Phase shift angles (Ɵ) 
Between group differences in the change in Ɵ were significantly different for ƟRC and ƟDIA 
including ƟRC and ƟDIA on the treated (but not untreated) side in the direction of benefit 
(towards zero˚) favouring the LVRS group when compared to control groups (table 5.11). 
Similar results are seen when comparing the change in ƟRC and ƟDIA between the BLVR and 
control groups (table 5.12) (except the between group difference in the change in ƟDIA on 
treated side which did not reach statistical significance), and all successful LVR subjects as 
compared to the control group (Table 5.13). 
 
Table 5.11: Difference in the change in Phase shift angle (Ɵ) during quiet breathing between the LVRS 
and Control groups. 
Mean change in Ɵ 
LVRS 
(n=9) 
Control 
(n=10) 
Between-Group Difference in 
Change from Baseline 
P-value¥ 
Number ± SD or (95% confidence interval) 
Ɵ RC -17.3 ± 13.5 16.1 ± 14.3 -33.3 (-75.0 to 8.4) 0.03 
Ɵ RC treated side -25.4 ± 14.2 17.8 ± 12.0 -43.2 (-82.2 to -4.3) 0.04 
Ɵ RC untreated side -11.9 ± 13.7 -5.4 ± 18.7 -6.5 (-56.4 to 43.4) 0.96 
Ɵ DIA 28.9 ± 8.0 -6.0 ± 16.4 34.8 (-5.1 to 74.8) 0.008 
Ɵ DIA treated side 32.8 ± 7.5 -11.2 ± 15.1 44.0 (7.2 to 80.8) 0.008 
Ɵ DIA untreated side 13.5 ± 17.1 -1.2 ± 4.4 14.7 (-20.7 to 50.1) 0.11 
¥Mann Whitney test. ƟRC, phase shift angle between RC,p and RC,a; ƟDIA, phase shift angle between RCa 
and Ab. 
 
 
 
Zaid Zoumot 
CID: 00541359      
 174 
 
Table 5.12: Difference in the change in Phase shift angle (Ɵ) during quiet breathing between the LVRS 
and Control groups. 
Mean change in Ɵ 
BLVR 
(n=7) 
Control 
(n=10) 
Between-Group Difference in 
Change from Baseline 
P-value¥ 
Number ± SD or (95% confidence interval) 
Ɵ RC -42.4 ± 11.5 16.1 ± 14.3 -58.4 (-100.3 to -16.6) 0.003 
Ɵ RC treated side -49.6 ± 13.7 17.8 ± 12.0 -67.40 (-106.6 to -28.2) 0.001 
Ɵ RC untreated side -25.3 ± 17.8 -5.4 ± 18.7 -19.9 (-77.3 to 37.4) 0.31 
Ɵ DIA 28.0 ± 14.6 -6.0 ± 16.4 34.0 (-15.4 to 83.3) 0.05 
Ɵ DIA treated side 30.0 ± 17.1 -11.2 ± 15.1 41.2 (-7.8 to 90.3) 0.07 
Ɵ DIA untreated side 16.4 ± 16.9 -1.2 ± 4.4 17.6 (-14.2 to 49.4) 0.131 
¥Mann Whitney test. ƟRC, phase shift angle between RC,p and RC,a; ƟDIA, phase shift angle between RCa 
and Ab. 
 
 
 
 
Table 5.13: Difference in the change in Phase shift angle (Ɵ) during quiet breathing between the all 
successful LVR patients and the control group. 
Mean change in Ɵ 
LVR 
(n=16) 
Control 
(n=10) 
Between-Group Difference in 
Mean Change from Baseline 
P-value¥ 
Number ± SD or (95% confidence interval) 
Ɵ RC 
 
-28.2 ± 9.4 
16.1 ± 14.3 -44.3 (-78.0 to -10.6) 0.003 
Ɵ RC treated side -36.0 ± 10.1 17.8 ± 12.0 -53.8 (-86.8 to -20.9) 0.003 
Ɵ RC untreated side -17.7 ± 10.7 -5.4 ± 18.7 -12.4 (-53.6 to 28.9) 0.62 
Ɵ DIA 28.5 ± 7.5 -6.0 ± 16.4 34.5 (1.42 to 67.5) 0.007 
Ɵ DIA treated side 31.6 ± 8.3 -11.2 ± 15.1 42.8 (10.2 to 75.4) 0.008 
Ɵ DIA untreated 
side 
14.8 ± 11.3 -1.2 ± 4.4 16.0 (-15.7 to 47.6) 0.13 
¥Mann Whitney test. ƟRC, phase shift angle between RC,p and RC,a; ƟDIA, phase shift angle between RCa 
and Ab.   
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5.4  DISCUSSION 
Successful lung volume reduction with radiological evidence of volume loss resulted in 
statistically and clinically significant improvements in lung function, exercise capacity and 
quality of life. This study showed that: (a) OEP measured static chest wall volumes did not 
change in tandem with lung volumes measured by body plethysmography; (b) Agreement 
between OEP measured dynamic chest wall volumes and spirometry measured volumes was 
stronger in quiet breathing than in forced manoeuvres (as expected), but with a weaker 
correlation and wider 95% limits of agreement than previously reported in the literature; (c) 
Change in the discrepancies between OEP and spirometry measured forced expiratory volumes 
was variable and did not correlate with clinical outcomes; and (d) Successful lung volume 
reduction resulted in significant improvements in phase shift angles ƟRC (asynchrony between 
Vrc,p and Vrc,a) and ƟDIA (asynchrony between Vrc,a and Vab) at 3 months compared to 
baseline, and compared to controls.  
Almost 15 years ago, Bloch and colleagues studied 19 patients before and after LVRS, and 
reported reductions in phase shift between the rib cage (as one compartment) and the 
abdomen.(78) They used respiratory inductive plethysmography (RespitracePT:Non-invasive 
Monitoring Systems, Florida, USA), a system using inductive bands which measure in 2 
dimension the lateral and antero-posterior dimensions of the rib cage and abdomen.   This is the 
first study to use OEP, a system integrating 3-dimentional volume measurements from multiple 
markers accurately placed to delineate the areas of interest, to demonstrate highly significant 
improvements in respiratory asynchrony following lung volume reduction (both surgical and 
bronchoscopic) compared to matched controls. OEP demonstrated this effectively (figure 5.16). 
Our findings may be different to those of Bloch and others who used RIP to measure 
asynchronous respiration, as only two measures were taken with RIP: abdominal and rib cage 
cross sectional areas. The rib cage was considered a single entity, however our OEP data 
demonstrates that the RC,p moved in tandem with Ab, but it is RC,a that was moving 
paradoxically. Hence for RIP to detect this change would require the thoracic band to be placed 
over the lower rib cage. Bloch reported placing the thoracic band 3cm below the nipple line, and 
whether this was above or below the level of the xiphisternum or the caudal limit of the zone of 
apposition would depend on patient height and degree of hyperinflation. OEP is thus much 
more accurate at assessing thoracoabdominal chest wall asynchrony.  
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The improvements in ƟRC and ƟDIA are strongly significant, more so on the treated side. 
Although improvements were seen in the non-treated side, these did not reach statistical 
significance. Mean ƟRC during quiet breathing reduced from 38.8 (37.0) to 9.5 (17.8) 3 months 
post treatment (p<0.004) in 16 patients who had successful LVR.  Using an upper limit of 
normal of 18˚ for ƟRC, 9 of 16 patients had asynchronous rib cage inspiratory movements 
during quiet breathing at baseline, and only 4 at 3 months post procedure. Similarly, large 
improvements in ƟDIA were seen (change of 28.5(38.6) towards zero˚, p=0.002) with 12 
patients before and 8 patients after having a ƟDIA of <-18 ˚ (note upper limit of normal 
unknown for ƟDIA). 
 
 
Figure 5.15: Volume-time traces of a representative patient before (left) and after (right) LVRS. 
Asynchrony of the Vrc,a compartment (Vrc,a second panel from top; Vrc,a left and right bottom 2 panels) 
on both treated and non-treated sides is almost completely corrected post LVRS. ƟRC and ƟDIA  pre LVRS 
were 87.5˚ and 92.3˚, and post LVRS -4.0˚ and 12.2˚, respectively. 
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Chest wall asynchrony during quiet breathing was predominantly due to asynchronous 
movements of the portion of the rib cage apposed to the flattened diaphragm, Vrc,a. Thus ƟRC 
(phase shift angle of Vrc,p in relation to Vrc,a) correlated extremely strongly with ƟDIA (phase 
shift angle of Vrc,a in relation to Vab) at baseline (r2 =0.94, p<0.0001) (figure 5.15).  The degree 
of asynchrony at baseline for both ƟRC and ƟDIA correlated strongly with the degree of 
improvement in the same measure, and in improvement in asynchrony of the other phase shift 
angle (figure 5.15). Hence the worse the asynchrony at baseline, the larger the improvement in 
asynchrony following lung volume reduction. I could not identify any relationship between the 
degree of chest wall asynchrony at baseline and the magnitude of improvements in various 
clinical parameters: change in FEV1, change in RV/TLC, change in FRC, change in TLCOc, change 
in SGRQ, and change in 6MWD. Therefore the degree of chest wall asynchrony at baseline did 
not predict clinical response to LVR. This may suggest that LVR is effective irrespective of 
whether there is chest wall asynchrony at baseline. On the other hand, it has previously been 
reported that abdominal paradoxical breathing is not associated with increased dyspnoea or a 
reduced exercise tolerance,(78, 157) and this was shown again in the two recent OEP studies of 
exercising COPD patients,(119, 148) though Aliverti’s study demonstrated earlier dynamic 
hyperinflation in those with chest wall asynchrony at rest as well as increased leg fatigue during 
exercise (but not dyspnoea) compared to those without paradoxical chest wall movements at 
rest. However if we consider the 9 LVR patients in our cohort who had significant 
improvements in asynchrony (defined arbitrarily as improvements in ƟRC by >30˚, or from 
above the upper limits of normal (18˚) to within normality), and compare their clinical 
responses with those who did not improve (no change post procedure or no asynchrony at 
baseline), we find that the benefits in clinical outcomes in those improvers are almost twice as 
large in most parameters than in the non-improvers (table 5.13). Statistical significance is 
reached only for the change in RV and change in RV/TLC, though in a larger group these 
differences may reach statistical significance. 
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Table 5.14: Change from baseline in clinical outcome measures comparing patients with improvements 
in rib cage asynchrony and those without. 
 
ƟRC 
Improvers 
(n=9) 
ƟRC non-
improvers 
(n=7) 
Between-Group Difference in 
Mean Change from Baseline P-value¥ 
Mean ± SD or (95% confidence interval) 
% change in FEV1 34.9 ± 38.7 21.9 ± 38.2 13.2 (-28.7 to 54.7) ns 
Change in RV (L) -1.24 ± 0.50 -0.62 ± 0.55 0.61 (-1.18  to -0.04) 0.02 
Change in RV/TLC (%) -10.9 ± 4.6 -3.4 ± 5.9 7.4 (-15.3 to 0.43) 0.04 
Change in FRC (L) -0.76 ± 0.44 -0.51 ± 0.47 0.26 (-0.74 to 0.23) ns 
% Change in TLCOc  16.3 ± 20.3 2.0 ± 12.57 14.3 (-4.5 to 33.1) ns 
Change in 6MWD (m) 56.0 ± 45.6 32.3 ± 56.5 23.7 (33.3 to 80.7) ns 
Change in SGRQ 
(points) 
-19.4 ± 17.6 -7.3 ± 12.2 12.0 (-28.8 to 4.8) ns 
¥Mann Whitney test. ƟRC, phase shift angle between RC,p and RC,a. 
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Figure 5.16: Phase shift in the lung volume reduction cohort at baseline and correlation with 
improvements in phase shift following treatment. 
Static thoraco-abdominal volumes measured using OEP did not change significantly, nor in 
tandem with lung volumes measured using body plethysmography, and there were no changes 
in compartmental volumes nor contributions to total Vcw after LVR. The pulmonary and 
abdominal rib cages are relatively fixed and not much volume change in these compartments is 
expected as a result of loss of lung volume, but theoretically diaphragm elevation should be 
accompanied by change in abdominal volume. However, reduced intra-abdominal pressures 
from diaphragm repositioning may well be accompanied by upwards shift in pelvic contents 
potentially counteracting any loss in lung volume.  
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Patient numbers in each group were relatively small, but this is the only study to use OEP to 
assess the effects of LVR to date. In fact, no published study has examined more than 30 patients 
with COPD using OEP in any context. The small numbers probably contributed to the large 
deviations from the group means in the change in static chest wall volumes (TV, IC, FEV1, FVC) 
at 3 months compared to baseline. Although OEP measures a different entity to body 
plethysmography, one would expect to see similar trends. Reasons for this discrepancy may 
reflect technical issues: We attempted to minimise differences in marker positioning by limiting 
this task to two individuals strictly following recognised anatomical landmarks, but exact 
marker placement may have differed between the two assessments. Differences in subject 
positioning during testing may also impact on compression of the chest wall (e.g. leaning 
forward or backwards), and to address this concern we sat patients down on the cycle 
ergometer seat adjusted at the same height for both tests, and ensured both legs were in a 
neutral position. During post-test preparation and optimisation of the geometric models, some 
markers had to be reconstructed using geospatial relationship with other adjacent markers. 
This served to improve the quality of the geometric model for analysis by “filling in the gaps” 
when camera views of markers was impeded, but may have reduced accuracy of measurement 
of specific compartmental volumes. Thus reconstructing markers which lay at the 
compartmental borders was avoided unless absolutely necessary. We sent raw data files and 
volume time traces to the team at Politecnico di Milano for quality control purposes, and we 
were reassured that technically the recordings and geometric models were of very high quality.  
Significant weight loss or weight gain will have an impact on total thoraco-abdominal chest wall 
volumes, and several subjects had fluctuations in weight. Specifically, three LVRS patients had 
extended hospital admissions (> 4 weeks, one having suffered a cerebrovascular accident), and 
two others had intercostal chest drains in situ for over 6 weeks restricting activity levels. These 
patients reported significant weight loss (not accurately measured for all patients and therefore 
not reported here). On the other hand, two other subjects in the BLVR group had gained a 
significant amount of weight. Weight reduction or gain may have augmented or reduced, 
respectively, any benefits from LVR as measured by OEP.  
We used OEP to attempt to detect a change in overall static lung volumes of around 0.68 (0.59) 
L (change in TLC as measured by body plethysmography in all LVR patients), however this as a 
proportion of the OEP measured total chest wall volume Vcw of 31.6 (6.5) L in the cohort is very 
small indeed. A very large number of patients would be required to detect such small changes 
(~2% of the total Vcw). Furthermore, minor marker positioning differences (e.g. 1 cm 
superiorly or inferiorly of the lower most horizontal line connecting the superior iliac crests) on 
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serial testing could conceivably significantly alter volume measurements by a few hundred mls. 
For this reason and other factors that can change chest wall and abdominal dimensions, OEP 
may not be a suitable technique for serial static total (and compartmental) chest wall volume 
measurements. However in the assessment of asynchrony between different chest wall 
compartments, the effect of minor marker positional changes is unlikely to significantly alter 
phase shift angles and hence the analysis of asynchrony. Here it is the direction of movement of 
different chest wall compartments in relation to each other that is assessed, and this is largely 
uninfluenced by exact marker positioning. Furthermore, the lower costal margin is very easy to 
identify and delineate anatomically, as is the xiphisternum, making it easier to replicate 
identical marker positioning on serial testing.  
Physiological reasons which may contribute to why Vcw did not correlate well with changes in 
plethysmographic lung volumes during dynamic manoeuvres include the effect changes in 
thoracic and abdominal pressures on the circulatory system (the role of blood shift (153)), on 
volume of solid organs, and on gas compression. Total thoracoabdominal chest wall volume 
should equal the sum of volume at mouth (spirometry), volume of compressed gas and volume 
of blood shifted out of trunk to the extremities.(151)Figure 5.7 illustrates how chest wall 
volumes do not necessarily correlate with air being expired from the mouth, with gas 
compression likely a major factor particularly in early phases of forced expiratory manoeuvres 
in patients with severe airways obstruction. In their study of six healthy adults exercised with 
expiratory flow limitation using a starling resistor, Iandelli and colleagues reported a mean (SE) 
difference of 489 (74) mls in tidal volume between OEP and spirometry at resistance of 30% of 
peak expiratory flow. Oesophageal and gastric pressure balloons were used to calculate 
intrathoracic and abdominal pressures and Boyle’s law was used to determine the proportion of 
this discrepancy due to gas compression (163 (24) mls) and the remaining was thus attributed 
to blood shift (326 (66.3) mls).(151) 
The effect of chest wall asynchrony itself on overall chest wall volumes is likely to be significant 
as the asynchronous portion of the chest wall counteracts some of the overall chest wall volume 
changes being measured by OEP. Changes in the amount of asynchrony will thus influence the 
change in static and dynamic OEP measured chest wall volumes. Furthermore, a theoretical 
limitation of OEP in assessing relative changes between Vrc,p and Vrc,a, previously described by 
Romaglioni et al.,(155) is that in patients with severe hyperinflation, the superior margin of the 
zone of apposition of the diaphragm to the rib cage is likely more caudal than normal, and 
therefore the proportion of the abdominal rib cage exposed to abdominal pressures may be 
smaller. Reductions in hyperinflation following LVR certainly shifts diaphragm positioning and 
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this may have an impact on changes in static Vrc,a in particular. Also, the horizontal line at the 
level of the xiphisternum used as the border between RC,p and RC,a may not exactly correspond 
to the true zone of apposition in our cohort with severe COPD, that is the portion of the rib cage 
exposed to muscles which act in a different manner to those in contact with the upper rib cage. 
Nevertheless, Iandelli and colleagues monitored the cephalic border of the area of apposition 
(i.e. border between RC,p and RC,a) with ultrasound during exercise and they demonstrated 
stability in this zone after inducing dynamic hyperinflation.(151) In the case of this study, we 
seek to identify any change in chest wall movements that can result from lung volume 
reduction, irrespective of possible changes in the zone of apposition. Thus if there is such a 
change in our cohort, it is unlikely to influence the outcomes or interpretation of data presented 
here.  
It is worth noting that several LVRS patients still had intercostal chest drains in situ at the time 
of discharge from hospital, and in two patients remained in place for over 6 weeks. Intercostal 
nerve injury is common following LVRS and neuropathic pains were reported by 5 of 9 LVRS 
patients at the time of their follow-up assessment. Pain, as well as incomplete recovery of the 
chest wall from the trauma of surgery, may well have reduced chest wall movements and thus 
total and dynamic chest wall volumes. Furthermore, patients may not have fully recovered back 
to their baseline levels of activity and fitness by 3 months, and a longer follow-up period may 
have been preferable for the LVRS group. 
The agreement between OEP and spirometry when measuring dynamic lung volumes and 
change over time was variable, with stronger relationships during quiet compared to forced 
manoeuvres (as expected). Different entities are being measured by the two systems, however 
other published data reveals much higher rates of agreement than that seen in this study 
suggesting that improvements can be made to our testing techniques. Improvements I believe 
need to be implemented to the OEP system at the Brompton include: 
1) A larger room allowing distancing further the infrared cameras from the subjects being 
tested, enabling greater freedom of movement of the subject being tested without risk of 
loss of marker detection. 
2) Alternative support system to the standard cycle ergometer handlebars as these 
markedly reduce quality of OEP marker recordings by both the impedance of camera 
views by outstretched arms, and by encouraging the subjects to lean forward. The 
hospital trust health and safety regulations precluded the use of temporary stabilisation 
devices on each side of the patient allowing the patient to sit up straighter and have 
Zaid Zoumot 
CID: 00541359      
 183 
 
their arms to the side, because of the risk of falls. Securing such devices to the floor was 
prohibited by the infection control department. Suspending handlebars from the ceiling 
was not possible for similar reasons.  
3) OEP recordings should be restricted to short intervals (90-120 seconds) to minimise 
data loss and ease analysis.   
4) More meticulous marker positioning around anatomical landmarks by trained and 
experienced individuals. 
The effect of chest wall asynchrony on exercise before and change in this after lung volume 
reduction needs to be studied. All patients had exercise testing as part of this study protocol. 
This occurred beyond the remit of this thesis and is the logical next step in furthering the 
analysis of this data. The data could also be used to assess OEP in the measurement of 
dynamic hyperinflation before and after LVR, which has not previously been reported. But 
first, substantial input will be required to improve the quality of the recorded geometric 
models during exercise which are on first look significantly degraded by movement artefact 
and marker loss. Comparing spirometry and OEP measured flow volume loops and time-
volume traces to further scrutinise the discrepancy between OEP and spirometry during 
forced manoeuvres is possible with the available data, and will be of interest in clarifying 
the reasons for this difference. Studies of a larger number of patients undergoing LVR 
procedures are needed before the effects of chest wall asynchrony at baseline and 
improvements in chest wall asynchrony can identify phenotypes most suitable for specific 
LVR techniques.   
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5.5 CONCLUSION 
OEP is a novel and unique tool which enables 3D assessment of the mechanics of ventilation in 
patients with emphysema undergoing lung volume reduction. This study demonstrated that in 
experienced hands, the setup and patient testing process is feasible and reasonably straight 
forward, though slightly time consuming. However considerable training and experience of a 
team of investigators is required before the technique can be mastered. In particular, data on 
unilateral chest wall volume change and on chest wall asynchrony is unique and informative. In 
this study, we found that statistically significant improvements in chest wall asynchrony 
occurred following successful lung volume reduction, particularly in the treated side, and these 
benefits were largest in those with the highest degrees of asynchrony at baseline and correlated 
with a range of clinical outcomes. OEP is an ideal tool to make assessments of chest wall 
asynchrony, however the clinical relevance of chest wall asynchrony in advanced COPD is yet 
unclear. How improvements in asynchrony correlate with clinical benefit is also unknown. 
Therefore further studies of larger cohorts of emphysema patients undergoing LVR are needed 
before this can be determined, and any change in asynchrony during exercise assessed. 
Although helpful with this respect, this study also reveals that OEP is not helpful in assessing 
change in static lung volumes following LVR especially as currently available techniques are 
reliable, easy to perform, cheaper, well validated and yield accurate and reproducible results. 
Movement during exercise markedly degrades recording quality and thus for the time being, it 
is likely that OEP will remain a tool for the researcher and is unlikely to come into regular 
clinical use in the context of LVR until the clinical relevance of chest wall paradoxical 
movements is established.   
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Chapter 6 
General discussion and future directions  
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6.1   SUMMARY OF FINDINGS 
This thesis reviews the current status of lung volume reduction for the treatment of severe 
emphysema. Studies of two novel techniques to achieve lung volume reduction are presented, as 
well as a study of the use of a novel 3D measurement system to shed light on the physiological 
mechanism of benefit from both surgical and bronchoscopic LVR. The trial of the LVR coils 
demonstrates, for the first time in a randomised controlled setting, that treatment with LVR 
coils results in statistically and clinically meaningful improvements in quality of life, lung 
function and exercise capacity compared with controls, and that benefits are largely maintained 
up to 12 months post treatment compared to baseline. The use of 180-240 mls of autologous 
blood instilled directly into a giant bullae is very promising, but appears ineffective when the 
volume is spread over 3 subsegments of emphysematous lung. The most interesting novel 
finding from the OEP study was the confirmation that lower rib cage paradoxical inspiratory 
movements in patients with hyperinflation improve significantly after lung volume reduction 
when compared to control patients undergoing a sham bronchoscopy, as assessed using 3D 
chest wall volume measurements. The improvements are statistically significant on the treated 
but not untreated sides. 
 
6.2  CRITIQUE OF METHOD AND FUTURE WORK 
 
6.2.1  LUNG VOLUME REDUCTION COILS 
The LVRC study had several inherent weaknesses. The first is the absence of a sham 
bronchoscopy and the unblinded nature of the treatments, which links directly to the second 
major weakness; the use of a self reported quality of life assessment tool as the primary 
outcome. Thirdly, the short controlled phase of the trial reduces the confidence with which firm 
conclusions can be drawn from the longer term data, especially that, finally, the small patient 
numbers under-power the statistical analyses. The not insignificant rate of pneumothoraces 
complicating LVRC treatment needs to be highlighted, and taken into account when considering 
the most appropriate lung volume reduction technique, whether bronchoscopic or surgical, to 
offer a particular patient. Nevertheless, the data is very encouraging with improvements in 
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quality of life correlating with changes in objective measures such as lung function and the 
6MWD, and this study with its weaknesses have informed the design and protocol of a larger 
(commercially funded) pivotal trial which is currently recruiting patients across North America 
and Europe; the Lung Volume Reduction Coil Treatment in Patients with Emphysema (RENEW) 
study (NCT01608490). 
Much is yet unknown about the mechanisms of action of the LVRCs, which do not cause lung 
volume reduction in the same manner as LVRS and other bronchoscopic techniques. It is 
hypothesised that increases in lung elasticity and a retensioning effect improves maintenance of 
airway patency preventing dynamic expiratory airway collapse, but this has not been directly 
studied. The optimal number of coils required per lung, the distribution of coil implantation 
(whether to restrict to one lobe or not), and longer term safety and efficacy information are 
needed, and in the author’s opinion should have preceded a large pivotal trial. The pressure on 
medical device manufacturers to generate income is understood, but perhaps optimising the 
treatment regime would in the long run improve yield from a treatment that is more effective. 
Trials investigating the following aspects of LVRCs should be considered: 
 Assessments of the effect of LVRC treatment on dynamic hyperinflation using cycle 
ergometry, to support the circulating notion that LVRCs improve dynamic hyperinflation 
and hence exercise tolerance in a degree which is out of proportion with improvements 
in lung function and on cross sectional imaging. 
  A study measuring lung compliance after the implantation of each coil to determine the 
relationship between the number of coils implanted and change in lung compliance. This 
will likely differ between individuals but may suggest loss of benefit after a certain 
number of coils are implanted, may establish a threshold after which the risk of 
pneumothorax increases, may help determine whether larger changes in compliance 
result from lobar or whole lung treatment, may be useful to perform during procedures 
to determine whether each coil is implanted in the optimal location, may help determine 
how proximal or distal the coils should ideally be placed, and inform the degree of 
segmental emphysematous destruction  on HRCT which would preclude any benefit 
from LVRCs. The compliance measurements could be performed using dedicated 
endobronchial blocking pressure measuring balloons akin to the Chartis catheter 
designed to measure collateral ventilation (section 1.3.8.3.2), or in patients under 
general anaesthesia as measured by the ventilator.  
 A study comparing the effectiveness of LVRC distribution (lobar or whole lung) in each 
of heterogeneous and homogeneous disease phenotypes.  
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 An assessment of the role any collateral ventilation may play in the efficacy of LVRC 
treatment. This could be retrospective using data from the study presented here. 
 A cost effectiveness study. 
 If proven effective in the pivotal trial, a trial randomising patients to LVRCs or other 
bronchoscopic LVR techniques such as endobronchial valves will ultimately be needed, 
to clarify the best treatment to offer patients who in theory could benefit from more 
than one technique. 
 
6.2.2  AUTOLOGOUS BLOOD LUNG VOLUME REDUCTION 
The expense and risks associated with the commercially funded bronchoscopic lung volume 
reduction techniques currently under development will restrict availability to a limited number 
of centres worldwide, and hinder patient access to LVR. We sought to investigate whether a 
simple inexpensive approach which does not involve leaving foreign bodies or material inside a 
patient’s airways could be successful. The two pilot studies presented in this thesis demonstrate 
the safety of bronchoscopically instilled endobronchial autologous blood using moderate 
sedation in patients with severe COPD, with proof of concept that intrabullous autologous blood 
can indeed cause significant reductions in the size of giant bullae leading to clinical benefit in 
selected patients. We have not treated enough patients to establish baseline predictors of who is 
most likely to respond, and indeed whether an intense inflammatory reaction (and adverse 
event) is a pre-requisite. Laboratory based studies examining the nature and amount of pro-
fibrotic contents contained in autologous blood is needed to guide volumes of blood to be 
instilled. The heterogeneous response to BIABI treatment may be at least partially explained by 
the varying amount of thrombin per ml of blood between individuals (anywhere between 20 iu 
and 100 iu as discussed in section 4.1). Personalising the treatment by studying each patient’s 
blood sample pre-procedure can guide therapy by informing autologous blood volume 
requirements for each person depending on thrombin content, and this may also help to predict 
response to treatment. Animal models could be used to assess whether varying concentrations 
of thrombin have different clinical effects, and establish whether there is a relationship between 
bulla size and the optimum volume of blood which should be instilled to instigate a response. 
Longer term follow-up data on efficacy and safety of BIABI treatment is needed. The natural 
course of bulla remodelling after BIABI treatment is unknown, as is the effect of repeat 
treatments and their timing.  A larger safety and feasibility trial designed by the author is 
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currently underway, the Bronchoscopic Intrabullous Autologous Blood Instillation (BIABI) for 
Emphysema trial (NCT01727037), with 10 of 30 patients already treated. The primary outcome 
time point is 6 months on this occasion, and early results have shown positive responses in 
several patients which is reassuring and complements the results seen in the pilot study 
presented here. In our small group we have seen progressive reductions in bulla size taking 
place beyond 6 months post treatment in one patient, but whether a repeat treatment could 
have amplified the effect or accelerated the speed of bulla shrinkage is unknown. 
 
6.2.3  OEP FOR THE ASSESSMENT OF LVR  
The OEP techniques used to measures chest wall volumes as presented in this thesis are 
unlikely to be a useful assessment tool for measuring changes in static total and compartmental 
volumes following LVR, due to the inherent variability of the measurements and dependence on 
exact marker positioning. OEP may be useful in measuring changes in dynamic volumes during 
respiration and has indeed been used accurately for measuring unforced manoeuvres by others. 
However we were unable to detect the changes seen on conventional lung function testing in 
our study with a degree of confidence or significance, though with a larger patient group this 
may have been different. Where the OEP system was of most interest was in measuring 
movements of different compartments of the chest wall in relation to each other. This is not 
reliant on precise marker placement and inspiratory paradoxical movement of the lower rib 
cage was clearly illustrated in this cohort with severe hyperinflation and flattened diaphragms. 
For the first time, improvements in these paradoxical movements following lung volume 
reduction and the return of the diaphragm to a more superior and natural position, were 
demonstrated to have occurred, and to a more significant extent on the treated side of the chest 
wall. Patients with the highest degree of asynchronous chest wall movements at baseline had 
the largest improvements in chest wall asynchrony, and those who had sizeable improvements 
in asynchrony had larger improvements in lung function, exercise capacity and quality of life 
compared to patients without asynchrony or any change thereof. Patient numbers were too 
small to draw firm conclusions on whether the degree of asynchrony at baseline predicts 
whether a patient is likely to respond more of less to LVR, or indeed to guide LVR treatment 
options. A large number of patients undergoing a variety of LVR procedures will be needed to 
establish whether a specific approach is more suited to, or likely to be more beneficial for, 
patients with varying degrees of chest wall asynchrony. More work is needed to clarify normal 
ranges for phase shift angles in normal subjects and patients with COPD, and how this correlates 
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with clinical parameters. Changes in phase shift angles during exercise following lung volume 
reduction is also of great interest. Ultimately the goal would be to improve patient selection and 
matching with the most appropriate LVR technique, discussed in more detail below.  
 
6.5  OVERALL LUNG VOLUME REDUCTION SUMMARY 
This thesis reviews the literature and presents the evidence behind the various lung volume 
reduction techniques currently available and/or under development, four of which are studied 
and presented here. The data in chapters 3, 4 and 5 clearly demonstrate that some patients with 
severe emphysema derive significant clinical benefit from LVRC treatment, intrabullous blood, 
and LVRS and endobronchial valves, respectively. However, at the time of writing the only 
established therapy with Grade A evidence of reduced mortality and cost effectiveness in 
patient with severe emphysema should be considered LVRS which is indicated for hyperinflated 
patients with heterogeneous upper zone disease, who exceed the NETT safety criteria, who 
experience symptoms despite pulmonary rehabilitation. Novel longer acting bronchodilators 
currently under development and some now available for clinical use appear to be more 
effective than their predecessors, and so ensuring that medical care of patients with COPD is 
optimised is essential before LVR is considered. LVR should remain a last resort for patients 
who remain significantly symptomatic despite best therapy including pulmonary rehabilitation, 
and although more minimally invasive techniques are becoming available they are likely to be 
associated with a not insignificant risk of complications and benefit will be limited by the 
usually markedly diseased remaining lungs.  
In trials of the BLVR techniques published thus far, including those presented in this thesis, 
there is large heterogeneity of response with a significant proportion of patients gaining no 
benefit. Maximising patient response rates is thus of critical importance moving forward, with 
optimal matching of patients with specific BLVR techniques being essential, particularly as there 
is overlap in emphysema subgroups or phenotypes that can potentially gain from more than one 
LVR approach. Future patient selection and matching with specific LVR techniques will be 
heavily reliant on detailed analysis of HRCTs, with focus not only on lobar heterogeneity and 
integrity of the interlobar fissures, but also on the degree of emphysematous destruction and 
bullae size, paraseptal vs. panacinar distribution, as well as the differing degree of segmental 
emphysema within lobes. Measures of chest wall asynchrony may also come into play along 
with the varying thresholds in lung function parameters for severity of gas trapping and airway 
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obstruction which are currently in flux. In the next three to five years, the pivotal randomised 
controlled trials currently underway should highlight the most favourable characteristics for a 
good response to each of the bronchoscopic LVR techniques as well as overall efficacy and 
safety. Long term efficacy and safety data for these novel bronchoscopic techniques, including 
the effect any implants may have on future thoracic surgery or lung resection, is limited but will 
emerge in the near future as further follow-up data is reported.  
Figure 6.1 includes a recommended algorithm to be followed when considering LVR, and is 
broadly in line with current practice at our institution. All non-surgical LVR should be offered as 
part of clinical trials until stronger evidence emerges to support their use, and the author has 
concerns regarding the proliferation of centres offering BLVR in Europe including the UK, under 
the cheery encouragement of the medical device manufacturers. The risk is to expose the wrong 
patients to inappropriate treatments which are inadequately performed, managed by physicians 
without the expertise to deal with the complications. These along with poor outcomes may 
reverberate to negatively impact the popularity of BLVR with both physicians and patients alike, 
akin to the negative image LVRS has attained from over exuberant use in the 1990s which it has 
not been able to recover from despite such a strong supportive evidence base. Furthermore, as 
the success of BLVR increases with improved patient selection, so too will complication rates. It 
is therefore best, at least for the time being, that LVR is offered through specialist centres able to 
adopt a multidisciplinary approach and carefully match patients with the optimal treatment 
from a range of surgical and non-surgical techniques, crucially with the ability to manage the 
complications.  
In the future, randomised controlled trials of LVRS versus BLVR techniques will be needed, and 
there will develop a need for trials randomising specific phenotypes or subgroups of 
emphysema patients to the different bronchoscopic techniques under development in order to 
the demonstrate superiority of certain approaches.
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Figure 6.1: Treatment Algorithm for lung volume reduction. (Author’s own work adapted with permission from Clinics in Chest Medicine (68))
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Details of contributions of others to work presented in 
this thesis 
The LVRC trial and autologous blood LVR studies were already recruiting on January 2011 when I 
commenced my fellowship. I was however an assigned study researcher assisting in the bronchoscopic 
procedures and post-procedure care on both these studies since April 2010 in my capacity as the 
respiratory specialist registrar at the Chelsea and Westminster Hospital where these procedures were 
performed. I also performed several follow-up assessments for the blood LVR study as a member of the 
blinded assessment team. In January 2011 I became study coordinator for all trials, subsequently 
recruiting all patients and conducting all follow-up assessments. Below are details of contributions of 
others and my own input into each of the studies: 
LVRC trial: The protocol was written by Dr. Pallav Shah (chief investigator and primary supervisor) in 
conjunction with the sponsor (PneumRx Inc.). Dr. Samuel Kemp (research fellow) obtained favourable 
ethics opinion, recruited the first 15 patients and performed ~20% of follow-up assessments. I recruited 
the remaining 21 patients and performed ~80% of all follow-up visits. I assisted Dr. Pallav Shah and the 
team in all but the first 2 bronchoscopic procedures which took place before I joined the team at Chelsea 
and Westminster hospital, and can perform the procedure independently without supervision. 
Autologous blood LVR trial: The protocol was written by Dr. Samuel Kemp (research fellow) who 
obtained favourable ethics opinion and recruited the first 8 patients. I recruited the remaining 9 patients 
and performed 20% of the follow-up visits as the blinded assessor before becoming study coordinator in 
January 2011. Cielito Caneja (research nurse) performed the remaining blinded follow-up assessments.  I 
assisted Dr. Pallav Shah as part of the bronchoscopy team in all but the first 4 bronchoscopic procedures 
and can perform the procedure independently without supervision. 
BIABI study: I conceived the study in conjunction with Dr. Shah, wrote the protocol, recruited all subjects, 
performed all bronchoscopic procedures and conducted all follow-up visits. 
OEP study: I conceived the study in conjunction with Drs. Nicholas Hopkinson and Pallav Shah, wrote the 
protocol, obtained favourable ethics opinion, recruited all patients, and conducted all but 2 of 104 OEP 
assessments. I performed all marker tracking, model reconstructions, data extraction and analysis. 
Antonella LoMauro designed the Matlab protocol enabling data extraction, and provided technical advice 
and assistance along with Andrea Aliverti, both of the Politecnico di Milano. 
For all studies, I personally collated all data from the source documents, inserted into spreadsheets and 
performed all the data and statistical analyses presented in this thesis. 
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